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ABSTRACT 
Colorectal cancer is the third most common type of cancer in the world and 
the second leading cause of death among humans. Extracts of water soluble 
compounds from the roots and leaves of Rumex crispus were screened for 
compounds that induced apoptosis in DLD-1 cells.  A compound referred to as L19 
was isolated using Accelerated Solvent Extraction (ASE) followed by High 
Performance Liquid Chromatography (HPLC).  Gas chromatography coupled with 
mass spectrometry was used to identify the L19 as a tetrahydrofuran with a 
molecular weight of 72.11 g/mole.  Each HPLC fraction resulted in 94.4% purity.  
In the present research, specific genes involved in apoptosis induction with the 
treatment of the DLD-1 cells with L19 were identified.  Apoptosis was measured 
by detecting levels of caspase 3 and 7 using the APO-one assay after treating 
synchronized DLD-1 cells with varying concentrations of L19 for 24 hrs. 
Furthermore, the mechanism of apoptosis was determined using quantitative real-
time polymerase chain reaction (qRT-PCR) and gene specific primers for 
caspases 6, 8, 10 (extrinsic pathways), 9 (intrinsic), 1, 4, 5 and 12 (ER stress). RT2 
Profiler PCR array for human apoptosis genes was used to explore additional 
changes in apoptotic gene expression.  Microarray analysis was performed using 
the Human OneArray® Microarray from Phalanx Biotech Group to determine 
which genes of other key cellular pathways were affected by L19.  Exposure of the 
DLD-1 cells to L19 for 6, 8, 12, and 24 hours and subsequent gene expression 
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analysis indicated primarily that ER stress was the mechanism of apoptosis along 
with inflammation.  The qRT-PCR results showed CASP 1 and 12 exhibited up-
regulation by 12 hours, after which, results from the RT² Profiler™ PCR array 
showed BCL2 an inhibitor for apoptosis down-regulated.  Apoptosis genes, CASP 
3, APAF-1 and BAX and those involved in ER Stress, BH3, FAS, and FASLG were 
up-regulated as were the genes involved in inflammation, CASP 1, 12. Based on 
these results, L19 induces ER stress, AIF pathway (apoptosis pathways) and 
inflammatory pathways were shown.  The microarray results show many more 
neurological, metabolic, and cell cycle processes affected by L19 that need to be 
investigated. 
 
 
 
 
 
 
 
 
 
 
  iii 
ACKNOWLEDGMENTS 
It was thanks to the incredible hard work of my professors and the support 
of the university staff that I was able to achieve such honors as the “Travel award” 
and admission to a Ph.D. program. Now, at the junction of ending of one era and 
beginning of a new one, I would like to show my deepest gratitude for my honorable 
professors, especially Dr. Clack, Dr. Taylor, and Dr. Parr, for their compassion and 
superb support. As my primary advisor, Dr. Clack has been somewhat of a mother-
figure to me, and she has been my pillar of strength. Furthermore, I would like to 
extend my special thanks to Dr. Mullin for his guidance. It was because of his 
confidence in me that I was able to work as a Laboratory Instructor and gain some 
of my best experiences. Additionally, I would like to thank my family, especially my 
parents and sisters, for their never-ending support and love, and all my friends, 
whose strength and mutual interest in science allowed me to overcome multiple 
obstacles in my professional or personal life. 
Research and exploration in the field of biotechnology has opened a new 
path in my life. It is my pleasure to share the heartwarming feeling of satisfaction 
from Stephen F Austin State University and its incredible professors. This great 
feeling encourages me to continue in this course; happier, determined and 
stronger than ever. 
  iv 
TABLE OF CONTENTS 
ABSTRACT ............................................................................................................... i 
ACKNOWLEDGMENTS ............................................................................................. iii 
LIST OF FIGURES ..................................................................................................... ix 
LIST OF TABLES ...................................................................................................... xii 
INTRODUCTION ...................................................................................................... 1 
Colorectal Cancer ................................................................................................... 1 
Apoptosis............................................................................................................... 2 
Extrinsic pathway ................................................................................................... 4 
Intrinsic pathway .................................................................................................... 5 
ER stress pathways ................................................................................................. 8 
DLD-1 Cell Line ..................................................................................................... 10 
Rumex crispus ...................................................................................................... 10 
Doxorubicin ......................................................................................................... 13 
Determination of Levels of Gene Expression by Quantitative Real Time PCR. ............ 14 
  v 
Use of Microarrays to Analyze Gene Expression in DLD-1 Cells................................. 15 
OBJECTIVES .......................................................................................................... 18 
MATERIALS AND METHODS ................................................................................... 19 
Media Preparation ............................................................................................... 20 
Cell culture........................................................................................................... 20 
Synchronization of Cells Prior to Dox or L19 Exposure ............................................. 21 
Acquiring Leaf Extract by Accelerated Solvent Extraction ........................................ 21 
Separation of Compound L19 by High Performance Liquid Chromatography ............. 22 
Gas Chromatography-Mass Spectrometry .............................................................. 23 
Optimization of the Number of Cells per well for Cell Viability Assays ...................... 23 
Measuring Dose-Response for L19 and Dox using Cell Viability ................................ 24 
Determination of Apoptosis Induction by Apoptotic Assay ...................................... 25 
Extraction of Total RNA of Treated and Untreated Cells for qRT-PCR ........................ 26 
cDNA Synthesis for Quantitative Real Time PCR...................................................... 28 
cDNA Purification ................................................................................................. 28 
  vi 
Quantitative Real Time PCR of cDNA Isolated from Untreated and Treated Cells at 
Different Time Points ............................................................................................ 29 
RT2 Profiler Human Apoptosis Array ...................................................................... 32 
Microarray Analysis- ............................................................................................. 35 
Fluorescent Labelling of cDNA- .............................................................................. 37 
Microarray Assay-................................................................................................. 38 
Hybridization- ...................................................................................................... 39 
Post Hybridization- ............................................................................................... 40 
Image Acquisition and Data Analysis-..................................................................... 40 
BRB-ARAY Tools ................................................................................................... 43 
RESULTS ............................................................................................................... 44 
Accelerated Solvent Extraction (ASE) ..................................................................... 44 
High Performance Liquid Chromatography (HPLC) .................................................. 44 
Gas Chromatography-Mass Spectrometry .............................................................. 46 
Optimization of Cell Viability Assay and Confirmation of Cytotoxicity of L19............. 46 
Dose-Response Assay ........................................................................................... 49 
  vii 
Induction of Caspase 3 and 7 and Cell viability of DLD-1 Cells Treated with Different 
HPLC Fractions ..................................................................................................... 54 
Induction of Caspase 3 and 7 and Cell Viability on DLD-1 by L19 .............................. 57 
Isolation of RNA ................................................................................................... 57 
cDNA Synthesis for qRT PCR .................................................................................. 60 
Determination of Changes in Caspase Gene Expression Using Quantitative Real Time 
PCR...................................................................................................................... 60 
RT² Profiler™ PCR Human Apoptosis Array ............................................................. 65 
Comparison of The Two qRT-PCR Results ............................................................... 71 
Microarray cDNA Quantification ............................................................................ 76 
Microarray Data Normalization Analysis ................................................................ 79 
Genes Affected by L19 .......................................................................................... 87 
DISCUSSION ....................................................................................................... 123 
Pathway 2: Inflammatory .................................................................................... 126 
Non-Apoptotic Genes Affected by L19.................................................................. 127 
REFERENCES ....................................................................................................... 129 
  viii 
APPENDIX I ........................................................................................................ 136 
APPENDIX II ....................................................................................................... 143 
VITA .................................................................................................................. 156 
 
 
 
 
 
 
 
 
 
 
 
  ix 
LIST OF FIGURES 
Figure 1.Intrinsic and extrinsic apoptosis pathways. ............................................. 7 
Figure 2. ER stress apoptosis pathway.. .............................................................. 9 
Figure 3. Rumex crispus plant sample used in this study harvested at 
31.6024865º N, 94.5677874º W in April, 2014. ........................................... 12 
Figure 4. Human OneArray v7 0412310923.. .................................................. 17 
Figure 5. Overview of materials and methods.. .................................................. 19 
Figure 6. RT2 Profiler Human Apoptosis PCR array (Cat no: PAHS-01Z) from SA 
Biosciences for analyzing 84 apoptosis and non-apoptosis (Qiagen, CA)... 34 
Figure 7. HPLC chromatograph of leaf ASE extract.. ......................................... 45 
Figure 8. GC-MS chromatograph of L19 compound (A) and Tetrahydrofuran 
molecular mass and structure (B). ............................................................... 47 
Figure 9. Cell viability of untreated DLD-1 Cells for optimizing the Aqueous One 
Assay........................................................................................................... 48 
Figure 10. Cell viability for treated DLD-1 Cells treated with different HPLC 
fractions. ...................................................................................................... 51 
Figure 11. Dose Response curve for L19. .......................................................... 52 
Figure 12. Dose Response curve for Doxorubicin. ............................................. 53 
  x 
Figure 13. Histogram of Caspase 3/7-fold change and percentage of cell viability 
by induction of HPLC Fractions DLD-1 cell Line. ......................................... 55 
Figure 14. Histogram of Caspase 3/7-fold change and percent cell viability in 
DLD-1 cells in response to different Dox concentrations.. ........................... 56 
Figure 15.  Caspase 3/7-fold change and percentage of cell viability by induction 
of L19 on DLD-1 cell Line.. .......................................................................... 58 
Figure 16. Quality Assessment of total RNA by 1% native agarose gel. ............ 59 
Figure 17.  qRTPCR of CASP Gene Expression in Response to L19 Exposure. y.
 .................................................................................................................... 64 
Figure 18. qRTPCR of DLD1 Cells Exposed to L19 at 6, 8, and 12 hours Using 
the RT2 Profiler Human Apoptosis PCR Array (Cat no: PAHS-01Z). .......... 70 
Figure 19.  Absorption spectra of Alexa Fluor® 555 labeled cDNA and Alexa 
Fluor® 647................................................................................................... 77 
Figure 20. Flip dye Histogram of distribution Alexa 555 vs Alexa 647 at different 
time points.. ................................................................................................. 80 
Figure 21. Scatter plots of the average distribution Alexa 555 vs Alexa 647 for 
raw intensity and log intensity at different time points in dye-swap 
experiment.. ................................................................................................. 81 
Figure 22. Specific intensity-dependent log (IB/A) plot (R-I plot). ....................... 83 
  xi 
Figure 23. Diagnostic plots for two different arrays in the dye-swap experiments. 
Blue scatter plots denoted Alexa 555 treated and Alexa 647 untreated and 
red plots represented Alexa 647 treated and Alexa 555 untreated DLD-1 
cells. ............................................................................................................ 85 
Figure 24. Hypothetical apoptosis pathway in treated colorectal cancer cells 
(DLD-1) by L19 through the qRT-PCR, and RT2 ProfilerTM PCR Array 
results for 6, 8, and 12 hours. .................................................................... 128 
 
 
 
 
 
 
 
 
  xii 
LIST OF TABLES 
Table 1. Caspase primer sequences obtained from the National Cancer Institute 
(NCI) primer database. ................................................................................ 31 
Table 2. Quality and total concentration of total RNA for representative L19 
treated and untreated DLD-1 cells at 6,8,12, and 24 hour exposure times.. 62 
Table 3.  cDNA isolated from L19 treated and untreated DLD-1 Cells at different 
time points of exposure for qRT-PCR. ......................................................... 63 
Table 4. RT² Profiler™ PCR Human Apoptosis Array (SA Biosciences, Cat no: 
PAHS-012Z) fold change (2-Ct) for 6, 8, and 12 hours. .......................... 67 
Table 5. Comparison of fold changes for CASP genes over different time 
intervals using RT² Profiler™ PCR Human Apoptosis Array (SA) and qRT-
PCR results (reported as means ± 1 SD). ................................................... 73 
Table 6. Summary of gene expression for three independent time points (Group) 
across genes for RT2 Profiler Human Apoptosis PCR array results. .......... 75 
Table 7. A two-factor analysis of variance for three independent time point 
groups (across genes) for RT2 Profiler Human Apoptosis PCR array results, 
that indicates F and P-value for total intensities of different time points and 
genes of RT2 Profiler Human Apoptosis PCR array results.. ...................... 75 
  xiii 
Table 8. Yield of labeled cDNA for both Alexa Fluor 555 and Alexa Fluor 647, 
amount of dye incorporation and frequency of incorporation (FOI) for two 
samples of treated and untreated cells. ....................................................... 78 
Table 9. Results of an analysis of variance for three independent time points 
groups for microarray gene expression results. ........................................... 86 
Table 10. Results of a one-way analysis of variance of three independent time 
points groups for Microarray gene expression results, F and P-value for total 
intensities of different time points for Microarray fold change results. ......... 86 
Table 11. Microarray genes affected by L19 at 6, 8, and 12 hours.. ................... 88 
 
  1 
INTRODUCTION 
Colorectal Cancer 
As reported by the American Cancer Society (ACS, 2017), colorectal cancer 
(CRC) is the third most common type of cancer in the world. Approximately 95,520 
Americans were diagnosed with colon cancer in 2017. CRC begins in either the 
colon or the rectum, sharing common symptoms and features. All data reported 
for the disease represent a combination of both cancers, collectively termed 
“colorectal cancer” (ACS, 2017) which are located in the ascending and transverse 
colon.  This region of colon is referred to as the proximal or descending and 
sigmoid colon, or the distal colon. According to the ACS (2017), the mortality rate 
attributable to CRC has decreased in the last two decades because of a decrease 
of red meat consumption and smoking, as well as an increase in the usage of 
aspirin.  In 2011, Zhang et al. showed that surgery followed by chemotherapy has 
been the most successful treatment to reduce the cancer. A recent study has 
shown various metabolites from plant tissue culture known as stilbenoids play a 
role in treating cancer (Redondo-Blanco et al., 2017).  Stilbenoids are inducible 
phenolic compounds produced as a self-defense mechanism against biotic and 
abiotic stresses in peanuts, grapes, and berries. In addition to their role in plant 
defense, they have potential applications in human 
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health because of their anticancer properties (Redondo-Blanco et al., 2017). 
Redondo-Blanco’s study illustrated the importance of stilbenoids in fruits and 
vegetables, using parsley as a model, to exhibit growth inhibition and cell cycle 
arrest in CRC (Redondo-Blanco et al., 2017).  Redondo-Blanco et al. (2017) 
showed that the addition of resveratrol enhanced the effects of 5-flourouracil in 
chemotherapy to induce apoptosis in CRC and inhibit its growth.  Identifying 
additional anti-cancer compounds from plants is necessary for enhancing 
chemotherapy effects and reducing harmful side-effects. Induction of apoptosis 
and not inflammation or toxicity is the focus of identifying new anticancer 
compounds from Rumex crispus, and is the focus of the study herein.  Previously, 
numerous extracts from Rumex crispus have been shown to contain compounds 
that induce apoptosis in CRC (Inkollu, 2007; Bhandari, 2015).  Apoptosis is a 
hallmark of cancer; cells failing to commit to apoptosis is one of the key reasons 
for the uncontrollable cell growth that leads to cancer (Gerl & Vaux, 2004).  
Apoptosis 
Apoptosis, cell death pathway, exhibits morphological characteristics 
including cell shrinking, membrane blebbing, chromatin condensation, and nuclear 
DNA fragmentation (Lowe & Lin, 2000). Abnormalities in apoptotic function drive 
both the pathogenesis of CRC and resistance to chemotherapy drugs and 
radiotherapy which are both vital in killing cancer cells (Riganti et al., 2005).  The 
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presence of several proteins in three major pathways, extrinsic, intrinsic and ER 
stress pathways, are key to cells undergoing apoptosis.  As a result, the proteins 
involved in apoptosis that have been mutated or whose expression has been 
down-regulated resulting in cancer formation are targets for the identification of 
new chemotherapy agents. There are several genes that are downregulated in 
CRC which should promote apoptosis, such as Bax, p53, CytC, and CASP9 
(AVIVA System Biology, San Diego, CA). Zhang et al. (2017) found that Apaf-1-
caspase 9 complex formation was associated with mitochondrial mediated TRAIL-
induced apoptosis (TNF-related apoptosis-inducing ligand) in cancer stem cells. In 
addition, cytochrome C inhibition in CRC led to a delay in apoptosis (Jing et al., 
2016).  Bhardwaj et al. (2016) found DNA damage in CRC treated with 5-Hydroxy-
7-methoxyflavone (HMF).  Cytochrome C was released from the mitochondria and 
Bcl2 proteins were inhibited.  Bhardwaj et al. (2016) reported a down regulation of 
Bcl2 protein which caused activation of BID, Bax and CASP3.   
There are three pathways that result in apoptosis: extrinsic, intrinsic, and 
ER stress. Each of these pathways are activated by cell death-receptors. Common 
to each pathway are the executioner caspases, 3 and 7; however, upstream, the 
pathways utilize different initiator caspases. Caspases 8 and 10 release DISC 
(death inducing signal complex) in the cytosol which can activate caspase 3 and 7 
(Malike et al., 2016). Caspase 3 must be cleaved by an initiator caspase 9 for 
activation (McIlwain et al., 2013).  Zhao et al. (2017) demonstrated that caspase 3 
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activation was dependent on the presence of caspase 5 (inflammatory caspase) 
in stretch induced apoptosis. Also, caspase 1 is activated by inflammasome factors 
such as HIN protein (hematopoietic expression, interferon-inducible nature) and 
NLR (nucleoid-binding domain, Leucine-rich repeat) which participate in 
autoinflammatory disease, tumor suppression and tissue repair (Man & 
Kanneganti, 2016).  In addition, Caspase 1, 4, and 5 are inflammatory caspases 
which can cause pyroptosis, a form of inflammation in humans to defend against 
bacterial, viral, or fungal infections (Man & Kanneganti, 2016). Caspase 12 
(inflammatory response) could also induce apoptosis by cleaving pro-caspase 3 
for activation (Zhang et al., 2016; McIlwain et al., 2013). 
Extrinsic pathway  
The extrinsic pathway is activated by death-receptors upon extracellular 
surface binding by ligands such as hormones, toxins, or growth factors (Figure 1). 
The death-receptors have 2 domains, one of which is an extracellular cysteine rich 
domain for ligand binding while the other is intracellular for transmitting apoptosis 
signals for the recruitment of effector caspases 8 and 10.  DISC is formed upon 
binding a pre-apoptosis ligand, tumor necrosis factor (TNF). TNF plays an 
essential role in the extrinsic pathway and can be either on the cell surface bound 
to its receptor or released into the extracellular space.  Pro-caspase 8 or 10 binds 
to DISC which then in turn activates caspase 8/10 resulting in cleaving procaspase 
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3, 6 and/or 7 with subsequent activation of caspase 3, 6 and/or 7. The extrinsic 
pathway has two different sub-pathways. The first pathway does not involve the 
mitochondria and occurs when pro-caspase 8 or 10 is produced and binds to DISC 
in the cells as described above. Conversely, the second pathway occurs when 
caspase 8 is not present (Figure 1) and instead, crosses over to play a role in the 
intrinsic pathway activating Bid through proteolysis (Favaloro et al., 2012).   
Intrinsic pathway  
The intrinsic pathway occurs intracellularly and causes the activation of 
caspase 3 and 7 via caspase 9. The intrinsic pathway is managed by Bcl-2 proteins 
and the mitochondria and is initiated by a response to stress signals such as heat 
and/or viral infection. Some factors, like growth factors, can cause activation of this 
pathway. For example, Patra et al. (2016) confirmed, that the high expression of 
Bax and cytosolic cytochrome C plus suppression of apoptosis by inhibiting 
caspase 9, prevented apoptosis indicating that the intrinsic pathway was the 
mechanism of apoptosis in liver cells treated with Parkia javanica HPLC extract. 
Patra et al. (2016) reported an up-regulation of p53, p21, Bax/BcL2, CytC and 
CASP9, all part of the intrinsic pathway of apoptosis.  Mitochondrial apogenic 
proteins are then expressed such as cytochrome C, apoptosis inducing factor and 
RNA/DNA endonuclease.  Cytochrome C is released from the mitochondria along 
with Apaf-1 and procaspase-9 to create the apoptosome complex. The 
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apoptosome complex cleaves procaspase-9 to the activated caspase 9 which in 
turn activates caspase 3, 6 and 7 after cleaving procaspases 3, 6 and 7 (Figure 1).  
  
  7 
 
 
Figure 1.  Intrinsic and Extrinsic Apoptosis Pathways. The intrinsic pathway is 
activated by many different forms of cellular stresses.  Activation is controlled by 
BH3 (a member of the Bcl-2 family) causing the release of CytC from the 
mitochondria which in turn activates caspase 9. The extrinsic pathway, which is 
the essential effector mechanism in the immune system, is activated by death 
receptors at the cell surface. When ligand binds to the cell membrane it forms a 
DISC complex that results in the activation of caspase 8. Caspase 8 and 9 activate 
caspases 3, 6, and 7 to initiate apoptosis (Favaloro et al., 2012). 
 
 
 
 
Apoptosis 
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ER stress pathways 
Bhardwaj et al. (2016) and Czabotar et al. (2014) demonstrated that 
endoplasmic reticulum (ER) stress plays an important role in apoptosis. 
Accumulation of unfolded proteins in the ER can cause stress to the ER resulting 
in the cellular machinery for transcription and translation to express the necessary 
factors for cell death, such as the Bcl-2-interacting domain (BID) and Bax proteins 
(Bhardwaj et al., 2016). The cell normally attempts to maintain homeostasis by 
removing unfolded proteins. However, cells can fail to properly remove unfolded 
proteins resulting in large amounts accumulating in the ER.  ER stress will also 
result in the up-regulation of the Bcl-2-interacting killer (BIK) and BID which 
determines the commitment of cells to apoptosis. Terminal activation of caspase 3 
and apoptosis is managed by the ER membrane-resident caspase 4 and 8 for ER 
stress induced apoptosis (Figure 2). Caspase 4 may directly activate caspase 3 
during ER stress induced apoptosis (Czabotar et al., 2014).  
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Figure 2. ER stress Apoptosis Pathway. ER stress is activated by ER membrane-
resident caspase 4, then caspase 4 activates caspase 8 by breaking pro-caspase 
8 and then caspase 8 cleaves pro-caspase 3 and induce caspase 3. Caspase 8 
also binds to the ER and mitochondrial membranes to cleave ER proteins Bap31 
producing Bap20. Cytochrome C is then released from the mitochondria. 
Cytochrome C activates caspase 9 then 8, followed by activation of caspase 3 
(Rosati et al., 2010). 
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DLD-1 Cell Line 
The cell line used in this study, DLD-1 which was originally isolated and 
established by Dexter et al. (1979), was purchased from the American Type 
Culture Collection (ATCC CCL-221TM).  DLD-1 cells are commonly used in 
colorectal cancer research, originally removed during surgery from a patient who 
did not use tumor suppression medication (Tibbettes et al., 1977).  DLD-1 cells 
contain a mutation in the p53 gene and overexpression of Cluster of Differentiation 
47 (CD47), which is also known as integrin associated protein (IAP; Rodrigues et 
al., 1990).  DLD-1 cells are characterized by mutations in C-MYC, K-RAS, H-RAS, 
N-RAS, MYB, SIS, and FOS which are pro-oncogenes and are part of the family 
of retroviral-associated DNA sequences (Ahmed et al., 2013). C-MYC and FOS 
code for a gene involved in cellular response to growth factors and nucleic acid 
metabolism. Overexpression of MYB and SIS which are coded transcriptional 
regulators cause tumors in humans. RAS (retroviral-associated DNA sequence) 
sequences correlated with Kristen-RAS, Harvey-RAS and Neuroblastoma-RAS 
have the same intron and exon and code for p21 protein.  
Rumex crispus 
Rumex crispus, in Family Polygonaceae, is a wild herbaceous plant 
commonly called yellow dock or French Sorrel (Figure 3).   Rumex crispus is found 
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in temperate climates and vegetates in acidic soil (Shiwani et al., 2012). This plant 
is native to Europe and Africa and has spread globally.  Its root has been shown 
to consist of anthraquinones and glycosides with a variety of tannins and oxalates 
that are poisonous (Wynn, 2007).  In a review by Wynn (2007), the leaves were 
utilized as a component of an herbal cancer remedy, Essiac tea in1930, but its 
medical use was not supported by most medical professionals. Studies elucidated 
that mixtures of this herb killed prostate cancer cells in vitro (Wynn, 2007). Other 
researchers found R. crispus to have anti-cancer and anti-inflammatory effects in 
animal models (Tokarnia el al., 2002). Specific water-soluble extracts of R. crispus 
leaf extract have demonstrated increased apoptosis in DLD-1 cells in particular 
L19, a HPLC fraction of the water-soluble extract and the focus of this study 
(Bhandari, 2015).  
  12 
                                        
 
Figure 3. Rumex crispus plant sample used in this study harvested at 31.6024865º 
N, 94.5677874º W in April, 2014. 
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Doxorubicin 
Doxorubicin (Dox) was used as a positive control in this study. Therefore, 
the effect of Dox on cell viability for inducing apoptosis was compared with the 
effect of L19 on the cells.  Dox is a chemotherapy drug that is an anthracycline, 
shown to slow or stop the proliferation of cancer cells by blocking topoisomerase 
II (Stewart & Wild, 2017). Dox has been shown to inhibit DNA polymerase activities 
and to suppress the Signal Transducer and Activator of Transcription 3 (STAT 3) 
signaling pathway (Jang et al., 2013).  Dox also has been shown to elicit the 
expression of p53 and Bax as well as expression of CASP9 and 3 in carcinoma 
cancer cells (A549; Sørensen et al., 2016). Dox has shown activation of caspases 
and disruption of the mitochondrial membrane (Eom et al., 2005) suggesting the 
intrinsic pathway is induced. Jang et al. (2013) demonstrated swelling and 
apoptotic shrinkage in human myeloma cells treated with Dox. In addition, Dox has 
been shown to induce apoptosis in DLD-1 cells (Sonavane, 2012; Kandaveeti, 
2015).  
Different concentrations of Dox show different effects depending on the cell 
type. A low dose (50 ng/mL) of Dox in human hepatocarcinoma cells (Huh-7) in 
culture showed down-regulation of mitotic proteins such as CENP-A/Mad 2 
(Centromere protein-A/Mitotic arrest deficient 2 gene), BudR1 (mitotic checkpoint 
kinase gene) and ChK1 (Checkpoint kinase 1 gene). A high dose of Dox at 
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10µg/mL, however, shows activation of NF-kβ, p53, c-Jun, and CASPs. Thus, both 
low and high doses of Dox demonstrate apoptosis in the Huh-7 cell line by 
releasing cytochrome C from the mitochondria to the cytosol (Eom et al., 2005).   
Determination of Levels of Gene Expression by Quantitative Real Time PCR.  
Quantitative Real Time PCR (qRT-PCR) allows for the quantification of 
gene expression by measuring the amount of double strand DNA products after 
each amplification cycle of the cDNA template. The detection is based on the 
increase in fluorescence attributable to either SYBR green present in the reaction 
mix or fluorescently labeled primer pairs.  The SYBR green detection was utilized 
in this study. SYBR green binds nonspecifically to double stranded DNA producing 
a fluorescent signal. The more amplicon produced, the higher the relative 
fluorescence signal (RFU).   qRT-PCR can be used to calculate the level of gene 
expression with high detection sensitivity, specificity, reproducibility and precision 
(Kralik & Ricchi, 2017). The housekeeping genes such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and/or β-actin were used to normalize the 
gene expression of the genes being analyzed. The work presented here in, utilizes 
qRT-PCR with the following 1) primer pairs complimentary to CASP1, 3, 4, 5, 6, 7, 
8, 9,10 and 12; and 2) gene specific primers for 84 apoptotic related genes in the 
commercially available RT2 Profiler Human Apoptosis array (SA Biosciences, 
Qiagen Corp., CA).  Already knowing that L19 induces apoptosis (Bhandari, 2015), 
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qRT-PCR was used to determine which apoptosis pathways were induced within 
the DLD-1 cells after 0, 6, 8, 12, 16 and 24 hrs exposure to L19 and compared to 
gene expression in untreated cells.  The 2-Ct was determined for apoptosis 
specific gene expression over time of exposure of DLD-1 cells to L19. 
Use of Microarrays to Analyze Gene Expression in DLD-1 Cells. 
Microarrays were utilized for monitoring gene expression and gene pattern 
profiling.  Microarrays are plastic or glass slides which contain a grid on the 
surface. Each grid depends on the research purpose and can have thousands of 
synthetic short single strand DNA sequences spotted within.  The spots of 
oligonucleotides of known sequence complimentary to the target cDNA along with 
spot controls are located in discreet rows and columns for identification.   
Microarray assays are used for examining gene expression and determining 
which genes are being expressed or suppressed in different cells or tissues such 
as cancer cells.  The information obtained from microarray analysis has been used 
to prescribe the best chemotherapy drugs for different cancers (Potaman & 
Sinden, 2000).  Huang et al. (2016) examined levels of gene expression in different 
CASP genes such as, CASP 8, 3, 4, 6, 7 and confirmed Fas and mitochondria-
mediated pathways were active through the analysis of microarray results for HL-
60 cells treated by 18 α-glycyrrhetinic acid (18α-GA) 
  In this study, whole human genome microarrays were used to detect the 
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effects of L19 on the mRNA expression of genes representing major cellular 
pathways in the DLD-1 cells.  The Human OneArray v7 (OneArray Corp. CA) 
was utilized to compare the gene expression of 29,000 human genes in the treated 
cells as compared to the untreated DLD-1 cells.  This data suggests a mechanism 
of action of L19 in the DLD-1 cells as well as to confirm specific apoptosis pathways 
in DLD-1 cells.  A reciprocal labelling method called dye-swap method was used 
with two dyes and two arrays for each sampling to account for dye bias and to 
serve as replicates within the microarray experiment. Oligonucleotides 
representing 29,000 human transcriptomes were spotted in a 50 ×16 mm area on 
a 25.1 x 72 mm flat glass slide (Figure 4). Spot layout per block was 112 columns 
x 350 rows with X, 142.8 µm Horizontal and Y, 142.8 µm Vertical spot pitch and 
80 ± 10 μm diameters. Each Human OneArray v7 was barcoded by the 
manufacturer for tracking and identification.  
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Figure 4. Human OneArray v7 0412310923. Oligonucleotides of human 
transcriptomes spotted on a 50 ×16 mm area on a 25.1 x 72 mm flat glass slide.  
The grid was composed of one block of 112 columns by 350 rows. 
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OBJECTIVES 
Objective 1. Extract a large amount of L19 using ASE and HPLC.  L19 was 
isolated utilizing the methods established by Bhandari (2015).  
Objective 2. Obtain four independent fractions from the L19 isolates.  
Objective 3. Identification of the apoptosis pathways in DLD-1 cells induced 
by L19.  qRT-PCR was used with the caspase gene specific primers for CASP8, 6 
and 10 to recognize the extrinsic pathway; Caspase 9 for the intrinsic pathway; 
and caspase 4, 5 and 12 for ER stress pathway (Nakagawa et al., 2000). 
Additionally, gene expression of caspase 1, 3, and 7 were determined. The cDNAs 
of treated and untreated cells after 0, 6, 8, 12 and 24 hr. exposure to L19 were 
used as template. 
Objective 4. The fourth goal of this research was to use Microarray analysis 
of the entire human transcriptome to determine if the genes of other key cellular 
pathways were affected by L19. As in Objective 3, cDNA of treated and untreated 
cells was used as a template, however, the cDNA in the microarray experiments 
were fluorescently labeled for dye swap experiments. 
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MATERIALS AND METHODS 
 
Figure 5. Overview of materials and methods. Rumex crispus leaves were 
extracted by Accelerated Solvent Extraction and analyzed by High Performance 
Liquid Chromatography.  The compound L19 was identified by Gas 
Chromatography-Mass Spectrometry. The percentage of cell viability of DLD-1 
cells remaining after treatment with L19 was calculated. Apoptosis assays were 
used to detect the level of caspase 3/7 present. Then qRT-PCR and Microarray 
technique were used to identify the apoptosis pathways in colorectal cancer cells.
Rumex crispus 
leaf  
ASE 
HPLC 
L-19  
q-RT-PCR 
Microarray  
er 
Cell- Viability  
Apoptosis assay  
GC-MS 
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Media Preparation  
Roswell Park Memorial Institute (RPMI) Media 1640 (Gibco Thermo Fisher 
Scientific, Waltham, MA, USA) consisting of 300 mg/L of L-Glutamine 
supplemented with 10% (v/v) Fetal Bovine Serum (FBS) (Atlanta Biologicals, 
Norcross, GA, USA) was used as cell culture medium. Penicillin and streptomycin 
antibiotics were added to a final 100 U/ML and 0.1 mg/mL, respectively. This media 
was referred to as RPMI-plus. 
Cell culture 
DLD-1 human colorectal cells (ATCC CCL-221TM) were originally 
purchased from the American Type Culture Collection (ATCC, Manassas, VA) and 
stored in liquid nitrogen. Cells were thawed at 37°C using a water bath and plated 
into 10 cm2 polystyrene tissue culture dishes consisting of 20 mL of RPMI-plus. 
Cells were incubated at 37°C in a humidified 6% CO2 incubator. The media was 
changed every 2 to 3 days until cell growth reached approximately 85% confluent 
at which time the cells were subcultured and split 1 into 3 plates to proliferate cells
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for storage and for the assays described below. Sub-culturing consisted of 
trypsinizing the cells with 0.25% (1x) Trypsin solution (JR Scientific Inc., Woodland, 
CA) using standard cell culture techniques (Bhandari, 2015).   
Synchronization of Cells Prior to Dox or L19 Exposure 
Cells were cultured with RPMI-plus medium and incubated at 37°C in a 
humidified 6% CO2 incubator for approximately 6 hours until they attached to the 
polystyrene tissue culture dishes. Then, media was discarded and replaced with 
RPMI-plus without FBS and placed in the incubator for 24 hours. After this period, 
cell recovery was achieved by replacing old medium with RPMI-plus containing the 
FBS and incubated for 12 hours.  Cells were then ready for being treated by either 
L19 or Dox. 
Acquiring Leaf Extract by Accelerated Solvent Extraction  
Rumex crispus, harvested by Bhandari in 2014 and stored in a -80°C 
freezer, was used as the sample source for these studies. Three grams of leaf 
powder obtained from liquid nitrogen pulverizing were weighed, mixed with sand 
at a 1:2 ratio and loaded into an 11-mL stainless steel extraction vessel according 
to the instruction manual for the Dionex Model ASE200 (Dionex Corp., Sunnyvale, 
CA, USA) Accelerated Solvent Extraction system (ASE). The extractions were 
performed at 85°C oven heat at 1500psi for 5min for three 11 mL cycles with a 
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final pooled elution volume of 35 mL. Deionized water and compressed nitrogen 
were used as solvent and to pressurize the system respectively. The extract was 
transferred to 50 mL polypropylene conical tubes and lyophilized using a Labconco 
Lyph-Lock 6 Lyophilizer Freeze Dryer (Labconco Corp., Woburn, MA). 
Separation of Compound L19 by High Performance Liquid Chromatography 
Twenty-five milligrams of lyophilized ASE extract were measured and suspended 
in 1 mL of 95% acidified water (pH 2.2) plus 5% acetonitrile (ACN). This extract 
was filtered through a 0.2-micron filter and transferred to a 1 mL HPLC sample 
vial.  Acidified deionized H2O at pH 2.2 with HPLC grade phosphoric acid and 
HPLC grade acetonitrile (ACN) were utilized as solvent A and B, respectively. A 
sample volume of 100 µL was injected onto a Zorbax® Eclipse Plus 18, 3.5 µm, 
4.6 ×100 mm column (reverse phase C18) with an AlphaBond C18 10-micron 
Supelco® guard column attached (Sigma-Aldrich, St. Louis, MO, USA). Peak 
fractions were separated using a Waters 2695 HPLC Separation Module and 
detected at 210 nm using a Waters 2487 Lambda Dual Absorption detector 
(Agilent Corp., Santa Clara, CA). The eluate was collected at 1 mL/min in 1 mL 
aliquots at room temperature, labeled and stored in the dark at -20°C.  All fractions 
were collected with fraction 19 being utilized for downstream experiments.  Other 
fractions were lyophilized and stored at -80°C for future experiments. HPLC was 
continually repeated to accumulate enough L19 for downstream experiments.  
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Gas Chromatography-Mass Spectrometry 
Gas chromatography-mass spectrometry (GC-MS) was used to identify the 
chemical composition of L19 and its purity. Four independent isolations of L19 
samples were individually collected in 1.5 mL microfuge tubes, frozen in -80ºC 
overnight then lyophilized and were sent to the Moore Analytical Lab (Houston, 
Texas).  GC-MS was performed for each sample resulting in four replicate 
determinations.  Acetonitrile was used as the solvent.  The sample volume 
analyzed was 10 µL.  
Optimization of the Number of Cells per well for Cell Viability Assays 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega Corp., Madison, Wl, USA) was used to determine the number of viable 
cells during maintenance of the cells and in parallel to dose response assays. This 
method uses 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium and Phenazine Methosulfate (PMS) as substrate in 
cells with intact mitochondria and electron transport chains (Promega Corp., 
Madison, Wl, USA).  The MTS is oxidized to a Formazan product detected at 490 
nm. As per the instructions, 20 µL of AQueous One Solution was added to cells 
containing 100 µL of RPMI-plus in each well of a 96 well assay plate.  The cells 
were incubated at 37C, 6% CO2 for 1-4 hours. Each hour, the absorbance in the 
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wells was measured at 490 nm.  Assays were optimized by varying the number of 
cells per well (103, 104, 2x104, 105 cells/well) and the time of incubation of cells in 
the substrate. The number of cells and time of incubation that resulted in the 
absorbance being less than 1 were chosen for optimal results. Because the 
Aqueous One assay detected only the live cells, standard trypan blue staining 
(GMP-Compliant Corp, Grand Island, NY) was also used to detect the number of 
living and dead cells during routine subculturing of cells. Viable cells are 
impermeable to the dye whereas dead cells are permeable and take up the dye 
(Promega Corp., Madison, WI, USA).  Trypan blue staining provided the ratio of 
live to dead cells which was needed for normalization of the viability assays and 
the apoptosis assays. 
Measuring Dose-Response for L19 and Dox using Cell Viability  
For every experiment where cells were treated with varying concentrations 
of L19 or Dox, cell viability of treated as compared to untreated cells were 
determined in order to generate a dose response curve. Cells were seeded into 
96-well tissue culture plates at the density of 1x104 cells/well in triplicate with 
200µL of RPMI-plus media and incubated for 20 hrs at 37C, 6% CO2 to attach to 
the well surface. The medium was removed followed by addition of 200 µL of 
RPMI-plus containing 10-fold dilutions ranging from 100 to 107 of either Dox at an 
initial concentration of 26.8 mM or L19 at 27.73 µM followed by incubation at 37C, 
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6% CO2 for 24 hours. The negative control for the dose response assays was 
RPMI-plus only and the positive control was Dox.  After 24 hours, the medium was 
removed and 10 µL of Aqueous One solution reagent and 100 µL of RPMI plus 
media was added to each well and incubated at 37C, 6% CO2 for 4 hrs. The 
absorbance was measured at 490 nm in order to calculate the percent viability of 
the treated cells relative to the untreated cells using the following formula: 
                                            Absorbance of treated cells (At) 
Percent of cell viability (%) =   -------------------------------------------------    x100      (1) 
                                                           Absorbance of untreated cells (Aut)  
At was the absorbance at 490 nm obtained from the treated cells.  Aut was the 
absorbance at 490 nm for the untreated cells.  
Determination of Apoptosis Induction by Apoptotic Assay 
The Apo-ONE™ Homogeneous Caspase-3/7 Assay (Promega Corp., 
Madison, WI, USA) was used to detect the level of caspase 3/7 induction in 
response to L19 and DOX (positive control). Based on the cell viability assay 
results, the cell culture plate was seeded with 1x104 DLD-1 cells/100 µL/well and 
was incubated in 6% CO2 at 37°C overnight. The media was then removed.  The 
positive control contained 100 µL of 50 µM DOX (Sigma-Aldrich, St. Louis, MO, 
USA) in RPMI-plus while the negative control was the untreated cells. The 
unknown was the L19 at varying concentrations starting at 27.73 and 30.5 µM. The 
plate was incubated in 6% CO2 at 37°C for 24 hours. The media from all wells was 
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removed and replaced with 25 µL of fresh RPMI-plus media. A working solution of 
Apo-ONE homogenous caspase-3/7 reagent (Promega Corp., Madison, WI, USA) 
was prepared by mixing the caspase-3/7 substrate, Z-DEVD-rhodamine 110 
conjugate and a lysis buffer provided according to the manufacturer’s technical 
bulletin #TB323 (Promega Corp., Madison, WI, USA). In each well, 25 µL of the 
working solution was added, mixed and incubated in the dark for one hour at room 
temperature as described previously by Bhandari (2015). The fluorescence was 
measured using the Typhoon™ FLA9500 (GE Healthscience, Pittsburgh, PA) with 
excitation at 499 nm and emission at 521 nm.  The trypan blue staining was used 
to provide the number of live to dead cells remaining after exposure with either L19 
or DOX and for normalization of Apo-ONE assays and large scale L19 or Dox 
treatment.    
Extraction of Total RNA of Treated and Untreated Cells for qRT-PCR  
The total RNA was extracted from three 10 cm2 plates of 106 DLD-1 cells 
for each time point using the TRizol® Plus RNA purification kit (AmbionTM Corp., 
Austin, TX).  After treating the cells with L19, the total 10mL of media on the cells 
in the 10 cm2 plates was collected into 15 mL conical tubes to collect any dead 
cells and/or floaters. The cells were removed from the plate surface with 0.25% 
(1x) trypsin solution (JR Scientific Inc., Woodland, CA, USA) and then collected in 
the same tube as any dead cells and centrifuged at room temperature for 5 minutes 
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at 256xg.  The media was then removed followed by the addition of 1 mL of 
TRIzolTM Reagent (ThermoFisher Scientific Corp., Grand Island, NY) pre-chilled to 
4°C.  The lysate was either stored at -80°C or incubated at room temperature for 
5 minutes after mixing well.  For every 1 mL of TRIzol, 200 µL of chloroform was 
added and incubated at room temperature for 2-3 minutes. Samples were then 
centrifuged for 15 minutes at 12,000xg at 4°C.  The RNA contained in the upper 
layer solution was transferred to a new 1.7 mL microcentrifuge tube to which an 
equal volume of 70% ethanol was added and mixed well.  The solution was added 
in 700 µl increments to a spin cartridge provided in the Invitrogen PureLink RNA 
Mini Kit and processed according to the manufacturer’s instructions (AmbionTM, 
Corp, Austin, TX).  After incubating with 50µL of RNAase free water for 1-2 
minutes, the RNA was eluted by centrifuging at 12000xg for 2 minutes.  The RNA 
was stored at -80°C.  A native 1% w/v agarose gel in TAE buffer (40 mM Tris-
acetate, 1 mM EDTA) was used to check the quality of the RNA followed by 
quantification of the RNA using a Varian Carry 50 spectrophotometer (Agilent 
Corp., Santa Clara, CA).  RNA concentrations were determined using the following 
formula: 
RNA concentration (µg/mL) =Abs260 x pathlength x Dilution Factor x 40 µg/mL                            (2) 
(Promega Corp., Madison, WI, USA)      
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cDNA Synthesis for Quantitative Real Time PCR 
GoScriptTM reverse transcriptase (Promega Corp., Madison, WI) was used 
to synthesize complementary DNA (cDNA) for quantitative Real time PCR (qRT-
PCR).  According to the manufacturer’s instructions, GoScript reverse 
transcriptase can convert up to 5 µg of total of RNA to first strand cDNA. 
Approximately 5 µg of total RNA was converted to cDNA in each process.  A 
BioRad Mycycler thermocycler was used for all incubations.  To synthesize the 
cDNA, the reverse transcriptase reaction was incubated at 42°C for 3 hours 
instead of one hour as suggested by the manufacturer.  The RNA was then 
hydrolyzed by adding 15 µL of 1N NaOH and incubated at 70°C for 10 minutes. 
The reaction was neutralized by adding 15 µL of 1N HCL with subsequent 
purification.  
cDNA Purification  
The cDNA was purified using the Wizard® SV Gel and PCR Clean Up 
System (Promega Corp., Madison, WI).  Equal volumes of membrane binding 
solution were added to the cDNA mixture and mixed. The mixture was transferred 
to a spin cartridge, incubated for 1 minute at room temperature, and then 
centrifuged at 16000 rpm for 1 minute.  The spin cartridge was transferred to the 
recovery tube, then 50 µL of nuclease free water was added and incubated for 5 
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minutes at room temperature.  The recovery tubes were centrifuged at 16000xg 
for 2 minutes. The eluate was stored at -80°C.  The cDNA was quantified using 
the Varian Carry 50 spectrophotometer (Agilent Corp., Santa Clara, CA).  The 
cDNA concentration was calculated using the following formula:   
 cDNA concentration (µg/mL) = A260 x pathlength x dilution factor x 37 µg/mL                          (3)    
(Promega Corp., Madison, WI, USA)    
Quantitative Real Time PCR of cDNA Isolated from Untreated and Treated Cells 
at Different Time Points 
The cDNA was used as a template in qRT PCR to determine the fold change 
in gene expression of CASP1, 3, 4, 5, 6, 7, 8, 9, 10 and 12. Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH), a housekeeping gene which shows no 
changes in gene expression after DOX treatment, was used for normalization of 
the qReal-Time PCR data. The respective caspase gene specific forward and 
reverse primers, listed in Table 1, were added to a final concentration of 0.5 µM 
and 10 µL of 2X SYBR Green Master Mix which contained the Taq and the dNTPs 
(Promega Corp., Madison, WI).  cDNA (20 ng) and nuclease free water were 
added to obtain 20 μL final volume per well. The RT PCR conditions, determined 
previously by Kondaveeti (2015), were:  An initial denaturation at 95°C for 10 min 
followed by 40 cycles of denaturation temperature at 95°C for 30 sec, annealing 
temperature at 60°C for 60 sec and an extension temperature at 72°C for 30 sec. 
Detection of amplicons was programmed after each annealing step.  A melting 
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curve from 65°C to 95°C was programmed to occur for each well after the 
completion of the PCR to ensure that only one size amplicon was produced by 
each primer pair and therefore, specific binding of primers to the template.   
The qRT-PCR resulted in Ct (Cycle threshold) values for each gene 
expressed in proportion to the copy number for the respective cDNA.  Both 
untreated and treated cDNAs were used as templates.  The ΔΔCt values for each 
cDNA were determined using the following formulas for cDNAx (X is the respective 
gene): 
 
Ct Untreated - Ct GAPDH Untreated = ΔCt Untreated                   (4) 
Ct Treated - Ct GAPDH Treated = ΔCt Treated                   (5) 
ΔCt Treated - ΔCt Untreated = ΔΔCt of cDNAx                   (6) 
 
The 2-Ct of each caspase cDNA represented the fold change in gene expression 
(Schmittgen & Livak, 2008) and in this case, which caspases were up-regulated or 
down-regulated in response to L19.  
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Table 1. Caspase primer sequences obtained from the National Cancer Institute 
(NCI) primer database. The respective forward and reverse primer pairs were used 
in the qRT-PCR. Primers were designed to give a PCR product of 200 bp +/- 10. 
Primers for caspase 12 were not found at the NCI primer database and therefore 
were designed using NCBI Primer-BLAST (Ye et al., 2012).  
Primers Primer Sequences Accession Numbers 
CASP3(Forward) 5’AGAACTGGACTGTGGCATTGAG NM_032991 
CASP3(Reverse) 5’GCTTGTCGGCATACTGTTTCAG NM_032991 
CASP4(Forward) 5’ATGGCAGGACAAATGCTTCT NM_033306.2 
CASP4(Reverse) 
 
5’TGCGGTTGTTTCTCTCCTTT NM_033306.2 
CASP5 (Forward) 5’CTGGGCTACACTGTGGTTGA NM_001136112.1 
CASP5 (Reverse) 5’GCAGTTGCGGTTGTTGAATA NM_001136112.1 
CASP6 (Forward) 5’AAGAGGAGGGCAAGGTGTCT NM_000305.2 
CASP6 (Reverse) 5’GCAATTCCTCTCCTCCTGTG NM_000305.2 
CASP7 (Forward) 5’TCAGTGGATGCTAAGCCAGA NM_001267056.1 
CASP7 (Reverse) 5’GAACGCCCATACCTGTCACT NM_001267056.1 
CASP8 (Forward) 5’CGGAATGTAGTCCAGGCTCA NM_001080125.1 
CASP8 (Reverse) 5’GGTCACTTGAACCTTGGGAA NM_001080125.1 
CASP9 (Forward) 5’CACGGCAGAAGTTCACATTG AB026979.1 
CASP9 (Reverse) 5’ACACCCAGACCAGTGGACAT AB026979.1 
CASP10 (Forward) 5’GGGAGGTAAAGCTGTGGTTG NM_032974.4 
CASP10 (Reverse) 5’GCCGAGTCGTATCAAGGAGA NM_032974.4 
CASP12 (Forward) 5’CCATCCAACGGTGTTCTGGT NM_001191016.2 
CASP12 (Reverse) 5’GCCTGCAATTTGAGCTGTCT NM_001191016.2 
GAPDH (Forward) 5’GAGTCCACTGGCGTCTTCA NM_001289746.1 
GAPDH (Reverse) 5’GGGGTGCTAAGCAGTTGGT NM_001289746.1 
  
32 
RT2 Profiler Human Apoptosis Array 
RT2 Profiler Human Apoptosis PCR array (Cat no: PAHS-01Z) from SA 
Biosciences (Qiagen, CA) was used to analyze 84 apoptosis and non-apoptosis 
genes in untreated and L19 treated DLD-1 cells.  Gene specific primer pairs were 
provided in the 96-tube plate to which 10 µL of 2X SYBR green master mix 
(Promega Corp., Madison, WI) and 20 ng cDNA template, provided buffer and 
nuclease free water were added to have a 20 µL final reaction volume.  The cDNA 
for either untreated or treated samples was prepared as a master mix and 
distributed into the 96 tubes within the plate. The plates were sealed with a thin 
plastic film and centrifuged at 300xg for 5 minutes to remove any bubbles then 
placed into a BioRad CFX96 Real-Time PCR thermocycler with the same setup as 
the qRT-PCR described above.  
One 96-tube plate was used for the cDNA isolated from the treated cells 
and another 96-well plate was used for the cDNA isolated from the untreated cells 
for each respective time point.  This was done for normalizing the data at each of 
the different time points.  Based on Figure 6, the plate contained 84 apo- and non-
apoptosis genes and controls which are listed in Appendix I. The controls included 
housekeeping genes (HK), Genomic DNA Contamination (GDC), Reverse 
Transcription Control (RTC) and Positive PCR Controls (PPC). There were 5 
different HK for normalization of the data. Of these, only those that did not change 
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because of the treatment over time were used in the normalization; HK should not 
change between treated and untreated cells. The HK genes were located in wells 
H1-H5 (Figure 6). GDC, located in well H6, had the purpose of detecting non-
transcript genomic DNA. RTC (wells H7-H9) and PPC (wells H10-H12) measured 
the efficiency of the RT2 Profiler array reaction and PCR, respectively (Figure 6).  
For data analysis, the www.sabiosciences.com website was used. At this 
website, under the resource tab, the data analysis option was chosen. Then, Web-
based software for Cataloged and Custom Arrays was chosen under the RT2 
Profiler PCR array option. Standard RT² PCR Array was selected under the 
Experiment Performed section and the code Cat no: PAHS-012Z was used for the 
Cataloged PCR Array.  Ct values from RT-PCR of treated and untreated cells were 
both saved in one single Excel sheet in XLS format as per the template provided 
then uploaded into the software available at the SA Biosciences website (Qiagen 
Corp., CA). 
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Figure 6. RT2 Profiler Human Apoptosis PCR array (Cat no: PAHS-01Z) from SA 
Biosciences for analyzing 84 apoptosis and non-apoptosis (Qiagen, CA). Controls 
included Housekeeping genes (HK), Genomic DNA Contamination (GDC), 
Reverse Transcription Control (RTC) and Positive PCR Control (PPC). There were 
5 different HK to normalize data because HK should not change between treated 
and untreated cells, they were located in wells H1-H5. GDC had the role of 
detecting non-transcript genomic DNA in well H6. RTC (wells H7-H9) and PPC 
(wells H10-H12) controlled the efficiency of RT2 Profiler array reaction and PCR, 
respectively.  The specific genes targeted in each well are listed in Appendix I. 
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Microarray Analysis- 
Synthesis of Labeled cDNA for Microarray-  
SuperScript™ Plus Indirect cDNA Labeling System was used to create 
cDNA for microarray analysis.  This system was used to transcribe 5-20 µg of total 
RNA to first strand cDNA. Approximately 5 µg of total RNA was used for cDNA 
synthesis.  The SuperScript™ protocol was used to prepare a 50x amino-allyl-
dUTP (aa-dUTP) plus dNTP mixture in lieu of using the indirect labeling kit aa-
dNTP mix as shown below (SuperScript® Indirect cDNA kit, ThermoFisher 
Scientific).  This was done to increase the frequency of incorporation (FOI) of the 
amino allyl dUTP for labeling.  First, the following solution was prepared: 
 
 
50X Amino allyl dNTP mixture: 
         Stock                          Volume  Final Conc. (µM) 
100mM dATP                         10 µL                         25 µM 
100mM dCTP                         10 µL                         25 µM 
100mM dGTP                         10 µL                         25 µM 
100mM dTTP                            2 µL                         50 µM 
50mM aa-dUTP                        8 µL                         10 µM 
                                                               __________ 
                                                                      40µL 
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The Total RNA and primer were pre-annealed in a priming reaction as follows: 
Priming Reaction: 
Anchored Oligo dT    2.5 µg/µL each                  2 µL 
Total RNA (Untreated/ Treated)  2-5 µg                                x µL 
DEPC-treated water                                                                x µL 
                                                     ______ 
                                                                          18 µL 
 
The priming reaction was well mixed and heated at 70°C for 5-8 minutes. Then, 
immediately chilled on ice for 1-5 minutes, centrifuged 10 seconds at 10,000 rpm 
and stored on ice until the RT reaction mix was ready.  
The RT reaction mix was prepared as follows according to the manufacturer’s 
instructions.   
RT Reaction Mix: 
5X First-Strand buffer                                           6 µL  
1 M DTT                                                              1.5 µL  
dNTP mix (50X amino allyl dNTP mix)                1.5 µL  
RNaseOUT™ (40 U/µl)                                1 µL  
SuperScript™ III RT (400 U/µl)                    2 µL  
                                                                   ______ 
                                                                              12µL            
           
The RT Reaction Mix was gently mixed with the annealing mix and 
then heated at 46°C for 2-3 hours.  The RT was inactivated by adding 15 µL 1N 
NaOH followed by neutralization with 15 µL of 1N HCl.  The cDNA was purified 
using the Wizard® SV Gel and PCR Cleanup System (Promega Corp., Madison, 
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WI) as described previously for the cDNA prepared for qRT-PCR. The cDNA was 
quantified using the Cary50 Spectrophotometer as described before.             
Fluorescent Labelling of cDNA- 
Prior to labeling, 2 µg of the amino allyl cDNA from above, was divided into 
two different light protective 1.5 mL microfuge tubes.  Each tube was then vacuum 
dried using a Dynavap v1000 (National Labnet Co., Inc., Woodbridge, NJ) at 45C 
for one hour. One fraction (1 µg) was labeled with an amino reactive Alexa Fluor™ 
that emits at 550 nm (green). The other fraction (1 µg) was labeled with Alexa 
Fluor™ emitting at 647 nm (red) (ThermoFisher Scientific Corp., Grand Island, 
NY). The amino allyl labeled cDNA from both untreated and treated cells was 
labeled as follows:  The cDNA was resuspended in 5 µL of nuclease free water 
and 3 µL of sodium bicarbonate buffer pH 8.5.  The dyes were resuspended in 2 
µL of dimethylsulfoxide.  The cDNA and dyes were mixed together and then 
vortexed.  The tubes were then incubated in the dark at room temperature for 1 
hour.  Hydroxylamine (4M) was added to a final concentration of 0.06 M to quench 
the unreacted dyes. The cDNA was neutralized by adding sodium acetate (NaOAc) 
pH 3.5 to a final concentration of 10mM.  The labeled cDNA was purified from the 
unreacted dye and salts using a Wizard® SV Gel and PCR Cleanup System 
according to the manufacturer’s protocol (Promega Corp., Madison, WI).   
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The amount of cDNA (ng) and dye incorporated was calculated using the 
following equations provided in the SuperScript® Indirect cDNA manual 
(ThermoFisher Scientific): 
 
Amount of cDNA (ng) = A260 X 37 ng/µL x path length x dilution factor x total volume (µL)        (7) 
pmole of Cy3 Alexa Fluor® 555 dye incorporated = (A555 X Total Volume (µL)) / 0.15         (8) 
pmole of Cy5 Alexa Fluor® 647 dye incorporated = (A647 X Total Volume (µL)) / 0.25        (9) 
 
The above equation used an absorption coefficient of 150,000 M-1cm-1 at 
555 nm for the Alexa Fluor® 555 and an absorption coefficient of 250,000 M-1cm-
1 at 647 nm for Alexa Fluor® 647 (Thermo Fisher Scientific Corp., Grand Island, 
NY).  The Frequency of Incorporation (FOI) is the number of dye labeled 
nucleotides in the cDNA per 1000 nucleotides of total cDNA. The FOI was 
calculated using the following equation:  
FOI = (pmole of dye Incorporated) X 324.5 g/mole/ng of cDNA        (10) 
Microarray Assay- 
The microarray assay was a dye swap assay using the Human 
OneArray®v7 (OneArray Corp., San Diego, CA) and therefore, two arrays were 
prepared for hybridization for each analysis.  
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Hybridization- 
The experimental design consisted of a dye swap where one array was 
hybridized with 1 μg of cDNA from untreated cells labeled with a 550 nm emitting 
Alexa FluorTM (green) and 1 μg of cDNA from treated cells labeled with a Alexa 
FluorTM that emits at 647 nm (red).  The second array was hybridized with the 
Alexa FluorTM labeled cDNAs swapped; the cDNA from the untreated cells was 
labeled with the 647 nm Alexa FluorTM and the cDNA of the treated cells labeled 
with the 550 nm fluor.  Each mixture was prepared in a 1.5 mL microfuge tube and 
vacuum dried in the dark, 45ºC, using a Labnet DyNA Vap Centrifugal Evaporator 
V-1000 (Labnet International Corp., Edison, NJ). 
The hybridization buffer consisting of freshly prepared 50% formamide, 5X 
saline sodium citrate (SSC), 0.1% SDS, and Sheared Salmon Sperm DNA (10 
µg/ml) was preheated at 60°C. The labeled dry cDNA was resuspended in 200 µL 
of hybridization buffer and mixed well. Before hybridization, the array was 
preheated at 50°C for less than 15 minutes. The Human Array slide and cover slip 
were sealed together by the manufacturer with a plastic cover with one side open. 
The mixture of cDNA and hybridization buffer was loaded within the space between 
the cover slip and array on one end of the slide assembly.  A plastic sleeve that 
was provided with the array kit was slipped over the opening to encase the array.  
The array was then placed and sealed in an array cassette (Sigma-Aldrich, St. 
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Louis, MO, USA). The hybridization sandwich was heated at 95°C for 5 minutes 
and then placed in a water bath at 50°C overnight.  
Post Hybridization- 
The hybridization chamber was unsealed and gently wiped dry. The array 
coverslip was removed with a sterile blade.  The array was placed in a slide rack 
that was submerged into a low stringency buffer wash buffer, buffer A (2X SSC, 
1% SDS) pre-warmed at 55°C.  A magnetic stir bar was added to the bottom of the 
chamber to stir the buffer during the wash for 5 minutes.  The array was then 
transferred to a medium stringency buffer, buffer B (0.1x SSC, 0.1% SDS) at 55°C 
for 5 minutes. The array was then transferred to the high stringency buffer, buffer 
C (0.1x SSC) at room temperature for 5 min. The slides were then rinsed with 
deionized water and dried with the use of a high-speed microarray centrifuge 
(ArrayIt Corp., Sunnyvale, CA) for 1 minute.  
Image Acquisition and Data Analysis-  
Scanning the Arrays-  The arrays were scanned using a Typhoon FLA 
9500 (GE Health Science, Pittsburgh, PA) scanner.  The arrays were placed face 
down.  The parameters for the scan consisted of a 10-micron resolution setting 
  
41 
with the Cy3 setting (555 nm) on channel 1 and the Cy5 setting (647 nm) on 
channel 2.  The images were saved in a 16-bit TIF file format.  
Quantification Using SpotXel-  SpotXel (Sicasys Software for Life 
Sciences, Heidelberg, Germany) was used to align the grid obtained from the array 
manufacturer using the .gal file provided and the control corner spots on the array.  
The gal file defined the grid as 16 x 50 mm, the spot layout was 112 spots per 
column x 350 spots per row in one block.  The horizontal and vertical spacing for 
each spot was 143 µm with a spot diameter of 71 µm. Spot detection was set to 
Flex-spot with border. The spot intensities were quantified for both the green and 
red channel once the grid was aligned.  Background was subtracted to provide 
corrected spot intensities in an output .gpr file. The local method was used for 
background correction.  The noise was processed using 50% of the spot size and 
30 was selected for largest size defect.   
Creation of MEV files with ExpresConverter- The .gpr file resulting from 
SpotXel was converted to a .mev (MultiExperiment Viewer) file using Express 
Converter version 2.1 (Saeed et al., 2006) for use in MIDAS version 2.22-b0 
(Microarray Data Analysis System).  Both MIDAS and ExpressConverter are part 
of the TM4 Software created by the J. Craig Venter Institute (Rockville, MD).  In 
ExpressConverter, the gpr file from SpotXel was uploaded by choosing the custom 
input format followed by opening the .gpr file.  The corresponding gene annotations 
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were uploaded by selecting the GAL option and inputting the .gal file provided by 
the Onearray manufacturer.  The header of the data file was identified by selecting 
the row showing the headers in the file: “Block” “Column” “Row” “Name” “ID” “X” 
“Y”, etc. The headings “Forward Mean” for each channel were dragged to IA and 
IB headers, respectively.  The files were converted to .mev files upon pressing the 
green “C” option in the menu bar.  
Dye Swap Normalization Using MIDAS-  MIDAS was used to normalize 
the intensities within an array, as well as between the dye swap pair of arrays, to 
remove any bias attributable to the different dyes. Each dye swap array pair was 
processed in MIDAS using the following parameters:   
Data file pair- Two quantified arrays in .mev format 
One Bad Channel Tolerance Policy- Generous 
No flag used for either channel A or B  
No background checking for either channel 
 A Signal/Noise Threshold of 2.0 
Total intensity was selected with Cy3 chosen as Reference.  A Lowess fit 
was selected with the following parameters: block mode 0.33, smoothing 
parameter (default) and reference as N/A.  An Iterative Log Mean Centering 
Normalization was selected with ± 3.0 and reference as Cy3.  Flip Dye Replicate 
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Consistency Checking was performed with SD Cut as Data Trim Option and ± 2.0 
for Cross Log Ratio Data Keep Range.  The last selection in the pipeline was a 
Virtual Trim selection and Output of Trimmed data.  Both text and PDF files were 
produced to visualize the results.  
BRB-ARAY Tools (Zhao & Simon, 2008) were used to obtain average fold 
changes in gene expression, p-values and gene families.  A spreadsheet was 
generated from the IA and IB channel intensities from each dye swap replicate into 
columns as pairs.  Each replicate dye swap was averaged to give one IA and one 
IB for each of the three time points analyzed.  The spreadsheet consisted of the 6 
hr IA and IB, 8 hr IA and IB and 12 hr IA and IB.  BRB-ArrayTools was then used 
to obtain the log-ratio for each time point, the p-value for the significance of change 
over the three time points for each gene and the gene ID for the genes hybridized 
on the array.  These genes were then matched to available BRBarray online 
databases to obtain the defined gene lists.  Files were saved in GCT format. Based 
on Excel’s final normalization, a 1-way analysis of variance (ANOVA) was used to 
compare response values between the 6, 8, and 12 hr time intervals.  The gene 
expression results for the arrays will be uploaded into the public GEO database.
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RESULTS  
Accelerated Solvent Extraction (ASE) 
ASE (Accelerated Solvent Extraction) was used to extract water soluble 
compounds from Rumix crispus leaves. Each tube produced 50-100 mg dry 
sample weight which was used for HPLC fractionation.  
High Performance Liquid Chromatography (HPLC) 
Figure 7 shows a typical chromatogram with all peak fractions that were 
separated and collected.  Fraction number 19 (L19; in the red rectangle, Figure 7), 
from the leaf extract was collected between 19 minutes and 14 seconds to 20 
minutes and 14 seconds after injection of 10 µL of lyophilized ASE sample at a 
final concentration of 100 mg/mL in acidified H2O with 5% ACN.  The fractions 
shown were collected in 1 mL aliquots at 1 mL/min. 
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Figure 7. HPLC chromatograph of leaf ASE extract.  Fifty milligrams of dry leaf 
extract were suspended in 0.5 mL 95% acidified water (pH 2.2) plus 5% ACN and 
filtered. Ten microliters of sample mix were injected onto the column. Compounds 
were detected at 210 nm.  A Zorbax Eclipse Plus 18 column with an Alpha Bond 
C18 10 µm guard column (Agilent Corp.) was used as the stationary phase.  The 
mobile phase was a gradient of acidified water (pH 2.2) plus 5% v/v ACN to 60% 
ACN over 60 min. with a flow rate of 1 mL/min.   
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Gas Chromatography-Mass Spectrometry  
Samples were outsourced to the Moore Analytical Lab (Houston, Texas). Four 
different samples were sent for 4 replicate analyses using mass spectrometry 
(MS).  Acetonitrile was used as buffer with 10 µL of sample injected. L19 was 
collected at 5.538-5.637 minutes and 61 seconds. L19 was found to be a 
Tetrahydrofuran at 94.4% purity for each isolation (Figure 8) with a molecular 
weight of 72.11 g/mole.  
Optimization of Cell Viability Assay and Confirmation of Cytotoxicity of L19  
Cell viability assays were performed to verify that the purified L19 was cytotoxic to 
DLD-1 cells.  The number of untreated cells per well in a 96 well plate was 
optimized to provide linear changes in the absorbance after incubating the cells in 
the Aqueous One reagent.  Figure 9 shows 1x103, 1x104, 2x104, and 1x105 DLD-
1 cells/well in a 96 well plate incubated over 4 hrs measuring the absorbance at 
490 nm each hour.  The optimum cell number was determined to be 1x104 
cells/well measured after 3 hrs incubation in Aqueous One reagent; the 
absorbance was 0.81 ± 0.06 thus providing a high enough absorbance to observe 
linear changes in absorbance as cells decreased in viability in response to L19 or 
Dox treatment.   
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Figure 8. GC-MS chromatograph of L19 compound (A) and Tetrahydrofuran 
molecular mass and structure (B).  Peak labeled 1 in (A) was isolated using GC 
followed by mass spectroscopy of peak 1 to obtain corresponding mass fragments 
of L19 in (B). 
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Figure 9. Cell viability of untreated DLD-1 Cells for optimizing the Aqueous One 
Assay. DLD-1 cells were seeded with different number of cells in wells of a 96 well 
plate and incubated overnight.  Reagent for the Cell Titer 96 Aqueous One 
Reagent was added according to the manufacturer’s protocol.  
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All of the HPLC fractions were applied to the DLD-1 cells (1x104 cells/well) 
for 0, 1, 2 and 3 hrs exposure to ensure that fraction L19 collected in this study 
exhibited the greatest cell toxicity as compared to the other fractions as previously 
seen (Bahandari, 2015).  The untreated cells were used as the 100% cell viability 
comparison in the normalization to determine the percent viability (Figure 10).  L19 
was confirmed to exhibit the highest cell toxicity as compared to the other HPLC 
fractions that were collected in the same volume (1 mL) per fraction from 100 
mg/mL of dried plant extract.  The positive control for cell toxicity, Dox, showed the 
expected decrease in cell viability for increased concentrations of DOX consistent 
with previous studies (Bahandari, 2015); concentrations of the cytotoxic 
compounds in the HPLC fractions were not known. 
Dose-Response Assay 
Cells treated with a log dilution of L19 showed a sigmoidal decrease in cell viability 
with increasing L19 consistent with a cell death mechanism other than simple 
toxicity as evidenced by the dose response curve (Figure 11). Dox was used as a 
positive control because it has been well documented to show a sigmoidal dose 
response curve (Figure 12; Bhardwaj et al., 2016). The concentration of L19 varied 
between 27.73 and 30.5 µM for each isolation used as the zero-dilution treatment 
at 27.73  1.96 µM. From the dose response curve, the LC50 for L19 was 2.73  
1.96 µM on 1x104 DLD-1 cells.  The concentration that was used to treat the cells 
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for the Apo-Assays, qRT-PCR, RT-Profiler and Microarray was the 2.73  1.96 µM 
(Figure 11).  The LC50 of Dox was 100 µM (Figure 12).  
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Figure 10. Cell viability for treated DLD-1 Cells treated with different HPLC 
fractions.  HPLC Fractions, each 1mL, were lyophilized, suspended in 1 mL RPMI-
plus, neutralized with 15 µL1N NaOH. Then, 100 µL of neutralized suspended 
fraction transferred to 1x104 DLD1 cells in a 96 well plate.  Treated and untreated 
was determined to be 100µM in this study consistent with that determined 
previously by Lee (2015).  Cells were incubated overnight at 37ºC, in humidified 
6% CO2.  Absorbance readings were measured at 1, 2, and 3 hours after adding 
reagent.  The percent cell viability was calculated by (CV%) = (AT/AUT) x 100%.  
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Figure 11. Dose-response curve for L19. Synchronized cells were seeded 1x104 
cells per well of a 96 well plate and incubated overnight. Cells were treated with 
100 µL of log dilutions of L19 for 24 hours at 37ºC. Cell Titer 96 Aqueous One 
Reagent was used to determine the percent cell viability.  The standard deviation 
represents experiments repeated more than three times and measured in triplicate.   
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Figure 12. Dose-response curve for Doxorubicin. Synchronized cells were seeded 
1x 104 cells per well of a 96 well plate. Cells were treated with 10-fold serial dilution 
of 26.8 mM dox for 24 hours incubation. Cell viability was determined using the 
Cell Titer 96 Aqueous One Reagent.  Percent viability was determined relative to 
the absorbance at 490 nm of untreated cells.  Error bars represent values from 
experiments that were repeated more than three times and done in triplicate.   
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Induction of Caspase 3 and 7 and Cell viability of DLD-1 Cells Treated with 
Different HPLC Fractions 
The Apo-ONE™ Homogeneous Caspase-3/7 Assay (Promega Corp.) was 
used to detect levels of caspase 3/7 induction from exposure to HPLC fractions 14 
through 21 of ASE extract to confirm the findings of Bhandari (2015) (Figure 13); 
DOX was used as the positive control (Figure 14).  Fraction L19 exhibited the 
lowest cell viability with highest caspase 3/7 activity (Figure 13).  Fraction 20 also 
showed low cell viability with induced caspase 3/7 activity, however it was less 
than L19 and most likely some L19 was present in fraction 20.  L19 was used for 
further study. 
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Figure 13. Histogram of Caspase 3/7-fold change and percentage of cell viability 
by induction of HPLC Fractions DLD-1 cell line.  The 96 well cell culture plate was 
seeded with 1x104 DLD-1 cells/100µL/well and was incubated in 6% CO2 at 37C 
overnight. The media was then removed. The 1 mL HPLC fractions were 
evaporated to dryness and suspended in 100 µL of RPMI-plus. The fluorescence 
was measured using an excitation at 499 nm and an emission at 521 nm. The 
viability was detected using the Aqueous One reagent and measuring the A490. 
Both the Fold Change in caspase 3/7 activity and the percent viability were 
normalized to the respective treatment of untreated cells. 
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Figure 14. Histogram of Caspase 3/7-fold change and percent cell viability in DLD-
1 cells in response to different Dox concentrations.  Synchronized DLD-1 cells 
were seeded 1x104 cells/100 µL/well and incubated in 6% CO2 at 37C overnight. 
The media was then removed. The different Dox concentrations were suspended 
in 100µL of RPMI-plus and added to the cells followed by incubation in 6% CO2 at 
37C for 24 hours. The media containing Dox was removed and replaced with 25 
µL of fresh RPMI-plus media. A working solution of Apo-ONE homogenous 
caspase-3/7 reagent was added, mixed and incubated in the dark for one hour at 
room temperature. The fluorescence was measured at 521nm (excitation at 
499nm) to determine the fold change in caspase 3/7 as compared to untreated 
cells.  Percent viability was determined as described in Figure 12.  
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Induction of Caspase 3 and 7 and Cell Viability on DLD-1 by L19 
DLD1 cells treated with serial dilutions of L19 showed a dose dependent decrease 
in cell viability and an increase in caspase 3/7 activity as L19 concentrations 
increased from 27.73 X 10-5  1.96 µM to 27.73  1.96 µM (Figure 15).  The 2.77 
 1.96 µM resulted in killing 52.4  1.32 percent of the cells and exhibited a 1.4  
0.38 fold increase in caspase 3/7 activity.  The undiluted L19 and L20 showed the 
lowest percent viability at 9.49  0.07% and 12.09  0.11% viability and 3.13  0.08 
and 2.76  0.098 fold increase in caspase 3/7 activity respectively. L19 at a 
concentration of 2.76  1.96 µM concentration used for treating the DLD-1 cells for 
the following experiments.     
 Isolation of RNA 
Figure 16 shows a representative native agarose gel of total RNA isolated 
from the untreated and treated cells after exposure to L19 for different exposure 
times.  The quality of total RNA was determined by examining the 28S and 18S 
rRNA on a 1% native agarose gel.  Total RNA for two different samples isolated 
from untreated cells, UT1 and UT2 are shown in lanes 1 and 2.  Lane 3 contains 
the All Purpose HI-LOTM DNA marker (50–10,000 bp) and the lanes labeled T1 
and T2 contain total RNA isolated from treated cells.  Each lane contained 5 µL 
total RNA and 5 µL bromophenol blue loading dye.  Based on the presence of two  
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Figure 15.  Caspase 3/7-fold change and percentage of cell viability by induction 
of L19 on DLD-1 cell line.  Cells were prepared and treated with L19 as described 
previously in Figure 12 and 13.   
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Figure 16. Quality assessment of total RNA by 1% native agarose gel. A total of 5 
µL of RNA plus 5µL of bromophenol blue dye were loaded in each well. The gel 
was run in 1X TAE buffer at 100 volts for 30 minutes.  Lane UT1 and UT2 = 
Untreated cells, MARKER= All Purpose HI-LOTM DNA marker (50bp-10,000bp), 
T1 and T2 = L19 treated cells.  
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sharp prominent bands for the 28S and 18S rRNA (Figure 16), samples were 
assumed to contain high quality mRNA.  The purity of the RNA was determined 
by measuring the A260:A280 ratio which should be between 1.8 and 2 (Table 2) 
(Lucena-Aguilar et al., 2016); a ratio less than 1.6 indicates protein 
contamination.  
cDNA Synthesis for qRT PCR 
 The concentration of cDNA was measured using the conversion factor of 
37 µg/mL of cDNA for an A260 of 1.  The measured A260 was multiplied by a path 
length of 0.1 cm and any dilution factors if it was diluted.  The quality of RNA was 
measured (Table 3). 
Determination of Changes in Caspase Gene Expression Using Quantitative Real 
Time PCR.   
Quantitative Real Time PCR was used to confirm microarray data and to 
determine the level of gene expression of different human caspases, CASP1, 3, 4, 
5, 6, 7, 8, 9, 10, 12.  The qRT-PCR experiment was performed in triplicate for the 
different L19 exposure times with GAPDH as the housekeeping gene. The  Ct 
is a measure of the fold change (Figure 17).  The error bars for each of the caspase 
measurements are large and most likely attributable to the variation in the cell 
number per well. CASP12 gene expression increased by 6 hours as evidenced by 
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a 25.13  4.8 fold increase showing a quick response to L19 (Figure 17).  CASP1, 
6, and 10 exhibited smaller fold changes of 1.84  2.54, 1.6  1.82, and 1.53  
0.73, respectively at the 6-hour exposure time. The fold changes were relatively 
small in these samples, and the large standard error indicates very little change in 
CASP 1, 6 and 10 gene expressions at 6 hours.  
CASP5 gene expression exhibited a maximum level in 8 hours of 2.23  
0.96 fold change.  CASP5 has been shown to have an inflammatory role 
(McIlwaine et al., 2017).  CASP 12 dropped to little to no expression.  After 12 
hours, CASP1 increased 2.57  0.87 while.  CASP3, 6, and 12 increased to 1.92 
 0.66, 2.12  0.70, and 2.15  1.28, respectively. CASP7 displayed down 
regulated by fold change 0.4  0.72 or a -2.5 decrease as compared to the 
untreated cells and the GAPDH housekeeping gene. After 24 hours of exposure 
to the L19, CASP 1 increased to 5.85 ± 1.8. All of the other CASP genes showed 
no significant expression at 24 hours. CASP3 showed only a small increase by 8 
hours then it returned to the same as untreated.  CASP4 was unaffected 
throughout the 24-hour period measured.  CASP6 shows only a slight increase by 
12 hours, then goes to no change.  CASP7 displayed a steady decrease through 
the 24-hour exposure of L19.  CASP8 and 9 were down regulated by 24 hours with 
no change before that. Same with CASP10 except at 12 hours it showed 
upregulation as mentioned before.  CASP12 has a huge positive increase by 6 
hours and then decreased to same as untreated by 8 hours.  
  
62 
Table 2. Quality and total concentration of total RNA for representative L19 treated 
and untreated DLD-1 cells at 6, 8, 12, and 24 hour exposure times. The 
concentration of RNA was measured using the conversion factor of 40 µg/mL of 
RNA for an A260 of 1.  The measured A260 was multiplied by a path length of 0.1 cm 
and any dilution factors (if it was diluted). Purity of RNA was measured by the 
A260nm/A280 nm ratio. 
 
 
 
 
 
  
Time Points A280 A260  A260/A280 
Concentration 
(µg/mL) 
T6 0.351 0.641 1.826 2564 
T8 0.105 0.21 2.000 840 
T12 0.219 0.407 1.858 1628 
T24 0.553 0.997 1.803 3988 
UT6 0.347 0.703 2.026 2812 
UT8 0.084 0.174 2.071 696 
UT12 0.173 0.355 2.052 1420 
UT24 0.173 0.298 1.723 1192 
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Table 3.  cDNA isolated from L19 treated and untreated DLD-1 cells at different 
time points of exposure for qRT-PCR. 
 
Time Points A280 A260 A260/A280 
Concentration 
(µg/mL) 
T6 0.632 1.166 1.845 43.142 
T8 0.18 0.328 1.822 12.136 
T12 0.396 0.694 1.753 25.678 
T24 0.357 0.663 1.857 24.531 
UT6 0.55 0.991 1.802 36.667 
UT8 0.19 0.372 1.958 13.764 
UT12 0.425 0.739 1.739 27.343 
UT24 0.328 0.586 1.787 21.682 
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Figure 17.  qRTPCR of CASP gene expression in response to L19 exposure.  DLD-
1 passage 18 cells were treated with L19 for different exposure times (6, 8, 12, 24 
hours). Caspase primer sequences (table. 1) were obtained from the NCBI primer 
data base. Primers were designed to give a PCR product of 200bp  10. GAPDH 
was used as a house keeping gene control. The annealing temperature was 60°C. 
Template was 20 ng of purified cDNA added to qRT SYBR Green master mix. The 
normalized Ct value for each caspase was relative to the Ct value of GADPH cDNA 
present.  The Ctvalue was calculated by subtracting the Ct of untreated cells 
from the Ct value of treated cells.  The fold change was determined as 2-Ct. 
Hashes, dots, gray and black bars showed 6, 8, 12 and 24 hours, respectively. 
 
CASP Genes  
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RT² Profiler™ PCR Human Apoptosis Array  
The RT² Profiler™ PCR Human Apoptosis Array (SA Biosciences, Cat no: 
PAHS-012Z) was used to analyze the expression of 84 apoptotic and anti-
apoptotic genes of DLD-1 cells treated by L19 at the different time points. This 
array was utilized to confirm the qRT-PCR results above and to determine the 
apoptosis mechanism/s for the L19 effect on DLD-1 cells.  Equal amounts of 
treated and untreated cDNA (20ng/well) were used per reaction. The average Ct 
of two housekeeping genes (HK), Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and beta actin (ACTB), were chosen for normalizing the Ct values 
because they both showed no change at different time points in response to the 
L19 treatment or as compared to the untreated cells; the fold changes were 1.03 
 0.18 and 0.85  0.06, respectively. The Ct values were analyzed using the online 
SABiosciences software (SA Biosciences Corp.) to determine any changes in gene 
expression (Table 4).  Column 1 lists the gene abbreviation, column 2 shows fold 
change (2-Ct) at each time of exposure to L19.  A fold change greater than 1.5 is 
up-regulated, whereas a fold change less than 0.7 is down-regulated. In other 
words, if Ct (ΔCtTreated - ΔCtUntreated = ΔΔCt) is equal zero, then ΔCtTreated= 
ΔCtUntreated and there is no up or down-regulation. If ΔΔCt=-1; than 2(-(-1)) = 2 which 
means the gene of interest is expressed two times more than the control genes 
(ACTB and GAPDH). Thus, genes showed significant upregulation. On the other 
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hand, if ΔΔCt=1, 2(-(1)) = ½= 0.5 the gene regulation was two times less than the 
control which shows a significant down regulation.   
Based on Table 4 (A) and figure 18 (B). CASP1 showed no changes in 6 
and 12 hours and significant down-regulated in 8 hours (0.51-fold change). 
CASP3, an executioner caspase, was marginally up-regulated at 1.61 and 1.43-
fold by 6 and 12 hours, respectively. CASP5 (0.95, 0.82-fold change) and CASP4 
(0.84, 1.00-fold change) (inflammatory CASPs) showed no significant changes in 
6 and 8 hours, respectively; however CASP5 showed up regulation at 12 hours 
(1.5 fold change). CASP6 and CASP7, both executioner caspases, did not show 
remarkable changes at any of the time points.  CASP8 showed significant up-
regulated in 6, hours to a fold change of 2.91 and down regulated at 8 hours (0.51-
fold change), then showed no changes at 12 hours (1.16).  CASP9 showed to be 
unchanged at 8 and 12 time points in RT² Profiler™; while it showed minimally 
downregulation in 6 hours (0.75).  CASP10 showed down-regulated by 0.59 at 8 
hours but returned to no significant change relative to untreated at 12 hours (1.27-
fold change).  CASP14, which encodes an anti-apoptotic protein showed no up or 
down regulation.  CASP2 had significant down-regulated in 8 hours by fold change 
0.45, CRADD (CASP2 and RIPK1 domain containing adaptor with death domain) 
was up-regulated (1.87) at 6 hours.  
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Table 4. RT² Profiler™ PCR Human Apoptosis Array (SA Biosciences, Cat no: 
PAHS-012Z) fold change (2-Ct) for 6, 8, and 12 hours. Column 1 (from left to 
right): gene abbreviation; column 2: fold change. For normalizing the Ct values, 
two housekeeping genes (HK) were chosen, Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and beta Actin, (ACTB), with 1.03  1.79 and 0.85  
0.06, respectively, because they showed no change in response to L19 treatment 
as compared to untreated at the different time points. Parts A and B represent up- 
and down-regulated genes, respectively.  Greater than 1.5-fold change and less 
than 0.7 were considered significant.  
 
 
B: Downregulated genes 
Gene 6 Hours Gene 8 Hours Gene 12 Hours 
BID 0.7983 BFAR 0.7789 NOD1 0.7876 
BRAF 0.7967 CASP3 0.778 BCL2L10 0.7531 
MCL1 0.7955 TRADD 0.7567 LTBR 0.7523 
LTBR 0.7952 
TNFRSF10
A 0.7566 TP53 0.7519 
DAPK1 0.7804 FADD 0.7493 TNFSF8 0.7484 
CASP9 0.7547 BAG1 0.7439 CRADD 0.7274 
TNFRSF10
B 0.7498 TRAF3 0.7395 CD40LG 0.6924 
A: Upregulated genes  
Gene 6 Hours Gene 8 Hours Gene 12 Hours 
CASP8 2.9099   CD27 2.469 
XIAP 2.6871   AIFM1 2.1145 
TNFRSF9 2.1078   PYCARD 1.8368 
BAX 1.9568   DIABLO 1.7717 
TNFSF10 1.8715   FAS 1.6986 
CASP3 1.6055   BNIP3L 1.6921 
BIRC2 1.5394   FASLG 1.6321 
IGF1R 1.5254   IL10 1.6161 
    BCL2L2 1.5668 
    CASP5 1.5017 
    CIDEA 1.4933 
    NAIP 1.4817 
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BAK1 0.7479 BCL2 0.7244 LTA 0.6831 
TP53 0.742 BCL2L2 0.6946 TNFRSF10A 0.6402 
AKT1 0.7054 TP73 0.6663 BAD 0.6262 
GADD45A 0.6983 BCL2L1 0.6639 DAPK1 0.625 
BIRC5 0.6959 DAPK1 0.6629 TNFRSF1A 0.5126 
TNFRSF25 0.6885 BCL2L11 0.6608 TRADD 0.4627 
NFKB1 0.6761 BIRC3 0.6343 AKT1 0.3506 
TNFRSF1A 0.6563 NOD1 0.6333 TRAF2 0.3419 
FADD 0.6441 BNIP3 0.6274 BCL2L1 0.2263 
HRK 0.6242 TP53 0.6274 BCL2 0.0931 
CIDEB 0.6169 
TNFRSF10
B 0.6117   
TP73 0.6139 XIAP 0.6105   
NOL3 0.5687 APAF1 0.6095   
  CASP10 0.5932   
  LTA 0.563   
  TNFRSF1B 0.5401   
  CYCS 0.5273   
  IGF1R 0.5244   
  TRAF2 0.5219   
  CASP1 0.5103   
  CASP8 0.5055   
  AKT1 0.4791   
  CASP2 0.4535   
  NAIP 0.3963   
  CIDEB 0.3865   
  CD27 0.3737   
  TNFRSF25 0.3262   
  PYCARD 0.2119   
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Figure 18. qRTPCR of DLD1 cells exposed to L19 at 6, 8, and 12 hours (legend) 
using the RT2 Profiler Human Apoptosis PCR Array (Cat no: PAHS-01Z).  The fold 
change was calculated using 2-Ct where the Ct of L19 treated cells were 
normalized to the Ct of untreated cells using the online software available at the 
manufacture’s website. Panels A, B, C and D display the results for 84 genes 
involved in apoptosis regulation.  The standard deviation represents the variance 
between triplicates within each experiment as well as replicate experiments.  
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TNF (Tumor necrosis factor) which activates TNF-R1 (Tumor necrosis 
factor receptor superfamily, member 10a) showed no significant changes at 6, 8 
and 12 hours by 0.94, 0.93 and 1.14-fold changes respectively (Table 4B; Figure 
18C). TRAF2 (TNF receptor-associated factor 2), which can activate TRADD 
(TNFRSF1A-associated via death domain) directly, was down-regulated after 8 
hours at 0.52 and 12 hours at 0.34 fold change.  FADD (Fas (TNFRSF6)-
associated via death domain) was minimally down-regulation at each time point by 
0.7-fold.  BAD (BCL2-associated agonist of cell death) was down-regulated at 12 
hours by 0.62.  Neither BID nor CYCS showed any significant changes at 6 or 12  
hours respectively by 1.29 (CYCS fold change at 6 hours) or 1.26 (BID fold change 
at 12 hours) (Figure 18B).  AIF (Apoptosis Inducing Factor) was up-regulated at 
12 hours by 2.11-fold changes, exhibiting no changes at 6 or 8 hours (0.91 and 
1.13-fold change, respectively).  
Comparison of The Two qRT-PCR Results 
  Ideally the two methods, qRT-PCR and the RT2 Profiler™, should show 
similar results or at least similar trends.  Differences observed might be attributable 
to the fact that the primers used in the qRT-PCR designed from the NCI primer 
database may not be the same as the primers used in the RT2 Profiler™ which are 
proprietary.   Table 5 lists the fold changes of key apoptotic genes to compare the 
results between the two methods.  CASP3 was down-regulated by 6 hours to a 
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0.41  3.3 fold change as indicated by qRT-PCR and by 1.61 from RT2 Profiler™.  
By 12 hours, CASP3 was up-regulation to a 1.92  0.66 fold change as indicated 
by qRT-PCR and by 1.43 from RT2 Profiler™.  Up regulation of CASP3 is 
supportive of apoptosis.  CASP1, 9 and 10 were up-regulated at 6 hours in qRT-
PCR (1.85  2.54, 1.49  1.42, and 1.53  0.74, respectively) but showed to be 
unchanged in RT² Profiler™. The standard deviations for the qRT-PCR results are 
high, and there was no significant change in the qRT-PCR consistent with the RT2 
Profiler™.  CASP1 showed to be up-regulated by 2.57  0.87 in 12 hours using 
qRT-PCR but no significant change using the RT² Profiler (1.05-fold change). 
CASP4, at 12 hours and CASP5 at 8hours, were up-regulated in the qRT-PCR 
data (1.45  0.46 and 2.23 0.96, respectively); while CASP5 and CASP4 stayed 
the same in RT² Profiler data (Table 5). CASP7 was down-regulated in qRT-PCR 
results, with only marginal up regulation (1.34-fold change) at 12 hours (Table 5). 
CASP8 showed significant up-regulation in 6 hours (2.91-fold change) and no 
changes in 8 and 12 hours.  The qRT-PCR data indicated marginal up-regulation 
of 1.33  1.41, 0.58  0.68 and 1.35  0.29, respectively, indicating no changes in 
6 and 12 hours and significant down regulated in 8 hours (Table 5).  
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Table 5. Comparison of fold changes for CASP genes over different time intervals 
using RT² Profiler™ PCR Human Apoptosis Array (SA) and qRT-PCR results 
(reported as means ± 1 SD).  
 
 
 
 
 
 
 
  Treatment Time  
 6 hrs 8 hrs 12 hrs 
 Gene SA qRT-PCR SA qRT-PCR SA qRT-PCR 
CASP1 0.95 1.85 ± 2.54 0.51 1.24 ± 0.73 1.05 2.57 ± 0.87 
CASP3 1.61 0.40 ± 3.30 0.78 1.23 ± 0.63 1.43 1.92 ± 0.66 
CASP4 0.84 1.03 ± 2.30 1.00 1.29 ± 0.29 1.12 1.45 ± 0.46 
CASP5 0.95 1.36 ± 3.04 0.82 2.23 ± 0.96 1.50 1.20 ± 0.83 
CASP6 1.16 1.60 ± 1.82 1.09 1.17 ± 0.16 1.17 2.12 ± 0.70 
CASP7 0.99 0.68 ± 1.38 0.88 0.64 ± 0.65 1.34 0.40 ± 1.59 
CASP8 2.91 1.33 ± 1.41 0.51 0.58 ± 0.64 1.16 1.35 ± 0.29 
CASP9 0.75 1.49 ± 1.42 0.89 0.69 ± 0.64 1.33 0.90 ± 0.16 
CASP10 0.95 1.53 ± 0.74 0.59 0.79 ± 0.82 1.27 1.54 ± 0.46 
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 The ANOVA results indicated that the hypothesis (H1) in the RT² Profiler™ 
assay was that all three time points (6, 8, and 12 hours) were statistically different 
for mean values of gene expression (dependent variable). The p-value of mean 
differences between time treatments rejected H0 (F2 = 18.99, p < 0.0001); however, 
the mean for different genes, rejected H1 (F83 = 1.17, p = 0.19). Thus, the difference 
between the 3-time points were statistically different but at least one gene showed 
no changes during the different times.    
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Table 6. Summary of gene expression for three independent time points (Group) 
across genes for RT2 Profiler Human Apoptosis PCR array results. The number of 
genes assayed were 84 (Count). 
 
Group Count Sum Average Variance 
6H 84 86.85 1.03 0.16 
8H 84 67.03 0.80 0.04 
12H 84 92.77 1.10 0.15 
 
 
Table 7. A two-factor analysis of variance for three independent time point groups 
(across genes) for RT2 Profiler Human Apoptosis PCR array results, that indicates 
F and P-value for total intensities of different time points and genes of RT2 Profiler 
Human Apoptosis PCR array results. The groups were defined as 84 genes in 
three different time intervals (6, 8, 12 hours).  
 
Source of 
Variation SS df MS F P-value 
Genes 11.10 83.00 0.13 1.17 0.19 
Hours  4.33 2.00 2.16 18.99 3.73492E-08 
Error 18.91 166.00 0.11   
Total 34.34 251.00       
 
 
 
 
 
Microarray cDNA Quantification  
The concentration of labeled cDNA was quantified from the absorbance at 
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260 nm for each of the purified samples (Table 8). The Frequency of Incorporation 
(FOI) for each dye was calculated using the absorption at 555nm and 647 nm for 
Alexa Fluor® 555 and Alexa Fluor® 647, which had absorption coefficients of 
150,000 Lmol-1cm-1 (555 nm) and 250,000 Lmol-1cm-1 (647 nm), respectively 
(Invitrogen; Carlsbad, CA). The measured absorption spectrum for each dye 
labeled cDNA in a 1mm path length is shown in Figure 19.  The yield of cDNA and 
the FOI are listed in Table 8.  The FOI range was 17.4  1.43 to 20.76  2.93 
consistent with the recommended minimum FOI by the manufacturer (Qiagen 
Corp.). 
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Figure 19.  Absorption spectra of Alexa Fluor® 555 labeled cDNA and Alexa 
Fluor® 647.  Amount of cDNA and dye incorporation was quantified using the A260 
and A555 or A647 respectively.  The path length was 1 mm.  The gray and yellow 
spectra are the Alexa Fluor 647 labeled cDNA with a maximum absorption at 647 
nm.  The black spectrum is the absorption for the Alexa Fluor 555 labeled cDNA 
with a maximum absorption at 555 nm. 
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Table 8. Yield of labeled cDNA for both Alexa Fluor 555 and Alexa Fluor 647, 
amount of dye incorporation and frequency of incorporation (FOI) for two samples 
of treated and untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treated 
Sample 1 1.55 70 17.5 1.44 75 17.67 
Sample 2 1.44 80 18.88 1.43 100 23.56 
Untreated 
Sample 1 1.83 80 17.77 1.11 75 22.97 
Sample 2 2.2 100 15.45 1.24 68.75 18.85 
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Microarray Data Normalization Analysis 
After preprocessing fluorescent intensity of each individual spot using the 
SpotXel software, data were normalized and filtered using MIDAS as described in 
Materials and Methods.  The average of the raw intensities of all replicate dye-
swap experiments for each time point was plotted with the different Alexa 555 raw 
intensity versus the Alexa 647 raw intensity (Figure 20).  The log of raw intensities 
of Alexa 555 versus Alexa 647 were scattered in a Gaussian distribution and most 
of them had equal variability (Figure 20).  Each individual point (each raw intensity) 
represents a positive hybridization of the respective labeled cDNA on the array 
slide after the background subtraction.  
When the log of the raw intensities of B vs the log intensities of A were 
plotted, the majority of the ratios (Alexa 647 intensity divided by the Alexa 555 
intensity) for the 6-hour time point clustered at the bottom left corner of the graph 
at minimal to no difference in intensity between the two different dye-labeled 
cDNAs (Figure 21). Many of these spots were control spots for hybridization and 
normalization which showed no difference post-normalization using SpotXel and 
MIDAS software (Figure 21).  However, the normalization process also brought the 
target genes out from the clustered origin as illustrated at the 8-hour time interval 
(Figure 21C and D).  
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Figure 20. Flip dye histogram of distribution Alexa 555 vs Alexa 647 at different 
time points. Flip dye histograms are for 6H, 8 H and 12H of untreated and treated 
DLD-1 cell’s labeled cDNA. X and Y axis represent the average frequency and log 
ratios of gene expression, respectively. Graphs after data normalization and 
filtering with SpotXel and MIDAS were plotted using the MIDAS software. 
6 H 
8 H 12 H 
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Figure 21. Scatter plots of the average distribution Alexa 555 vs Alexa 647 for raw 
intensity and log intensity at different time points in dye-swap experiment. Log10(IA) 
vs log10(IB) scatter plots are for 6H (A), 8 H (C) and 12H (E) of untreated and 
treated DLD-1 cell’s labeled cDNA. X and Y coordinates represented average 
Alexa 647 (IA) and Alexa 555 (IB) log intensities respectively. Plots B, D, and F 
corresponded to the log vs log for 6, 8 and 12 hour intervals, respectively. Graphs 
after data normalization and filtering with SpotXel and MIDAS were plotted using 
the MIDAS software.  
A B 
C 
D 
E F 
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If the two intensities are equal to each other the spots will follow the trend 
line.  The spot intensities higher than this line represent upregulated genes. The 
spot intensities below the trend line are down regulated in response to L19 
treatment.  Based on Stekel (2003), if the log intensities behaved equally, all points 
should show the bell shape in the histogram which is evident for these experiments 
(Figure 20) and be scattered across the regression line (Figure 21B, D and F).   
The ratio to Intensity plots (R-I plots) remove dye bias and low quality data 
or noise (Quackenbush, 2002; Figure 22).  RI plot normalization was chosen to 
disclose specific intensities dependent on Log2(IB/IA).  Locally Weighted Linear 
Regression (Lowess) normalization was displayed as Log2(IB/IA) expression 
versus the log10 of the Alexa 555 times the Alexa 647 intensities (Log10(IA*IB)).  
The RI plot facilitates data comparison and correct spatial and symmetric variation 
(Quackenbush, 2002).  Most of the total intensity spots were located near the lower 
left of each panel especially for 6 hr (Figure 22A), indicating that the majority or 
genes were not affected by L19.  The 8 hr exposure showed the most dispersed 
set of genes in response to L19 (Figure 22B).  After 12 hours, fewer genes were 
visible (Figure 22C).  The genes that showed differential expression are listed in 
Table 11. 
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Figure 22. Specific intensity-dependent log (IB/A) plot (R-I plot).  Lowess data 
normalization analysis has been applied for average total intensity of Labelled 
cDNA of treated and untreated DLD-1 cells. IA and IB are defined as channel A 
and channel B spot intensity respectively. R-I graphs were plotted for each of 6H 
(A), 8H (B) and 12H (C). Data were normalized and visualized using MIDAS.  
  
A B 
C 
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 Flip-dye Diagnostic normalization was used to remove inconsistent or 
questionable data as compared to the two dye swapped arrays.  Figure 23 shows 
the results for the dye-swap experiments, blue scatter plots denoted treated cDNA 
labeled with Alexa Fluor 555 and untreated cDNA labeled with Alexa Fluor 647.  
The red scatter plot showed opposite labeling of blue plot (Alexa Fluor 555 labeled 
untreated with Alexa Fluor 647 labeled treated).  Most of the total intensities spots 
in plots C and D were widely distributed which showed more gene expression in 8 
hours in comparison to 6 and 12 hours (Figure 23).  
 The ANOVA compared all three independent time points of the microarray 
gene expression (Tables 9, 10).  The one-way ANOVA showed a large difference 
between the mean of each of the three-time point groups (F2,32776 = 8.77, p < 0.001; 
Table 10) and therefore, the null hypothesis was rejected. 
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Figure 23. Diagnostic plots for two different arrays in the dye-swap experiments. 
Blue scatter plots denoted Alexa 555 treated and Alexa 647 untreated and red 
plots represented Alexa 647 treated and Alexa 555 untreated DLD-1 cells.  Panels 
A & B (6 hour), C & D (8 hour) and E & F (12 hour) represent each of the treatement 
time intervals. These plots were normalized by Spotxel and plotted by Tiger 
MIDAS. 
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Table 9. Results of an analysis of variance for three independent time points 
groups for microarray gene expression results. 
 
Groups Count             Sum Average ± variance 
6hr IB ave 7794 275.105 0.035 ± 0.177 
8hr IB ave 11850 41.508 0.003 ± 0.222 
12hr IB ave 13135 248.499 0.018 ± 0.378 
 
 
 
Table 10. Results of a one-way analysis of variance of three independent time 
points groups for Microarray gene expression results, F and P-value for total 
intensities of different time points for Microarray fold change results. 
 
Source of Variation SS df MS F     P-value 
Between Groups 4.814 2 2.407 8.772 0.000 
Within Groups 8993.627 32776 0.274 
  
Total 8998.442 32778       
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Genes Affected by L19  
 BRB Array tools was used to match the gene IDs to their function in order 
to determine other cellular processes that were affected by exposure to L19. Some 
genes had their respective functions up- or down-regulated (Table 11).  There are 
several cancer genes in key signaling pathways that have players both-up and 
down-regulated such as:  MAPKinsase pathway, Interleukin (IL) cytokine pathway, 
Cell death (CD), and p53.  Additionally, there are numerous neurological, olfactory, 
and metabolic pathways affected, suggesting that L19 could be applied against 
diseases other than cancer, but could also have detrimental side effects.      
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Table 11. Microarray genes affected by L19 at 6, 8, and 12 hours.  Greater than 
1.5-fold change and lower than 0.5 were considered significant.  BRB-Array Tools 
was used to generate the Defined Genelists. 
 
  
 
A: Upregulated genes 
 
6 Hours  
Symbol Defined Gene Lists Fold 
Change  
OR2C1 Olfactory transduction 3.573 
TAOK1 MAPK signaling pathway 2.485 
EFNA2 Axon guidance 1.447 
8 Hours  
PTH1R Neuroactive ligand-receptor interaction 2.193 
RANBP2 
Cycling of Ran in nucleocytoplasmic transport, Mechanism of 
Protein Import into the Nucleus, Sumoylation by RanBP2 
Regulates Transcriptional Repression, RNA transport 1.655 
PRCP Protein digestion and absorption 1.406 
12 Hours  
SLC16A10 Protein digestion and absorption 2.276 
PRLHR Neuroactive ligand-receptor interaction 2.155 
NUDT12 Nicotinate and nicotinamide metabolism, Peroxisome 2.036 
CD74 
Antigen Processing and Presentation, Antigen processing and 
presentation 1.944 
RAP2B Phospholipase C-epsilon pathway 1.892 
OR1D5 Olfactory transduction 1.814 
PEX13 Peroxisome 1.662 
DLST Citrate cycle (TCA cycle), Lysine degradation, Metabolic pathways 1.551 
DCTN1 
Lissencephaly gene (LIS1) in neuronal migration and 
development, Huntington's disease, Vasopressin-regulated water 
reabsorption 1.551 
SNF8 Endocytosis 1.512 
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B: Downregulated genes 
 
6 Hours 
Symbol Defined Gene Lists Fold 
Change 
FZD9FZD9+
S18:US20:U
183 
Basal cell carcinoma, Melanogenesis, Pathways in cancer, Wnt 
signaling pathway 0.791 
GRIN3A Neuroactive ligand-receptor interaction 0.788 
FOLH1 Vitamin digestion and absorption 0.778 
SLC1A5 Protein digestion and absorption 0.766 
NPC1L1 Fat digestion and absorption 0.766 
POGLUT1 Other types of O-glycan biosynthesis 0.766 
GSTK1 
Drug metabolism - cytochrome P450, Glutathione metabolism, 
Metabolism of xenobiotics by cytochrome P450, Peroxisome 0.762 
NNT Metabolic pathways, Nicotinate and nicotinamide metabolism 0.762 
NR0B1 CARM1 and Regulation of the Estrogen Receptor 0.748 
RAD9A Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility 0.724 
PLA2G2A 
alpha-Linolenic acid metabolism, Arachidonic acid metabolism, 
Ether lipid metabolism, Fat digestion and absorption, Fc epsilon RI 
signaling pathway, Glycerophospholipid metabolism, GnRH 
signaling pathway, Linoleic acid metabolism, Long-term 
depression, MAPK signaling pathway, Metabolic pathways, 
Pancreatic secretion, Toxoplasmosis, Vascular smooth muscle 
contraction, VEGF signaling pathway 0.722 
GNAT1 Phototransduction 0.722 
SNAP29 SNARE interactions in vesicular transport 0.722 
PPP2R1B 
Chagas disease (American trypanosomiasis), Hepatitis C, Long-
term depression, mRNA surveillance pathway, Oocyte meiosis, 
TGF-beta signaling pathway, Tight junction, Wnt signaling 
pathway 0.722 
MAP3K8 
MAPKinase Signaling Pathway, MAPK signaling pathway, T cell 
receptor signaling pathway, Toll-like receptor signaling pathway 0.722 
NUTF2 Mechanism of Protein Import into the Nucleus 0.700 
DPYD 
beta-Alanine metabolism, Drug metabolism - other enzymes, 
Metabolic pathways, Pantothenate and CoA biosynthesis, 
Pyrimidine metabolism 0.678 
ENTPD4 Lysosome, Purine metabolism, Pyrimidine metabolism 0.678 
  
90 
PCNA 
p53 Signaling Pathway, Base excision repair, Cell cycle, DNA 
replication, Mismatch repair, Nucleotide excision repair 0.678 
B3GAT1 
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan 
sulfate, Glycosaminoglycan biosynthesis - heparan sulfate / 
heparin, Metabolic pathways 0.678 
ABCC6 ABC transporters 0.678 
IRF7 
The information-processing pathway at the IFN-beta enhancer, 
Cytosolic DNA-sensing pathway, Hepatitis C, RIG-I-like receptor 
signaling pathway, Toll-like receptor signaling pathway 0.678 
IL3 
Cytokine Network, Cytokines and Inflammatory Response, 
Dendritic cells in regulating TH1 and TH2 Development, 
Erythrocyte Differentiation Pathway, IL 17 Signaling Pathway, IL 3 
signaling pathway, Regulation of BAD phosphorylation, Regulation 
of hematopoiesis by cytokines, The Role of Eosinophils in the 
Chemokine Network of Allergy, Apoptosis, Asthma, Cytokine-
cytokine receptor interaction, Fc epsilon RI signaling pathway, 
Hematopoietic cell lineage, Jak-STAT signaling pathway 0.670 
OR52H1 Olfactory transduction 0.637 
MYL5 
Focal adhesion, Leukocyte transendothelial migration, Regulation 
of actin cytoskeleton, Tight junction 0.632 
SESN3 p53 signaling pathway 0.632 
DLG4 
Nitric Oxide Signaling Pathway, Synaptic Proteins at the Synaptic 
Junction, Huntington's disease 0.632 
LAMB2 
Amoebiasis, ECM-receptor interaction, Focal adhesion, Pathways 
in cancer, Small cell lung cancer, Toxoplasmosis 0.632 
PIGB 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis, Metabolic 
pathways 0.632 
ZAP70 
Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor, Lck and Fyn tyrosine 
kinases in initiation of TCR Activation, T Cell Receptor Signaling 
Pathway, Natural killer cell mediated cytotoxicity, Primary 
immunodeficiency, T cell receptor signaling pathway 0.632 
NDUFS5 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.632 
AVP 
Control of skeletal myogenesis by HDAC & calcium/calmodulin-
dependent kinase (CaMK), Vasopressin-regulated water 
reabsorption 0.631 
RBKS Pentose phosphate pathway 0.614 
NDST1 
Glycosaminoglycan biosynthesis - heparan sulfate / heparin, 
Metabolic pathways 0.609 
LILRB2 Osteoclast differentiation 0.601 
STX2 SNARE interactions in vesicular transport 0.585 
RFT1 N-Glycan biosynthesis 0.585 
RXRA 
Basic mechanism of action of PPARa, PPARb(d) and PPARg and 
effects on gene expression, Control of Gene Expression by 
Vitamin D Receptor, Degradation of the RAR and RXR by the 
proteasome, FXR and LXR Regulation of Cholesterol Metabolism, 0.585 
  
91 
Map Kinase Inactivation of SMRT Corepressor, Mechanism of 
Gene Regulation by Peroxisome Proliferators via PPARa(alpha), 
Nuclear receptors coordinate the activities of chromatin 
remodeling complexes and coactivators to facilitate initiation of 
transcription in carcinoma cells, Role of PPAR-gamma 
Coactivators in Obesity and Thermogenesis, Transcription 
Regulation by Methyltransferase of CARM1, Visceral Fat Deposits 
and the Metabolic Syndrome, Adipocytokine signaling pathway, 
Bile secretion, Hepatitis C, Non-small cell lung cancer, Pathways 
in cancer, PPAR signaling pathway, Small cell lung cancer, 
Thyroid cancer 
ADAM17 
g-Secretase mediated ErbB4 Signaling Pathway, Presenilin action 
in Notch and Wnt signaling, Proteolysis and Signaling Pathway of 
Notch , Alzheimer's disease, Epithelial cell signaling in 
Helicobacter pylori infection, Notch signaling pathway 0.585 
PPP2R5B 
mRNA surveillance pathway, Oocyte meiosis, Wnt signaling 
pathway 0.585 
CUL3 Ubiquitin mediated proteolysis 0.585 
PFN3 Regulation of actin cytoskeleton, Shigellosis 0.585 
SLC1A3 Malate-aspartate shuttle 0.585 
PSMD3 Proteasome 0.536 
TSHR 
Autoimmune thyroid disease, Neuroactive ligand-receptor 
interaction 0.536 
LIN7A Chaperones modulate interferon Signaling Pathway 0.536 
CBLB 
Bacterial invasion of epithelial cells, Chronic myeloid leukemia, 
Endocytosis, ErbB signaling pathway, Insulin signaling pathway, 
Jak-STAT signaling pathway, Pathways in cancer, T cell receptor 
signaling pathway, Ubiquitin mediated proteolysis 0.536 
PDE6A Visual Signal Transduction, Phototransduction, Purine metabolism 0.536 
TSC1 
mTOR Signaling Pathway, Insulin signaling pathway, mTOR 
signaling pathway 0.536 
TAS2R20 Taste transduction 0.536 
LIPT2 Lipoic acid metabolism, Metabolic pathways 0.531 
PARD6B Endocytosis, Tight junction 0.526 
ATP5A1 
Electron Transport Reaction in Mitochondria, Alzheimer's disease, 
Huntington's disease, Metabolic pathways, Oxidative 
phosphorylation, Parkinson's disease 0.521 
TXNRD1 Pyrimidine metabolism, Selenocompound metabolism 0.485 
GNA14 
Amoebiasis, Calcium signaling pathway, Chagas disease 
(American trypanosomiasis) 0.485 
CLDN10 
Cell adhesion molecules (CAMs), Hepatitis C, Leukocyte 
transendothelial migration, Tight junction 0.485 
PSME3 Antigen processing and presentation, Hepatitis C, Proteasome 0.485 
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COX6B2 
Alzheimer's disease, Cardiac muscle contraction, Huntington's 
disease, Metabolic pathways, Oxidative phosphorylation, 
Parkinson's disease 0.485 
ATF6B Protein processing in endoplasmic reticulum 0.485 
IFNW1 
Cytokine-cytokine receptor interaction, Jak-STAT signaling 
pathway, RIG-I-like receptor signaling pathway 0.485 
HNF4G Maturity onset diabetes of the young 0.485 
IL33 Cytosolic DNA-sensing pathway 0.485 
ARSA Lysosome, Sphingolipid metabolism 0.485 
RPS11 Ribosome 0.485 
FGA 
Acute Myocardial Infarction, Extrinsic Prothrombin Activation 
Pathway, Fibrinolysis Pathway, Intrinsic Prothrombin Activation 
Pathway, Complement and coagulation cascades 0.485 
BMP4 
ALK in cardiac myocytes, Basal cell carcinoma, Hedgehog 
signaling pathway, Pathways in cancer, TGF-beta signaling 
pathway 0.466 
DDX3Y RIG-I-like receptor signaling pathway 0.455 
EED 
The PRC2 Complex Sets Long-term Gene Silencing Through 
Modification of Histone Tails 0.444 
RELA 
Acetylation and Deacetylation of RelA in The Nucleus, Activation 
of PKC through G protein coupled receptor, AKT Signaling 
Pathway, ATM Signaling Pathway, Bone Remodelling, Cadmium 
induces DNA synthesis and proliferation in macrophages, CD40L 
Signaling Pathway, Ceramide Signaling Pathway, Chaperones 
modulate interferon Signaling Pathway, Corticosteroids and 
cardioprotection, CXCR4 Signaling Pathway, Double Stranded 
RNA Induced Gene Expression, Erythropoietin mediated 
neuroprotection through NF-kB, fMLP induced chemokine gene 
expression in HMC-1 cells, Free Radical Induced Apoptosis, HIV-I 
Nef: negative effector of Fas and TNF, Human Cytomegalovirus 
and Map Kinase Pathways, Inactivation of Gsk3 by AKT causes 
accumulation of b-catenin in Alveolar Macrophages, Induction of 
apoptosis through DR3 and DR4/5 Death Receptors , Influence of 
Ras and Rho proteins on G1 to S Transition, Keratinocyte 
Differentiation, MAPKinase Signaling Pathway, Mechanism of 
Gene Regulation by Peroxisome Proliferato ... 0.433 
HS6ST2 Glycosaminoglycan biosynthesis - heparan sulfate / heparin 0.433 
PAFAH1B2 Ether lipid metabolism, Metabolic pathways 0.433 
CYP26A1 
Nuclear Receptors in Lipid Metabolism and Toxicity, Retinol 
metabolism 0.433 
DIAPH2 Regulation of actin cytoskeleton 0.433 
PRKCQ 
Keratinocyte Differentiation, Adipocytokine signaling pathway, T 
cell receptor signaling pathway, Tight junction, Vascular smooth 
muscle contraction 0.433 
ATP5J 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.433 
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GRIK2 Neuroactive ligand-receptor interaction 0.433 
BET1L SNARE interactions in vesicular transport 0.433 
TNFRSF11
B Cytokine-cytokine receptor interaction, Osteoclast differentiation 0.433 
HLA-DMB 
Allograft rejection, Antigen processing and presentation, Asthma, 
Autoimmune thyroid disease, Cell adhesion molecules (CAMs), 
Graft-versus-host disease, Intestinal immune network for IgA 
production, Leishmaniasis, Phagosome, Rheumatoid arthritis, 
Staphylococcus aureus infection, Systemic lupus erythematosus, 
Toxoplasmosis, Type I diabetes mellitus, Viral myocarditis 0.431 
MTHFR Metabolic pathways, One carbon pool by folate 0.415 
SUV420H2 Lysine degradation 0.415 
PVRL3 Adherens junction, Cell adhesion molecules (CAMs) 0.402 
PHF5A Spliceosome 0.399 
CD9 Hematopoietic cell lineage 0.383 
NAMPT Nicotinate and nicotinamide metabolism 0.383 
NKX2-2 Maturity onset diabetes of the young 0.379 
HIST1H3G Systemic lupus erythematosus 0.379 
CREB5 
Huntington's disease, Prostate cancer, Vasopressin-regulated 
water reabsorption 0.379 
GHSR Neuroactive ligand-receptor interaction 0.379 
AGK Glycerolipid metabolism, Metabolic pathways 0.379 
FZR1 
Cell cycle, Progesterone-mediated oocyte maturation, Ubiquitin 
mediated proteolysis 0.379 
PNLIP 
Fat digestion and absorption, Glycerolipid metabolism, Metabolic 
pathways, Pancreatic secretion, Vitamin digestion and absorption 0.379 
CR1 
B Lymphocyte Cell Surface Molecules, Complement and 
coagulation cascades, Hematopoietic cell lineage, Leishmaniasis, 
Malaria 0.379 
CDC40 Spliceosome 0.379 
CARD8 NOD-like receptor signaling pathway 0.379 
AKT3 
Acute myeloid leukemia, Adipocytokine signaling pathway, 
Apoptosis, B cell receptor signaling pathway, Carbohydrate 
digestion and absorption, Chagas disease (American 
trypanosomiasis), Chemokine signaling pathway, Chronic myeloid 
leukemia, Colorectal cancer, Endometrial cancer, ErbB signaling 
pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated 
phagocytosis, Focal adhesion, Glioma, Hepatitis C, Insulin 
signaling pathway, Jak-STAT signaling pathway, MAPK signaling 
pathway, Melanoma, mTOR signaling pathway, Neurotrophin 
signaling pathway, Non-small cell lung cancer, Osteoclast 
differentiation, Pancreatic cancer, Pathways in cancer, 
Progesterone-mediated oocyte maturation, Prostate cancer, Renal 
cell carcinoma, Small cell lung cancer, T cell receptor signaling 0.379 
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pathway, Tight junction, Toll-like receptor signaling pathway, 
Toxoplasmosis, VEGF signaling pathway 
CRB3 Tight junction 0.379 
CDK7 
Cyclins and Cell Cycle Regulation, Degradation of the RAR and 
RXR by the proteasome, Estrogen-responsive protein Efp controls 
cell cycle and breast tumors growth, Sonic Hedgehog (SHH) 
Receptor Ptc1 Regulates cell cycle, Cell cycle, Nucleotide excision 
repair 0.379 
IQSEC3 Endocytosis 0.379 
VAMP1 SNARE interactions in vesicular transport 0.363 
GUCY1A3 
Ion Channels and Their Functional Role in Vascular Endothelium, 
Gap junction, Long-term depression, Purine metabolism, Salivary 
secretion, Vascular smooth muscle contraction 0.359 
COX7C 
Alzheimer's disease, Cardiac muscle contraction, Huntington's 
disease, Metabolic pathways, Oxidative phosphorylation, 
Parkinson's disease 0.348 
OR4A15 Olfactory transduction 0.334 
TWIST1 Tumor Suppressor Arf Inhibits Ribosomal Biogenesis 0.333 
SRSF2 Spliceosomal Assembly, Spliceosome 0.322 
PAQR7 How Progesterone Initiates the Oocyte Maturation 0.322 
RENBP Amino sugar and nucleotide sugar metabolism 0.322 
XCL1 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction 0.322 
KCNMA1 
Pancreatic secretion, Salivary secretion, Vascular smooth muscle 
contraction 0.322 
TPM2 
Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic 
cardiomyopathy (HCM) 0.322 
FOLR2 Endocytosis 0.322 
JAK3 
IL 2 signaling pathway, IL 4 signaling pathway, IL 6 signaling 
pathway, IL-2 Receptor Beta Chain in T cell Activation, IL22 
Soluble Receptor Signaling Pathway , IL-7 Signal Transduction, 
Stat3 Signaling Pathway, Chemokine signaling pathway, Jak-
STAT signaling pathway, Primary immunodeficiency 0.322 
OR10C1 Olfactory transduction 0.322 
SETD7 Lysine degradation 0.322 
LDHAL6B 
Cysteine and methionine metabolism, Glycolysis / 
Gluconeogenesis, Metabolic pathways, Propanoate metabolism, 
Pyruvate metabolism 0.322 
TAS2R60 Taste transduction 0.322 
RELT Cytokine-cytokine receptor interaction 0.322 
PRKCSH Protein processing in endoplasmic reticulum 0.322 
POLR3H 
Cytosolic DNA-sensing pathway, Metabolic pathways, Purine 
metabolism, Pyrimidine metabolism, RNA polymerase 0.303 
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KLK2 
Erk1/Erk2 Mapk Signaling pathway, Nerve growth factor pathway 
(NGF), Phosphorylation of MEK1 by cdk5/p35 down regulates the 
MAP kinase pathway, Trka Receptor Signaling Pathway 0.300 
GABRA5 
Cardiac Protection Against ROS, Gamma-aminobutyric Acid 
Receptor Life Cycle, Neuroactive ligand-receptor interaction 0.284 
NT5C2 
Metabolic pathways, Nicotinate and nicotinamide metabolism, 
Purine metabolism, Pyrimidine metabolism 0.284 
SGPP2 Sphingolipid metabolism 0.263 
ARAF 
Acute myeloid leukemia, Bladder cancer, Chronic myeloid 
leukemia, Colorectal cancer, Endometrial cancer, ErbB signaling 
pathway, Glioma, Hepatitis C, Insulin signaling pathway, Long-
term depression, Long-term potentiation, Melanoma, Natural killer 
cell mediated cytotoxicity, Non-small cell lung cancer, Pancreatic 
cancer, Pathways in cancer, Progesterone-mediated oocyte 
maturation, Prostate cancer, Regulation of actin cytoskeleton, 
Renal cell carcinoma, Vascular smooth muscle contraction 0.263 
PSMA8 Proteasome 0.263 
HRH1 
Calcium signaling pathway, Neuroactive ligand-receptor 
interaction 0.263 
EPO 
EPO Signaling Pathway, Erythrocyte Differentiation Pathway, 
Erythropoietin mediated neuroprotection through NF-kB, Hypoxia-
Inducible Factor in the Cardiovascular System, Regulation of 
hematopoiesis by cytokines, Cytokine-cytokine receptor 
interaction, Hematopoietic cell lineage, Jak-STAT signaling 
pathway 0.263 
CYP27A1 
Metabolic pathways, PPAR signaling pathway, Primary bile acid 
biosynthesis 0.263 
NDUFS3 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.263 
RICTOR mTOR signaling pathway 0.263 
ATP5B 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.263 
MAFK Oxidative Stress Induced Gene Expression Via Nrf2 0.263 
SMS 
Arginine and proline metabolism, beta-Alanine metabolism, 
Cysteine and methionine metabolism, Glutathione metabolism, 
Metabolic pathways 0.263 
GRIN2B 
Nitric Oxide Signaling Pathway, Alzheimer's disease, Amyotrophic 
lateral sclerosis (ALS), Huntington's disease, Long-term 
potentiation, Neuroactive ligand-receptor interaction, Systemic 
lupus erythematosus 0.263 
OCLN 
Cell adhesion molecules (CAMs), Hepatitis C, Leukocyte 
transendothelial migration, Pathogenic Escherichia coli infection, 
Tight junction 0.263 
BMP8A Hedgehog signaling pathway, TGF-beta signaling pathway 0.263 
UTS2R Neuroactive ligand-receptor interaction 0.263 
ABCG8 ABC transporters, Bile secretion, Fat digestion and absorption 0.263 
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GNRH2 GnRH signaling pathway 0.254 
CLDN4 
Cell adhesion molecules (CAMs), Hepatitis C, Leukocyte 
transendothelial migration, Tight junction 0.252 
ACTN3 
Cell to Cell Adhesion Signaling, Integrin Signaling Pathway, 
uCalpain and friends in Cell spread, Adherens junction, 
Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy 
(ARVC), Focal adhesion, Leukocyte transendothelial migration, 
Regulation of actin cytoskeleton, Systemic lupus erythematosus, 
Tight junction 0.241 
H2AFJ Systemic lupus erythematosus 0.222 
AP4E1 Lysosome 0.214 
PQBP1 Spliceosome 0.214 
CACNG1 
Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac 
muscle contraction, Dilated cardiomyopathy, Hypertrophic 
cardiomyopathy (HCM), MAPK signaling pathway 0.202 
IDH3G Citrate cycle (TCA cycle), Metabolic pathways 0.202 
POMT1 Other types of O-glycan biosynthesis 0.202 
BDKRB1 
Calcium signaling pathway, Complement and coagulation 
cascades, Neuroactive ligand-receptor interaction, Regulation of 
actin cytoskeleton 0.202 
SPCS3 Protein export 0.202 
RRBP1 Protein processing in endoplasmic reticulum 0.202 
UBE2NL Ubiquitin mediated proteolysis 0.202 
GEMIN8 RNA transport 0.202 
MSR1 Phagosome 0.202 
HERC1 Ubiquitin mediated proteolysis 0.202 
ADCY3 
Bile secretion, Calcium signaling pathway, Chemokine signaling 
pathway, Dilated cardiomyopathy, Gap junction, Gastric acid 
secretion, GnRH signaling pathway, Melanogenesis, Olfactory 
transduction, Oocyte meiosis, Pancreatic secretion, Progesterone-
mediated oocyte maturation, Purine metabolism, Salivary 
secretion, Vascular smooth muscle contraction, Vasopressin-
regulated water reabsorption, Vibrio cholerae infection 0.202 
EIF4E1B 
Insulin signaling pathway, mTOR signaling pathway, RNA 
transport 0.202 
TIMP1 Inhibition of Matrix Metalloproteinases 0.202 
TPH1 Metabolic pathways, Tryptophan metabolism 0.202 
ORC5 CDK Regulation of DNA Replication, Cell cycle 0.202 
PIGH 
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis, Metabolic 
pathways 0.202 
OR4A16 Olfactory transduction 0.202 
HNF4A Maturity onset diabetes of the young 0.193 
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STAT4 
IL12 and Stat4 Dependent Signaling Pathway in Th1 
Development, NO2-dependent IL 12 Pathway in NK cells, Jak-
STAT signaling pathway 0.193 
ORC4 CDK Regulation of DNA Replication, Cell cycle 0.184 
EIF2S1 
Apoptotic Signaling in Response to DNA Damage, Double 
Stranded RNA Induced Gene Expression, Eukaryotic protein 
translation, Regulation of eIF2, Skeletal muscle hypertrophy is 
regulated via AKT/mTOR pathway, VEGF, Hypoxia, and 
Angiogenesis, Hepatitis C, Protein processing in endoplasmic 
reticulum, RNA transport 0.170 
TAAR9 Neuroactive ligand-receptor interaction 0.170 
CYP19A1 Metabolic pathways, Steroid hormone biosynthesis 0.163 
GSK3A 
Phosphoinositides and their downstream targets., Chemokine 
signaling pathway 0.152 
F5 
Extrinsic Prothrombin Activation Pathway, Intrinsic Prothrombin 
Activation Pathway, Complement and coagulation cascades 0.138 
CPA2 Pancreatic secretion, Protein digestion and absorption 0.138 
SLIT1 Axon guidance 0.138 
OR6C75 Olfactory transduction 0.138 
LSM5 RNA degradation, Spliceosome 0.138 
UGT2B15 
Ascorbate and aldarate metabolism, Drug metabolism - 
cytochrome P450, Drug metabolism - other enzymes, Metabolic 
pathways, Metabolism of xenobiotics by cytochrome P450, Other 
types of O-glycan biosynthesis, Pentose and glucuronate 
interconversions, Porphyrin and chlorophyll metabolism, Retinol 
metabolism, Starch and sucrose metabolism, Steroid hormone 
biosynthesis 0.138 
RAN 
Cycling of Ran in nucleocytoplasmic transport, Mechanism of 
Protein Import into the Nucleus, Role of Ran in mitotic spindle 
regulation, Sumoylation by RanBP2 Regulates Transcriptional 
Repression, Ribosome biogenesis in eukaryotes, RNA transport 0.138 
CSF3R 
Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, 
Jak-STAT signaling pathway, Pathways in cancer 0.138 
PLCD3 
Calcium signaling pathway, Inositol phosphate metabolism, 
Metabolic pathways, Phosphatidylinositol signaling system 0.138 
GALNT7 Metabolic pathways, Mucin type O-Glycan biosynthesis 0.138 
RRM2 
Glutathione metabolism, Metabolic pathways, p53 signaling 
pathway, Purine metabolism, Pyrimidine metabolism 0.138 
XPC Nucleotide excision repair 0.138 
SEMA3C Axon guidance 0.138 
CHI3L1 Amino sugar and nucleotide sugar metabolism 0.138 
ERBB2 
Role of ERBB2 in Signal Transduction and Oncology, Trefoil 
Factors Initiate Mucosal Healing, Adherens junction, Bladder 
cancer, Calcium signaling pathway, Endometrial cancer, ErbB 0.138 
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signaling pathway, Focal adhesion, Non-small cell lung cancer, 
Pancreatic cancer, Pathways in cancer, Prostate cancer 
CHST13 
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan 
sulfate, Sulfur metabolism 0.138 
CCL21 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction 0.138 
PPP1R1A Long-term potentiation 0.138 
RAP2B Phospholipase C-epsilon pathway 0.138 
RPTOR Insulin signaling pathway, mTOR signaling pathway 0.131 
NOP56 Ribosome biogenesis in eukaryotes 0.131 
U2AF1 Spliceosomal Assembly, Shigellosis, Spliceosome 0.112 
MAPK9 
MAPKinase Signaling Pathway, Adipocytokine signaling pathway, 
Chagas disease (American trypanosomiasis), Colorectal cancer, 
Epithelial cell signaling in Helicobacter pylori infection, ErbB 
signaling pathway, Fc epsilon RI signaling pathway, Focal 
adhesion, GnRH signaling pathway, Hepatitis C, Insulin signaling 
pathway, MAPK signaling pathway, Neurotrophin signaling 
pathway, NOD-like receptor signaling pathway, Osteoclast 
differentiation, Pancreatic cancer, Pathways in cancer, 
Progesterone-mediated oocyte maturation, Protein processing in 
endoplasmic reticulum, RIG-I-like receptor signaling pathway, 
Shigellosis, T cell receptor signaling pathway, Toll-like receptor 
signaling pathway, Toxoplasmosis, Type II diabetes mellitus, Wnt 
signaling pathway 0.111 
OR4C46 Olfactory transduction 0.111 
ATP2B2 
Calcium signaling pathway, Pancreatic secretion, Salivary 
secretion 0.091 
CNTN1 Cell adhesion molecules (CAMs) 0.070 
TIAM2 Chemokine signaling pathway, Regulation of actin cytoskeleton 0.070 
CNOT7 RNA degradation 0.070 
CHRNA3 Neuroactive ligand-receptor interaction 0.070 
PARN RNA degradation 0.070 
PELP1 
CARM1 and Regulation of the Estrogen Receptor, Pelp1 
Modulation of Estrogen Receptor Activity 0.070 
POLG Metabolic pathways 0.070 
IL4R 
IL 4 signaling pathway, Selective expression of chemokine 
receptors during T-cell polarization, Th1/Th2 Differentiation, 
Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, 
Jak-STAT signaling pathway 0.070 
OR4C15 Olfactory transduction 0.070 
BMS1 Ribosome biogenesis in eukaryotes 0.070 
NLRX1 RIG-I-like receptor signaling pathway 0.070 
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ODC1 
Arginine and proline metabolism, Glutathione metabolism, 
Metabolic pathways 0.070 
ATXN3 Protein processing in endoplasmic reticulum 0.070 
ACSL6 
Adipocytokine signaling pathway, Fatty acid degradation, 
Metabolic pathways, Peroxisome, PPAR signaling pathway 0.070 
TRAF5 Pathways in cancer, Small cell lung cancer 0.070 
GRIK3 Neuroactive ligand-receptor interaction 0.070 
ACTC1 
Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic 
cardiomyopathy (HCM) 0.070 
RPL41 Ribosome 0.070 
F13A1 Fibrinolysis Pathway, Complement and coagulation cascades 0.070 
CPSF4 Polyadenylation of mRNA, mRNA surveillance pathway 0.070 
CDH2 
Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell 
adhesion molecules (CAMs) 0.070 
CXCL6 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction, Rheumatoid arthritis 0.070 
MRVI1 Vascular smooth muscle contraction 0.069 
THBS4 
ECM-receptor interaction, Focal adhesion, Malaria, Phagosome, 
TGF-beta signaling pathway 0.067 
CD8B 
Antigen processing and presentation, Cell adhesion molecules 
(CAMs), Hematopoietic cell lineage, Primary immunodeficiency, T 
cell receptor signaling pathway 0.067 
CXCR6 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction 0.067 
CCNB2 
Estrogen-responsive protein Efp controls cell cycle and breast 
tumors growth, Cell cycle, Oocyte meiosis, p53 signaling pathway, 
Progesterone-mediated oocyte maturation 0.064 
MBTPS2 
SREBP control of lipid synthesis, Protein processing in 
endoplasmic reticulum 0.057 
LEF1 
Inactivation of Gsk3 by AKT causes accumulation of b-catenin in 
Alveolar Macrophages, Multi-step Regulation of Transcription by 
Pitx2, Acute myeloid leukemia, Adherens junction, Arrhythmogenic 
right ventricular cardiomyopathy (ARVC), Basal cell carcinoma, 
Colorectal cancer, Endometrial cancer, Melanogenesis, Pathways 
in cancer, Prostate cancer, Thyroid cancer, Wnt signaling pathway 0.052 
DUSP3 MAPK signaling pathway 0.052 
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B: Downregulated genes 
 
8 Hours 
Symbol Defined Gene Lists Fold Change 
MBTPS2 
SREBP control of lipid synthesis, Protein processing in 
endoplasmic reticulum 0.788 
GSK3A 
Phosphoinositides and their downstream targets., Chemokine 
signaling pathway 0.786 
POLG Metabolic pathways 0.781 
THTPA Metabolic pathways, Thiamine metabolism 0.778 
GMPPA 
Amino sugar and nucleotide sugar metabolism, Fructose and 
mannose metabolism, Metabolic pathways 0.778 
IFIT1B Hepatitis C 0.766 
GABRG1 Neuroactive ligand-receptor interaction 0.766 
OR10C1 Olfactory transduction 0.766 
HTR5A 
Calcium signaling pathway, Neuroactive ligand-receptor 
interaction 0.766 
TRPC5 
Ion Channels and Their Functional Role in Vascular 
Endothelium 0.766 
FZR1 
Cell cycle, Progesterone-mediated oocyte maturation, 
Ubiquitin mediated proteolysis 0.764 
KCNJ13 Protein digestion and absorption 0.762 
ITPR1 
Alzheimer's disease, Calcium signaling pathway, Gap 
junction, Gastric acid secretion, GnRH signaling pathway, 
Huntington's disease, Long-term depression, Long-term 
potentiation, Oocyte meiosis, Pancreatic secretion, 
Phosphatidylinositol signaling system, Salivary secretion, 
Vascular smooth muscle contraction 0.750 
ENPP1 
Regulators of Bone Mineralization, Metabolic pathways, 
Nicotinate and nicotinamide metabolism, Pantothenate and 
CoA biosynthesis, Purine metabolism, Riboflavin metabolism, 
Starch and sucrose metabolism 0.747 
MPZL1 Cell adhesion molecules (CAMs) 0.741 
GRIK2 Neuroactive ligand-receptor interaction 0.737 
RAF1 
Angiotensin II mediated activation of JNK Pathway via Pyk2 
dependent signaling, Aspirin Blocks Signaling Pathway 
Involved in Platelet Activation, BCR Signaling Pathway, 
Bioactive Peptide Induced Signaling Pathway, Cadmium 
induces DNA synthesis and proliferation in macrophages, 
CCR3 signaling in Eosinophils, Ceramide Signaling Pathway, 
CXCR4 Signaling Pathway, EGF Signaling Pathway, EPO 
Signaling Pathway, Erk and PI-3 Kinase Are Necessary for 
Collagen Binding in Corneal Epithelia, Erk1/Erk2 Mapk 0.724 
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Signaling pathway, Fc Epsilon Receptor I Signaling in Mast 
Cells, fMLP induced chemokine gene expression in HMC-1 
cells, Growth Hormone Signaling Pathway, IGF-1 Signaling 
Pathway, IL 2 signaling pathway, IL 3 signaling pathway, IL 6 
signaling pathway, IL-2 Receptor Beta Chain in T cell 
Activation, Influence of Ras and Rho proteins on G1 to S 
Transition, Inhibition of Cellular Proliferation by Gleevec, 
Insulin Signaling Pathway, Integrin Signaling Pathway, 
Keratinocyte Differentiation,  
RET Endocytosis, Pathways in cancer, Thyroid cancer 0.722 
CORO1A Phagosome 0.720 
SLC19A3 Vitamin digestion and absorption 0.714 
ADAM17 
g-Secretase mediated ErbB4 Signaling Pathway, Presenilin 
action in Notch and Wnt signaling, Proteolysis and Signaling 
Pathway of Notch, Alzheimer's disease, Epithelial cell 
signaling in Helicobacter pylori infection, Notch signaling 
pathway 0.697 
MYL5 
Focal adhesion, Leukocyte transendothelial migration, 
Regulation of actin cytoskeleton, Tight junction 0.695 
HIF1A 
Erythropoietin mediated neuroprotection through NF-kB, 
Hypoxia and p53 in the Cardiovascular system, Hypoxia-
Inducible Factor in the Cardiovascular System, VEGF, 
Hypoxia, and Angiogenesis, mTOR signaling pathway, 
Pathways in cancer, Renal cell carcinoma 0.695 
GEMIN8 RNA transport 0.686 
RPL26 Ribosome 0.686 
DIAPH2 Regulation of actin cytoskeleton 0.684 
FMO5 Drug metabolism - cytochrome P450 0.678 
OR51B2 Olfactory transduction 0.678 
ZCCHC7 RNA degradation 0.678 
SOS2 
Acute myeloid leukemia, B cell receptor signaling pathway, 
Chemokine signaling pathway, Chronic myeloid leukemia, 
Dorso-ventral axis formation, Endometrial cancer, ErbB 
signaling pathway, Fc epsilon RI signaling pathway, Focal 
adhesion, Gap junction, Glioma, GnRH signaling pathway, 
Hepatitis C, Insulin signaling pathway, Jak-STAT signaling 
pathway, MAPK signaling pathway, Natural killer cell 
mediated cytotoxicity, Neurotrophin signaling pathway, Non-
small cell lung cancer, Pathways in cancer, Prostate cancer, 
Regulation of actin cytoskeleton, Renal cell carcinoma, T cell 
receptor signaling pathway 0.678 
COX7C 
Alzheimer's disease, Cardiac muscle contraction, 
Huntington's disease, Metabolic pathways, Oxidative 
phosphorylation, Parkinson's disease 0.670 
GJD2 Gap junction 0.666 
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WHSC1L1 Lysine degradation 0.661 
LAMC2 
Amoebiasis, ECM-receptor interaction, Focal adhesion, 
Pathways in cancer, Small cell lung cancer, Toxoplasmosis 0.634 
CPEB1 
Dorso-ventral axis formation, Oocyte meiosis, Progesterone-
mediated oocyte maturation 0.632 
EP300 
Acetylation and Deacetylation of RelA in The Nucleus, 
CARM1 and Regulation of the Estrogen Receptor, Cell Cycle: 
G2/M Checkpoint, Control of Gene Expression by Vitamin D 
Receptor, Hypoxia and p53 in the Cardiovascular system, 
Hypoxia-Inducible Factor in the Cardiovascular System, IL-7 
Signal Transduction, Mechanism of Gene Regulation by 
Peroxisome Proliferators via PPARa(alpha), Melanocyte 
Development and Pigmentation Pathway, Multi-step 
Regulation of Transcription by Pitx2, NFkB activation by 
Nontypeable Hemophilus influenzae, Pelp1 Modulation of 
Estrogen Receptor Activity, Role of ERBB2 in Signal 
Transduction and Oncology, Role of MEF2D in T-cell 
Apoptosis, Role of PPAR-gamma Coactivators in Obesity 
and Thermogenesis, TGF beta signaling pathway, 
Transcription Regulation by Methyltransferase of CARM1, 
Adherens junction, Cell cycle, Huntington's disease, Jak-
STAT signaling pathway, Long-term potentiation, 
Melanogenesis, Notch signaling pathway, Pathways in 
cancer, Prostate cancer, Rena ... 0.632 
CNOT1 RNA degradation 0.628 
HIST1H2BI Systemic lupus erythematosus 0.624 
TRMU Sulfur relay system 0.623 
RBM8A mRNA surveillance pathway, RNA transport, Spliceosome 0.606 
ELAC2 RNA transport 0.585 
CSGALNACT2 
Glycosaminoglycan biosynthesis - chondroitin sulfate / 
dermatan sulfate, Metabolic pathways 0.585 
SSR2 Protein processing in endoplasmic reticulum 0.585 
RFC2 DNA replication, Mismatch repair, Nucleotide excision repair 0.585 
SPCS3 Protein export 0.585 
COL4A4 
Acute Myocardial Infarction, Angiotensin-converting enzyme 
2 regulates heart function, Intrinsic Prothrombin Activation 
Pathway, Platelet Amyloid Precursor Protein Pathway, 
Regulators of Bone Mineralization, Vitamin C in the Brain, 
Amoebiasis, ECM-receptor interaction, Focal adhesion, 
Pathways in cancer, Protein digestion and absorption, Small 
cell lung cancer 0.585 
SPCS2 Protein export 0.585 
RASGRP3 B cell receptor signaling pathway, MAPK signaling pathway 0.570 
KCNJ11 Type II diabetes mellitus 0.564 
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STAT4 
IL12 and Stat4 Dependent Signaling Pathway in Th1 
Development, NO2-dependent IL 12 Pathway in NK cells, 
Jak-STAT signaling pathway 0.555 
CKS1B 
Regulation of p27 Phosphorylation during Cell Cycle 
Progression, Pathways in cancer, Small cell lung cancer 0.554 
MMP14 
Inhibition of Matrix Metalloproteinases, GnRH signaling 
pathway 0.550 
NFYC 
Overview of telomerase RNA component gene hTerc 
Transcriptional Regulation, Antigen processing and 
presentation 0.547 
COX6B1 
Alzheimer's disease, Cardiac muscle contraction, 
Huntington's disease, Metabolic pathways, Oxidative 
phosphorylation, Parkinson's disease 0.544 
RELA 
Acetylation and Deacetylation of RelA in The Nucleus, 
Activation of PKC through G protein coupled receptor, AKT 
Signaling Pathway, ATM Signaling Pathway, Bone 
Remodelling, Cadmium induces DNA synthesis and 
proliferation in macrophages, CD40L Signaling Pathway, 
Ceramide Signaling Pathway, Chaperones modulate 
interferon Signaling Pathway, Corticosteroids and 
cardioprotection, CXCR4 Signaling Pathway, Double 
Stranded RNA Induced Gene Expression, Erythropoietin 
mediated neuroprotection through NF-kB, fMLP induced 
chemokine gene expression in HMC-1 cells, Free Radical 
Induced Apoptosis, HIV-I Nef: negative effector of Fas and 
TNF, Human Cytomegalovirus and Map Kinase Pathways, 
Inactivation of Gsk3 by AKT causes accumulation of b-
catenin in Alveolar Macrophages, Induction of apoptosis 
through DR3 and DR4/5 Death Receptors , Influence of Ras 
and Rho proteins on G1 to S Transition, Keratinocyte 
Differentiation, MAPKinase Signaling Pathway, Mechanism of 
Gene Regulation by Peroxisome Proliferato ... 0.541 
RPL39 Ribosome 0.536 
SEC11C Protein export 0.536 
HSPA1B 
Antigen processing and presentation, Endocytosis, MAPK 
signaling pathway, Protein processing in endoplasmic 
reticulum, Spliceosome, Toxoplasmosis 0.536 
GRIN1 
Erythropoietin mediated neuroprotection through NF-kB, 
Nitric Oxide Signaling Pathway, Synaptic Proteins at the 
Synaptic Junction, Alzheimer's disease, Amyotrophic lateral 
sclerosis (ALS), Calcium signaling pathway, Huntington's 
disease, Long-term potentiation, Neuroactive ligand-receptor 
interaction 0.531 
NUDT9 Purine metabolism 0.526 
VAMP1 SNARE interactions in vesicular transport 0.524 
CHAD ECM-receptor interaction, Focal adhesion 0.524 
HLA-DRA 
Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor, Antigen Dependent B 0.518 
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Cell Activation, Antigen Processing and Presentation, B 
Lymphocyte Cell Surface Molecules, Bystander B Cell 
Activation, Cytokines and Inflammatory Response, IL 5 
Signaling Pathway, Lck and Fyn tyrosine kinases in initiation 
of TCR Activation, Th1/Th2 Differentiation, The Co-
Stimulatory Signal During T-cell Activation, The Role of 
Eosinophils in the Chemokine Network of Allergy, Allograft 
rejection, Antigen processing and presentation, Asthma, 
Autoimmune thyroid disease, Cell adhesion molecules 
(CAMs), Graft-versus-host disease, Hematopoietic cell 
lineage, Intestinal immune network for IgA production, 
Leishmaniasis, Phagosome, Rheumatoid arthritis, 
Staphylococcus aureus infection, Systemic lupus 
erythematosus, Toxoplasmosis, Type I diabetes mellitus, 
Viral myocarditis 
WDR36 Ribosome biogenesis in eukaryotes 0.510 
PIAS3 
Hepatitis C, Jak-STAT signaling pathway, Pathways in 
cancer, Small cell lung cancer, Ubiquitin mediated proteolysis 0.509 
TIAM2 
Chemokine signaling pathway, Regulation of actin 
cytoskeleton 0.507 
RORA Circadian rhythm 0.507 
COL5A3 
Amoebiasis, ECM-receptor interaction, Focal adhesion, 
Protein digestion and absorption 0.505 
HK2 
Amino sugar and nucleotide sugar metabolism, Butirosin and 
neomycin biosynthesis, Carbohydrate digestion and 
absorption, Fructose and mannose metabolism, Galactose 
metabolism, Glycolysis / Gluconeogenesis, Insulin signaling 
pathway, Metabolic pathways, Starch and sucrose 
metabolism, Type II diabetes mellitus 0.500 
THOC6 RNA transport 0.491 
PSMD6 Proteasome 0.485 
CA7 Nitrogen metabolism 0.485 
MGAT4A Metabolic pathways, N-Glycan biosynthesis 0.485 
PHKA2 Calcium signaling pathway, Insulin signaling pathway 0.485 
CAMK2A 
Calcium signaling pathway, ErbB signaling pathway, Gastric 
acid secretion, Glioma, GnRH signaling pathway, Long-term 
potentiation, Melanogenesis, Neurotrophin signaling 
pathway, Olfactory transduction, Oocyte meiosis, Wnt 
signaling pathway 0.485 
SNF8 Endocytosis 0.485 
CASP5 NOD-like receptor signaling pathway 0.481 
VAMP2 
Blockade of Neurotransmitter Relase by Botulinum Toxin, 
Salivary secretion, SNARE interactions in vesicular transport, 
Vasopressin-regulated water reabsorption 0.478 
CCL16 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction 0.476 
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POM121L2 RNA transport 0.474 
SLIT1 Axon guidance 0.472 
KLK2 
Erk1/Erk2 Mapk Signaling pathway, Nerve growth factor 
pathway (NGF), Phosphorylation of MEK1 by cdk5/p35 down 
regulates the MAP kinase pathway, Trka Receptor Signaling 
Pathway 0.472 
CD276 Cell adhesion molecules (CAMs) 0.472 
TMEM173 
Cytosolic DNA-sensing pathway, RIG-I-like receptor signaling 
pathway 0.472 
PSMB8 Antigen Processing and Presentation, Proteasome 0.472 
OR4D10 Olfactory transduction 0.469 
TPM1 
Cardiac muscle contraction, Dilated cardiomyopathy, 
Hypertrophic cardiomyopathy (HCM) 0.459 
AP2S1 Endocytosis, Huntington's disease 0.455 
NTN3 Axon guidance 0.444 
ADCY4 
Bile secretion, Calcium signaling pathway, Chemokine 
signaling pathway, Dilated cardiomyopathy, Gap junction, 
Gastric acid secretion, GnRH signaling pathway, 
Melanogenesis, Oocyte meiosis, Pancreatic secretion, 
Progesterone-mediated oocyte maturation, Purine 
metabolism, Salivary secretion, Taste transduction, Vascular 
smooth muscle contraction 0.444 
CLN5 Lysosome 0.444 
PCNA 
p53 Signaling Pathway, Base excision repair, Cell cycle, DNA 
replication, Mismatch repair, Nucleotide excision repair 0.441 
IDH3G Citrate cycle (TCA cycle), Metabolic pathways 0.433 
UBE2NL Ubiquitin mediated proteolysis 0.433 
ITGAD Regulation of actin cytoskeleton 0.433 
TAF9 
Basal transcription factors, Ribosome biogenesis in 
eukaryotes 0.426 
PNLIP 
Fat digestion and absorption, Glycerolipid metabolism, 
Metabolic pathways, Pancreatic secretion, Vitamin digestion 
and absorption 0.426 
GSTK1 
Drug metabolism - cytochrome P450, Glutathione 
metabolism, Metabolism of xenobiotics by cytochrome P450, 
Peroxisome 0.415 
PSMC6 Proteasome 0.415 
ABCG8 
ABC transporters, Bile secretion, Fat digestion and 
absorption 0.415 
MOCS1 Sulfur relay system 0.406 
PRKCSH Protein processing in endoplasmic reticulum 0.404 
B3GAT1 
Glycosaminoglycan biosynthesis - chondroitin sulfate / 
dermatan sulfate, Glycosaminoglycan biosynthesis - heparan 
sulfate / heparin, Metabolic pathways 0.401 
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LRP1 Alzheimer's disease, Malaria 0.396 
DNAH8 
Lissencephaly gene (LIS1) in neuronal migration and 
development 0.389 
ALDH18A1 Arginine and proline metabolism, Metabolic pathways 0.383 
CASC3 mRNA surveillance pathway, RNA transport 0.383 
RPS6KA1 
Cell Cycle: G2/M Checkpoint, Erk1/Erk2 Mapk Signaling 
pathway, Growth Hormone Signaling Pathway, How 
Progesterone Initiates the Oocyte Maturation, MAPKinase 
Signaling Pathway, Melanocyte Development and 
Pigmentation Pathway, Multiple antiapoptotic pathways from 
IGF-1R signaling lead to BAD phosphorylation, Regulation of 
BAD phosphorylation, Role of Erk5 in Neuronal Survival, 
Transcription factor CREB and its extracellular signals, Long-
term potentiation, MAPK signaling pathway, mTOR signaling 
pathway, Neurotrophin signaling pathway, Oocyte meiosis, 
Progesterone-mediated oocyte maturation 0.379 
EPO 
EPO Signaling Pathway, Erythrocyte Differentiation Pathway, 
Erythropoietin mediated neuroprotection through NF-kB, 
Hypoxia-Inducible Factor in the Cardiovascular System, 
Regulation of hematopoiesis by cytokines, Cytokine-cytokine 
receptor interaction, Hematopoietic cell lineage, Jak-STAT 
signaling pathway 0.379 
EXOC3 Tight junction 0.373 
ABCD4 ABC transporters, Peroxisome 0.363 
SEMA6A Axon guidance 0.351 
JAK3 
IL 2 signaling pathway, IL 4 signaling pathway, IL 6 signaling 
pathway, IL-2 Receptor Beta Chain in T cell Activation, IL22 
Soluble Receptor Signaling Pathway , IL-7 Signal 
Transduction, Stat3 Signaling Pathway, Chemokine signaling 
pathway, Jak-STAT signaling pathway, Primary 
immunodeficiency 0.351 
KCNMB1 Vascular smooth muscle contraction 0.350 
SHISA5 p53 signaling pathway 0.344 
IL9R 
Cytokine-cytokine receptor interaction, Hematopoietic cell 
lineage, Jak-STAT signaling pathway 0.334 
AGTR2 
Angiotensin-converting enzyme 2 regulates heart function, 
Bioactive Peptide Induced Signaling Pathway, Role of EGF 
Receptor Transactivation by GPCRs in Cardiac Hypertrophy, 
Neuroactive ligand-receptor interaction, Renin-angiotensin 
system 0.331 
CYP27A1 
Metabolic pathways, PPAR signaling pathway, Primary bile 
acid biosynthesis 0.330 
HIST2H2BE Systemic lupus erythematosus 0.330 
MAPK1 
Agrin in Postsynaptic Differentiation, Angiotensin II mediated 
activation of JNK Pathway via Pyk2 dependent signaling, 
Aspirin Blocks Signaling Pathway Involved in Platelet 0.327 
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Activation, Bioactive Peptide Induced Signaling Pathway, 
Cadmium induces DNA synthesis and proliferation in 
macrophages, CCR3 signaling in Eosinophils, Ceramide 
Signaling Pathway, CXCR4 Signaling Pathway, Erk and PI-3 
Kinase Are Necessary for Collagen Binding in Corneal 
Epithelia, Erk1/Erk2 Mapk Signaling pathway, Fc Epsilon 
Receptor I Signaling in Mast Cells, fMLP induced chemokine 
gene expression in HMC-1 cells, Growth Hormone Signaling 
Pathway, How Progesterone Initiates the Oocyte Maturation, 
Human Cytomegalovirus and Map Kinase Pathways, IL-2 
Receptor Beta Chain in T cell Activation, Influence of Ras 
and Rho proteins on G1 to S Transition, Integrin Signaling 
Pathway, Keratinocyte Differentiation, Links between Pyk2 
and Map Kinases, MAPKinase Signaling Pathway, 
Mechanism of Gene Regulation by Peroxisome Prolifer. 
SDHC 
Electron Transport Reaction in Mitochondria, Alzheimer's 
disease, Citrate cycle (TCA cycle), Huntington's disease, 
Metabolic pathways, Oxidative phosphorylation, Parkinson's 
disease 0.322 
MRVI1 Vascular smooth muscle contraction 0.322 
ADA 
Metabolic pathways, Primary immunodeficiency, Purine 
metabolism 0.322 
ORC4 CDK Regulation of DNA Replication, Cell cycle 0.322 
ETV5 
IL12 and Stat4 Dependent Signaling Pathway in Th1 
Development 0.314 
COL9A3 Protein digestion and absorption 0.312 
GNRH2 GnRH signaling pathway 0.310 
NF1 
Chromatin Remodeling by hSWI/SNF ATP-dependent 
Complexes, MAPK signaling pathway 0.300 
B4GALT2 
Galactose metabolism, Glycosaminoglycan biosynthesis - 
keratan sulfate, Glycosphingolipid biosynthesis - lacto and 
neolacto series, Metabolic pathways, N-Glycan biosynthesis, 
Other types of O-glycan biosynthesis 0.297 
PHKA1 Calcium signaling pathway, Insulin signaling pathway 0.294 
AGK Glycerolipid metabolism, Metabolic pathways 0.293 
RENBP Amino sugar and nucleotide sugar metabolism 0.290 
HRH1 
Calcium signaling pathway, Neuroactive ligand-receptor 
interaction 0.290 
ACOX1 
Mechanism of Gene Regulation by Peroxisome Proliferators 
via PPARa(alpha), alpha-Linolenic acid metabolism, 
Biosynthesis of unsaturated fatty acids, Fatty acid 
degradation, Metabolic pathways, Peroxisome, PPAR 
signaling pathway 0.285 
CTSC Lysosome 0.278 
CD9 Hematopoietic cell lineage 0.276 
  
108 
TPM2 
Cardiac muscle contraction, Dilated cardiomyopathy, 
Hypertrophic cardiomyopathy (HCM) 0.272 
CDKN1A 
ATM Signaling Pathway, Cell Cycle: G1/S Check Point , Cell 
Cycle: G2/M Checkpoint, Cyclins and Cell Cycle Regulation, 
Effects of calcineurin in Keratinocyte Differentiation, 
Erythropoietin mediated neuroprotection through NF-kB, 
Hypoxia and p53 in the Cardiovascular system, Influence of 
Ras and Rho proteins on G1 to S Transition, p53 Signaling 
Pathway, Bladder cancer, Cell cycle, Chronic myeloid 
leukemia, ErbB signaling pathway, Glioma, Hepatitis C, 
Melanoma, p53 signaling pathway, Pathways in cancer, 
Prostate cancer 0.268 
IL1A 
Adhesion and Diapedesis of Granulocytes, Adhesion and 
Diapedesis of Lymphocytes, Cells and Molecules involved in 
local acute inflammatory response, Cytokine Network, 
Cytokines and Inflammatory Response, Erythrocyte 
Differentiation Pathway, IL-10 Anti-inflammatory Signaling 
Pathway, NF-kB Signaling Pathway, Signal transduction 
through IL1R, Stress Induction of HSP Regulation, Apoptosis, 
Cytokine-cytokine receptor interaction, Graft-versus-host 
disease, Hematopoietic cell lineage, Leishmaniasis, MAPK 
signaling pathway, Osteoclast differentiation, Prion diseases, 
Rheumatoid arthritis, Type I diabetes mellitus 0.263 
TAAR9 Neuroactive ligand-receptor interaction 0.263 
PHF5A Spliceosome 0.263 
FAAH Metabolism of Anandamide, an Endogenous Cannabinoid 0.263 
OR1D5 Olfactory transduction 0.252 
A2M Complement and coagulation cascades 0.248 
SRSF2 Spliceosomal Assembly, Spliceosome 0.245 
POMT1 Other types of O-glycan biosynthesis 0.241 
SEMA3C Axon guidance 0.241 
NOB1 Ribosome biogenesis in eukaryotes 0.237 
CHST13 
Glycosaminoglycan biosynthesis - chondroitin sulfate / 
dermatan sulfate, Sulfur metabolism 0.234 
OR52K2 Olfactory transduction 0.222 
MUSK 
Agrin in Postsynaptic Differentiation, Role of nicotinic 
acetylcholine receptors in the regulation of apoptosis 0.222 
RORC Circadian rhythm 0.218 
DUSP3 MAPK signaling pathway 0.216 
ALG13 Metabolic pathways, N-Glycan biosynthesis 0.214 
FRAT1 WNT Signaling Pathway, Wnt signaling pathway 0.206 
TSHR 
Autoimmune thyroid disease, Neuroactive ligand-receptor 
interaction 0.206 
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CD79A 
B Cell Receptor Complex, BCR Signaling Pathway, CTCF: 
First Multivalent Nuclear Factor, B cell receptor signaling 
pathway, Primary immunodeficiency 0.202 
IL23R 
Cytokine-cytokine receptor interaction, Jak-STAT signaling 
pathway 0.202 
PARN RNA degradation 0.202 
COMP 
ECM-receptor interaction, Focal adhesion, Malaria, 
Phagosome, TGF-beta signaling pathway 0.202 
TUBA1C 
Gap junction, Pathogenic Escherichia coli infection, 
Phagosome 0.202 
OR52E2 Olfactory transduction 0.202 
CUL4B Nucleotide excision repair, Ubiquitin mediated proteolysis 0.202 
CTSE Lysosome 0.200 
DDX3Y RIG-I-like receptor signaling pathway 0.193 
CHRNA3 Neuroactive ligand-receptor interaction 0.193 
ATP2B3 
Calcium signaling pathway, Pancreatic secretion, Salivary 
secretion 0.188 
CLDN10 
Cell adhesion molecules (CAMs), Hepatitis C, Leukocyte 
transendothelial migration, Tight junction 0.186 
CREB5 
Huntington's disease, Prostate cancer, Vasopressin-
regulated water reabsorption 0.177 
SESN3 p53 signaling pathway 0.175 
ATP5A1 
Electron Transport Reaction in Mitochondria, Alzheimer's 
disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.175 
CNOT7 RNA degradation 0.173 
FOLR2 Endocytosis 0.170 
DSC2 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.170 
GNG4 Chemokine signaling pathway 0.160 
CLDN4 
Cell adhesion molecules (CAMs), Hepatitis C, Leukocyte 
transendothelial migration, Tight junction 0.158 
PLA2G2A 
alpha-Linolenic acid metabolism, Arachidonic acid 
metabolism, Ether lipid metabolism, Fat digestion and 
absorption, Fc epsilon RI signaling pathway, 
Glycerophospholipid metabolism, GnRH signaling pathway, 
Linoleic acid metabolism, Long-term depression, MAPK 
signaling pathway, Metabolic pathways, Pancreatic secretion, 
Toxoplasmosis, Vascular smooth muscle contraction, VEGF 
signaling pathway 0.156 
ATG3 Regulation of autophagy 0.140 
RRM2 
Glutathione metabolism, Metabolic pathways, p53 signaling 
pathway, Purine metabolism, Pyrimidine metabolism 0.127 
PAQR7 How Progesterone Initiates the Oocyte Maturation 0.126 
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WASF3 
Y branching of actin filaments, Adherens junction, Fc gamma 
R-mediated phagocytosis 0.126 
PICALM Endocytotic role of NDK, Phosphins and Dynamin 0.122 
OR4A16 Olfactory transduction 0.115 
NDUFS3 
Alzheimer's disease, Huntington's disease, Metabolic 
pathways, Oxidative phosphorylation, Parkinson's disease 0.104 
IL3 
Cytokine Network, Cytokines and Inflammatory Response, 
Dendritic cells in regulating TH1 and TH2 Development, 
Erythrocyte Differentiation Pathway, IL 17 Signaling Pathway, 
IL 3 signaling pathway, Regulation of BAD phosphorylation, 
Regulation of hematopoiesis by cytokines, The Role of 
Eosinophils in the Chemokine Network of Allergy, Apoptosis, 
Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI 
signaling pathway, Hematopoietic cell lineage, Jak-STAT 
signaling pathway 0.103 
TALDO1 Metabolic pathways, Pentose phosphate pathway 0.100 
SUMO4 RNA transport 0.096 
MYC 
Cadmium induces DNA synthesis and proliferation in 
macrophages, CTCF: First Multivalent Nuclear Factor, 
Erk1/Erk2 Mapk Signaling pathway, IL-2 Receptor Beta 
Chain in T cell Activation, Inhibition of Cellular Proliferation by 
Gleevec, MAPKinase Signaling Pathway, Mechanism of 
Gene Regulation by Peroxisome Proliferators via 
PPARa(alpha), Neuropeptides VIP and PACAP inhibit the 
apoptosis of activated T cells, Overview of telomerase protein 
component gene hTert Transcriptional Regulation , p38 
MAPK Signaling Pathway , Role of EGF Receptor 
Transactivation by GPCRs in Cardiac Hypertrophy, 
Telomeres, Telomerase, Cellular Aging, and  Immortality, 
Tumor Suppressor Arf Inhibits Ribosomal Biogenesis, WNT 
Signaling Pathway, Acute myeloid leukemia, Bladder cancer, 
Cell cycle, Chronic myeloid leukemia, Colorectal cancer, 
Endometrial cancer, ErbB signaling pathway, Jak-STAT 
signaling pathway, MAPK signaling pathway, Pathways in 
cancer, Small cell lung cancer, TGF-beta signaling pathway,  0.093 
OCLN 
Cell adhesion molecules (CAMs), Hepatitis C, Leukocyte 
transendothelial migration, Pathogenic Escherichia coli 
infection, Tight junction 0.091 
LEPR 
Reversal of Insulin Resistance by Leptin, Adipocytokine 
signaling pathway, Cytokine-cytokine receptor interaction, 
Jak-STAT signaling pathway, Neuroactive ligand-receptor 
interaction 0.084 
FOLH1 Vitamin digestion and absorption 0.074 
NPY5R Neuroactive ligand-receptor interaction 0.072 
PEX13 Peroxisome 0.061 
ACP2 Lysosome, Riboflavin metabolism 0.059 
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RCC1 
Cycling of Ran in nucleocytoplasmic transport, Mechanism of 
Protein Import into the Nucleus, Role of Ran in mitotic spindle 
regulation 0.051 
GRIN2B 
Nitric Oxide Signaling Pathway, Alzheimer's disease, 
Amyotrophic lateral sclerosis (ALS), Huntington's disease, 
Long-term potentiation, Neuroactive ligand-receptor 
interaction, Systemic lupus erythematosus 0.049 
CCNB2 
Estrogen-responsive protein Efp controls cell cycle and 
breast tumors growth, Cell cycle, Oocyte meiosis, p53 
signaling pathway, Progesterone-mediated oocyte maturation 0.042 
GIT1 
Endocytosis, Epithelial cell signaling in Helicobacter pylori 
infection, Regulation of actin cytoskeleton 0.041 
MEFV NOD-like receptor signaling pathway 0.041 
GNA14 
Amoebiasis, Calcium signaling pathway, Chagas disease 
(American trypanosomiasis) 0.035 
GRIA1 
Amyotrophic lateral sclerosis (ALS), Long-term depression, 
Long-term potentiation, Neuroactive ligand-receptor 
interaction 0.031 
TNKS Telomeres, Telomerase, Cellular Aging, and Immortality 0.027 
XPC Nucleotide excision repair 0.019 
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B: Downregulated genes 
 
12 Hours 
 
Symbol 
 
Defined Gene Lists 
 
Fold Change  
ATP2B2 
Calcium signaling pathway, Pancreatic secretion, Salivary 
secretion 0.799 
PHKA1 Calcium signaling pathway, Insulin signaling pathway 0.798 
ATP2A1 
Alzheimer's disease, Calcium signaling pathway, Pancreatic 
secretion 0.787 
JAG2 Notch signaling pathway 0.787 
CAMK2A 
Calcium signaling pathway, ErbB signaling pathway, Gastric 
acid secretion, Glioma, GnRH signaling pathway, Long-term 
potentiation, Melanogenesis, Neurotrophin signaling pathway, 
Olfactory transduction, Oocyte meiosis, Wnt signaling pathway 0.781 
E2F1 
Cell Cycle: G1/S Check Point , Cyclin E Destruction Pathway, 
Cyclins and Cell Cycle Regulation, E2F1 Destruction Pathway, 
IL-2 Receptor Beta Chain in T cell Activation, Influence of Ras 
and Rho proteins on G1 to S Transition, METS affect on 
Macrophage Differentiation, p53 Signaling Pathway, Regulation 
of p27 Phosphorylation during Cell Cycle Progression, Tumor 
Suppressor Arf Inhibits Ribosomal Biogenesis, Bladder cancer, 
Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-
small cell lung cancer, Pancreatic cancer, Pathways in cancer, 
Prostate cancer, Small cell lung cancer 0.781 
CXCR6 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction 0.781 
VIPR2 
Neuropeptides VIP and PACAP inhibit the apoptosis of activated 
T cells, Neuroactive ligand-receptor interaction 0.781 
OR13C3 Olfactory transduction 0.781 
CTNS Lysosome 0.772 
OR4C16 Olfactory transduction 0.751 
HK2 
Amino sugar and nucleotide sugar metabolism, Butirosin and 
neomycin biosynthesis, Carbohydrate digestion and absorption, 
Fructose and mannose metabolism, Galactose metabolism, 
Glycolysis / Gluconeogenesis, Insulin signaling pathway, 
Metabolic pathways, Starch and sucrose metabolism, Type II 
diabetes mellitus 0.748 
MARS2 Aminoacyl-tRNA biosynthesis, Selenocompound metabolism 0.748 
SLC25A5 
Calcium signaling pathway, Huntington's disease, Parkinson's 
disease 0.748 
ZBP1 Cytosolic DNA-sensing pathway 0.748 
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AGPAT4 
Glycerolipid metabolism, Glycerophospholipid metabolism, 
Metabolic pathways 0.748 
FADD 
Acetylation and Deacetylation of RelA in The Nucleus, Ceramide 
Signaling Pathway, FAS signaling pathway (CD95), HIV-I Nef: 
negative effector of Fas and TNF, Induction of apoptosis through 
DR3 and DR4/5 Death Receptors , NF-kB Signaling Pathway, 
SODD/TNFR1 Signaling Pathway, TNFR1 Signaling Pathway, 
Alzheimer's disease, Apoptosis, Chagas disease (American 
trypanosomiasis), Pathways in cancer, RIG-I-like receptor 
signaling pathway, Toll-like receptor signaling pathway 0.735 
EPB41L3 Tight junction 0.727 
NPFFR1 Neuroactive ligand-receptor interaction 0.725 
HTR5A 
Calcium signaling pathway, Neuroactive ligand-receptor 
interaction 0.717 
CDK7 
Cyclins and Cell Cycle Regulation, Degradation of the RAR and 
RXR by the proteasome, Estrogen-responsive protein Efp 
controls cell cycle and breast tumors growth, Sonic Hedgehog 
(SHH) Receptor Ptc1 Regulates cell cycle, Cell cycle, 
Nucleotide excision repair 0.714 
LEF1 
Inactivation of Gsk3 by AKT causes accumulation of b-catenin in 
Alveolar Macrophages, Multi-step Regulation of Transcription by 
Pitx2, Acute myeloid leukemia, Adherens junction, 
Arrhythmogenic right ventricular cardiomyopathy (ARVC), Basal 
cell carcinoma, Colorectal cancer, Endometrial cancer, 
Melanogenesis, Pathways in cancer, Prostate cancer, Thyroid 
cancer, Wnt signaling pathway 0.714 
TSC1 
mTOR Signaling Pathway, Insulin signaling pathway, mTOR 
signaling pathway 0.714 
LRP5 Wnt signaling pathway 0.708 
GALNT7 Metabolic pathways, Mucin type O-Glycan biosynthesis 0.693 
FCAR Phagosome, Staphylococcus aureus infection 0.693 
ACSL6 
Adipocytokine signaling pathway, Fatty acid degradation, 
Metabolic pathways, Peroxisome, PPAR signaling pathway 0.679 
RELT Cytokine-cytokine receptor interaction 0.679 
PRKCD 
HIV-I Nef: negative effector of Fas and TNF, Keratinocyte 
Differentiation, Chemokine signaling pathway, Fc epsilon RI 
signaling pathway, Fc gamma R-mediated phagocytosis, GnRH 
signaling pathway, Neurotrophin signaling pathway, Tight 
junction, Type II diabetes mellitus, Vascular smooth muscle 
contraction 0.679 
MNX1 Maturity onset diabetes of the young 0.679 
PRDM4 Neurotrophin signaling pathway 0.679 
OR52H1 Olfactory transduction 0.679 
TRAF5 Pathways in cancer, Small cell lung cancer 0.679 
NUDT9 Purine metabolism 0.679 
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CRB3 Tight junction 0.679 
SEMA4D Axon guidance 0.678 
FOSL2 Bone Remodelling, Osteoclast differentiation 0.676 
OR52D1 Olfactory transduction 0.676 
AKT3 
Acute myeloid leukemia, Adipocytokine signaling pathway, 
Apoptosis, B cell receptor signaling pathway, Carbohydrate 
digestion and absorption, Chagas disease (American 
trypanosomiasis), Chemokine signaling pathway, Chronic 
myeloid leukemia, Colorectal cancer, Endometrial cancer, ErbB 
signaling pathway, Fc epsilon RI signaling pathway, Fc gamma 
R-mediated phagocytosis, Focal adhesion, Glioma, Hepatitis C, 
Insulin signaling pathway, Jak-STAT signaling pathway, MAPK 
signaling pathway, Melanoma, mTOR signaling pathway, 
Neurotrophin signaling pathway, Non-small cell lung cancer, 
Osteoclast differentiation, Pancreatic cancer, Pathways in 
cancer, Progesterone-mediated oocyte maturation, Prostate 
cancer, Renal cell carcinoma, Small cell lung cancer, T cell 
receptor signaling pathway, Tight junction, Toll-like receptor 
signaling pathway, Toxoplasmosis, VEGF signaling pathway 0.674 
PGM2 
Amino sugar and nucleotide sugar metabolism, Galactose 
metabolism, Glycolysis / Gluconeogenesis, Metabolic pathways, 
Pentose phosphate pathway, Purine metabolism, Starch and 
sucrose metabolism 0.669 
ATXN3 Protein processing in endoplasmic reticulum 0.669 
CNOT1 RNA degradation 0.660 
PAX3 Regulation of transcriptional activity by PML 0.656 
NEFH Amyotrophic lateral sclerosis (ALS) 0.644 
HMGB2 
Apoptotic DNA fragmentation and tissue homeostasis, 
Granzyme A mediated Apoptosis Pathway 0.644 
ITGA10 
Arrhythmogenic right ventricular cardiomyopathy (ARVC), 
Dilated cardiomyopathy, ECM-receptor interaction, Focal 
adhesion, Hypertrophic cardiomyopathy (HCM), Regulation of 
actin cytoskeleton 0.644 
FGF1 
BTG family proteins and cell cycle regulation, MAPK signaling 
pathway, Melanoma, Pathways in cancer, Regulation of actin 
cytoskeleton 0.644 
CAMK2B 
Calcium signaling pathway, ErbB signaling pathway, Gastric 
acid secretion, Glioma, GnRH signaling pathway, Long-term 
potentiation, Melanogenesis, Neurotrophin signaling pathway, 
Olfactory transduction, Oocyte meiosis, Wnt signaling pathway 0.644 
PLCD3 
Calcium signaling pathway, Inositol phosphate metabolism, 
Metabolic pathways, Phosphatidylinositol signaling system 0.644 
GADD45B Cell cycle, MAPK signaling pathway, p53 signaling pathway 0.644 
IMPDH2 
Drug metabolism - other enzymes, Metabolic pathways, Purine 
metabolism 0.644 
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CCR5 
HIV Induced T Cell Apoptosis, IL12 and Stat4 Dependent 
Signaling Pathway in Th1 Development, NO2-dependent IL 12 
Pathway in NK cells, Pertussis toxin-insensitive CCR5 Signaling 
in Macrophage, Selective expression of chemokine receptors 
during T-cell polarization, Chemokine signaling pathway, 
Cytokine-cytokine receptor interaction, Endocytosis, 
Toxoplasmosis 0.644 
CNR2 
Metabolism of Anandamide, an Endogenous Cannabinoid, 
Neuroactive ligand-receptor interaction 0.644 
LAT 
Ras-Independent pathway in NK cell-mediated cytotoxicity, T 
Cell Receptor Signaling Pathway, Fc epsilon RI signaling 
pathway, Fc gamma R-mediated phagocytosis, Natural killer cell 
mediated cytotoxicity, T cell receptor signaling pathway 0.644 
CHRNB1 
Role of nicotinic acetylcholine receptors in the regulation of 
apoptosis, Neuroactive ligand-receptor interaction 0.644 
GRIA1 
Amyotrophic lateral sclerosis (ALS), Long-term depression, 
Long-term potentiation, Neuroactive ligand-receptor interaction 0.632 
TNKS Telomeres, Telomerase, Cellular Aging, and Immortality 0.615 
ITGAD Regulation of actin cytoskeleton 0.611 
CARS Aminoacyl-tRNA biosynthesis 0.607 
HTR7 
Calcium signaling pathway, Neuroactive ligand-receptor 
interaction 0.607 
NUP43 RNA transport 0.607 
TAS2R60 Taste transduction 0.607 
CXXC4 Wnt signaling pathway 0.607 
ACP2 Lysosome, Riboflavin metabolism 0.589 
SLC27A1 PPAR signaling pathway 0.573 
RPS29 Ribosome 0.573 
PDE6A 
Visual Signal Transduction, Phototransduction, Purine 
metabolism 0.573 
HSPA1B 
Antigen processing and presentation, Endocytosis, MAPK 
signaling pathway, Protein processing in endoplasmic reticulum, 
Spliceosome, Toxoplasmosis 0.570 
CDKN1A 
ATM Signaling Pathway, Cell Cycle: G1/S Check Point , Cell 
Cycle: G2/M Checkpoint, Cyclins and Cell Cycle Regulation, 
Effects of calcineurin in Keratinocyte Differentiation, 
Erythropoietin mediated neuroprotection through NF-kB, 
Hypoxia and p53 in the Cardiovascular system, Influence of Ras 
and Rho proteins on G1 to S Transition, p53 Signaling Pathway, 
Bladder cancer, Cell cycle, Chronic myeloid leukemia, ErbB 
signaling pathway, Glioma, Hepatitis C, Melanoma, p53 
signaling pathway, Pathways in cancer, Prostate cancer 0.570 
ADCY2 
Bile secretion, Calcium signaling pathway, Chemokine signaling 
pathway, Dilated cardiomyopathy, Gap junction, Gastric acid 
secretion, GnRH signaling pathway, Melanogenesis, Oocyte 
meiosis, Pancreatic secretion, Progesterone-mediated oocyte 0.570 
  
116 
maturation, Purine metabolism, Salivary secretion, Vascular 
smooth muscle contraction 
EIF4A2 
Eukaryotic protein translation, Internal Ribosome entry pathway, 
mTOR Signaling Pathway, Regulation of eIF4e and p70 S6 
Kinase, RNA transport 0.570 
OR4A47 Olfactory transduction 0.570 
ITPKA 
Calcium signaling pathway, Inositol phosphate metabolism, 
Metabolic pathways, Phosphatidylinositol signaling system 0.551 
LMNB2 
Caspase Cascade in Apoptosis, FAS signaling pathway (CD95), 
HIV-I Nef: negative effector of Fas and TNF, TNFR1 Signaling 
Pathway 0.540 
FGA 
Acute Myocardial Infarction, Extrinsic Prothrombin Activation 
Pathway, Fibrinolysis Pathway, Intrinsic Prothrombin Activation 
Pathway, Complement and coagulation cascades 0.537 
COL4A4 
Acute Myocardial Infarction, Angiotensin-converting enzyme 2 
regulates heart function, Intrinsic Prothrombin Activation 
Pathway, Platelet Amyloid Precursor Protein Pathway, 
Regulators of Bone Mineralization, Vitamin C in the Brain, 
Amoebiasis, ECM-receptor interaction, Focal adhesion, 
Pathways in cancer, Protein digestion and absorption, Small cell 
lung cancer 0.531 
ATP2B3 
Calcium signaling pathway, Pancreatic secretion, Salivary 
secretion 0.531 
IL2RB 
IL 2 signaling pathway, IL-2 Receptor Beta Chain in T cell 
Activation, Cytokine-cytokine receptor interaction, Endocytosis, 
Jak-STAT signaling pathway 0.531 
INPP4A 
Inositol phosphate metabolism, Metabolic pathways, 
Phosphatidylinositol signaling system 0.531 
CLN5 Lysosome 0.531 
OR6B1 Olfactory transduction 0.531 
NFYC 
Overview of telomerase RNA component gene hTerc 
Transcriptional Regulation, Antigen processing and presentation 0.531 
ZCCHC7 RNA degradation 0.531 
MAPK1 
Agrin in Postsynaptic Differentiation, Angiotensin II mediated 
activation of JNK Pathway via Pyk2 dependent signaling, Aspirin 
Blocks Signaling Pathway Involved in Platelet Activation, 
Bioactive Peptide Induced Signaling Pathway, Cadmium 
induces DNA synthesis and proliferation in macrophages, CCR3 
signaling in Eosinophils, Ceramide Signaling Pathway, CXCR4 
Signaling Pathway, Erk and PI-3 Kinase Are Necessary for 
Collagen Binding in Corneal Epithelia, Erk1/Erk2 Mapk Signaling 
pathway, Fc Epsilon Receptor I Signaling in Mast Cells, fMLP 
induced chemokine gene expression in HMC-1 cells, Growth 
Hormone Signaling Pathway, How Progesterone Initiates the 
Oocyte Maturation, Human Cytomegalovirus and Map Kinase 
Pathways, IL-2 Receptor Beta Chain in T cell Activation, 
Influence of Ras and Rho proteins on G1 to S Transition, 
Integrin Signaling Pathway, Keratinocyte Differentiation, Links 0.530 
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between Pyk2 and Map Kinases, MAPKinase Signaling 
Pathway, Mechanism of Gene Regulation by Peroxisome 
Prolifer. 
PHKA2 Calcium signaling pathway, Insulin signaling pathway 0.528 
ORC5 CDK Regulation of DNA Replication, Cell cycle 0.528 
COL5A3 
Amoebiasis, ECM-receptor interaction, Focal adhesion, Protein 
digestion and absorption 0.524 
DNAH8 
Lissencephaly gene (LIS1) in neuronal migration and 
development 0.524 
DUSP16 MAPK signaling pathway 0.524 
WHSC1L1 Lysine degradation 0.521 
RORA Circadian rhythm 0.518 
CYP19A1 Metabolic pathways, Steroid hormone biosynthesis 0.513 
H2AFJ Systemic lupus erythematosus 0.504 
VHL 
Hypoxia-Inducible Factor in the Cardiovascular System, VEGF, 
Hypoxia, and Angiogenesis, Pathways in cancer, Renal cell 
carcinoma, Ubiquitin mediated proteolysis 0.499 
FSHR 
Regulation of Spermatogenesis by CREM, Neuroactive ligand-
receptor interaction 0.498 
CBLB 
Bacterial invasion of epithelial cells, Chronic myeloid leukemia, 
Endocytosis, ErbB signaling pathway, Insulin signaling pathway, 
Jak-STAT signaling pathway, Pathways in cancer, T cell 
receptor signaling pathway, Ubiquitin mediated proteolysis 0.492 
OGDH 
Citrate cycle (TCA cycle), Lysine degradation, Metabolic 
pathways, Tryptophan metabolism 0.492 
ITCH Endocytosis, Ubiquitin mediated proteolysis 0.492 
MMP14 Inhibition of Matrix Metalloproteinases, GnRH signaling pathway 0.492 
PFN3 Regulation of actin cytoskeleton, Shigellosis 0.492 
RPS11 Ribosome 0.492 
DSC2 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.488 
OR4C46 Olfactory transduction 0.485 
EXOSC2 RNA degradation 0.474 
NEUROG3 Maturity onset diabetes of the young 0.461 
HLA-DRA 
Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor, Antigen Dependent B 
Cell Activation, Antigen Processing and Presentation, B 
Lymphocyte Cell Surface Molecules, Bystander B Cell 
Activation, Cytokines and Inflammatory Response, IL 5 
Signaling Pathway, Lck and Fyn tyrosine kinases in initiation of 
TCR Activation, Th1/Th2 Differentiation, The Co-Stimulatory 
Signal During T-cell Activation, The Role of Eosinophils in the 
Chemokine Network of Allergy, Allograft rejection, Antigen 
processing and presentation, Asthma, Autoimmune thyroid 0.451 
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disease, Cell adhesion molecules (CAMs), Graft-versus-host 
disease, Hematopoietic cell lineage, Intestinal immune network 
for IgA production, Leishmaniasis, Phagosome, Rheumatoid 
arthritis, Staphylococcus aureus infection, Systemic lupus 
erythematosus, Toxoplasmosis, Type I diabetes mellitus, Viral 
myocarditis 
RELN 
Lissencephaly gene (LIS1) in neuronal migration and 
development, Reelin Signaling Pathway, ECM-receptor 
interaction, Focal adhesion 0.451 
HIST1H2BI Systemic lupus erythematosus 0.451 
ADA 
Metabolic pathways, Primary immunodeficiency, Purine 
metabolism 0.446 
MTHFR Metabolic pathways, One carbon pool by folate 0.437 
RPL36 Ribosome 0.432 
POGLUT1 Other types of O-glycan biosynthesis 0.426 
AP3M1 Lysosome 0.421 
TAOK1 MAPK signaling pathway 0.416 
FRAT2 Wnt signaling pathway 0.416 
SMS 
Arginine and proline metabolism, beta-Alanine metabolism, 
Cysteine and methionine metabolism, Glutathione metabolism, 
Metabolic pathways 0.409 
CCL16 
Chemokine signaling pathway, Cytokine-cytokine receptor 
interaction 0.409 
GPX4 Glutathione metabolism 0.409 
ARSA Lysosome, Sphingolipid metabolism 0.409 
ACOX1 
Mechanism of Gene Regulation by Peroxisome Proliferators via 
PPARa(alpha), alpha-Linolenic acid metabolism, Biosynthesis of 
unsaturated fatty acids, Fatty acid degradation, Metabolic 
pathways, Peroxisome, PPAR signaling pathway 0.393 
CUL3 Ubiquitin mediated proteolysis 0.392 
ODC1 
Arginine and proline metabolism, Glutathione metabolism, 
Metabolic pathways 0.391 
CLEC7A Phagosome 0.388 
LDHAL6B 
Cysteine and methionine metabolism, Glycolysis / 
Gluconeogenesis, Metabolic pathways, Propanoate metabolism, 
Pyruvate metabolism 0.368 
EFNA2 Axon guidance 0.366 
NUMBL Notch signaling pathway 0.366 
MAFK Oxidative Stress Induced Gene Expression Via Nrf2 0.366 
CKS1B 
Regulation of p27 Phosphorylation during Cell Cycle 
Progression, Pathways in cancer, Small cell lung cancer 0.366 
HEY2 Segmentation Clock 0.366 
DBF4 Cell cycle 0.354 
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MCM3 CDK Regulation of DNA Replication, Cell cycle, DNA replication 0.348 
TNFRSF11
B Cytokine-cytokine receptor interaction, Osteoclast differentiation 0.348 
TPH1 Metabolic pathways, Tryptophan metabolism 0.344 
NLRX1 RIG-I-like receptor signaling pathway 0.326 
SERPINB9 Amoebiasis 0.322 
VAMP2 
Blockade of Neurotransmitter Relase by Botulinum Toxin, 
Salivary secretion, SNARE interactions in vesicular transport, 
Vasopressin-regulated water reabsorption 0.322 
TIMP1 Inhibition of Matrix Metalloproteinases 0.322 
PON1 Metabolic pathways 0.322 
AKR1C1 
Metabolism of xenobiotics by cytochrome P450, Steroid 
hormone biosynthesis 0.322 
S1PR1 
Phospholipids as signalling intermediaries, Neuroactive ligand-
receptor interaction 0.322 
SIKE1 RIG-I-like receptor signaling pathway 0.322 
SNAP29 SNARE interactions in vesicular transport 0.322 
ALDH18A1 Arginine and proline metabolism, Metabolic pathways 0.304 
C8A 
Alternative Complement Pathway, Classical Complement 
Pathway, Complement Pathway, Lectin Induced Complement 
Pathway, Amoebiasis, Complement and coagulation cascades, 
Prion diseases, Systemic lupus erythematosus 0.276 
CSF3R 
Cytokine-cytokine receptor interaction, Hematopoietic cell 
lineage, Jak-STAT signaling pathway, Pathways in cancer 0.276 
CTSD 
Downregulated of MTA-3 in ER-negative Breast Tumors, 
Lysosome 0.276 
GCAT Glycine, serine and threonine metabolism 0.276 
NMRK1 Nicotinate and nicotinamide metabolism 0.276 
RAN 
Cycling of Ran in nucleocytoplasmic transport, Mechanism of 
Protein Import into the Nucleus, Role of Ran in mitotic spindle 
regulation, Sumoylation by RanBP2 Regulates Transcriptional 
Repression, Ribosome biogenesis in eukaryotes, RNA transport 0.272 
CARD8 NOD-like receptor signaling pathway 0.268 
CDC40 Spliceosome 0.255 
CD44 
Adhesion Molecules on Lymphocyte, Monocyte and its Surface 
Molecules, Neutrophil and Its Surface Molecules, ECM-receptor 
interaction, Hematopoietic cell lineage, Shigellosis 0.229 
EIF2S1 
Apoptotic Signaling in Response to DNA Damage, Double 
Stranded RNA Induced Gene Expression, Eukaryotic protein 
translation, Regulation of eIF2, Skeletal muscle hypertrophy is 
regulated via AKT/mTOR pathway, VEGF, Hypoxia, and 
Angiogenesis, Hepatitis C, Protein processing in endoplasmic 
reticulum, RNA transport 0.229 
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ACTN3 
Cell to Cell Adhesion Signaling, Integrin Signaling Pathway, 
uCalpain and friends in Cell spread, Adherens junction, 
Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy 
(ARVC), Focal adhesion, Leukocyte transendothelial migration, 
Regulation of actin cytoskeleton, Systemic lupus erythematosus, 
Tight junction 0.229 
POLR2F 
Huntington's disease, Metabolic pathways, Purine metabolism, 
Pyrimidine metabolism, RNA polymerase 0.229 
SETD7 Lysine degradation 0.229 
RXFP1 Neuroactive ligand-receptor interaction 0.229 
CPA3 
Pancreatic secretion, Protein digestion and absorption, Renin-
angiotensin system 0.229 
RBKS Pentose phosphate pathway 0.213 
ALDH3A2 
Arginine and proline metabolism, Ascorbate and aldarate 
metabolism, beta-Alanine metabolism, Fatty acid degradation, 
Glycerolipid metabolism, Glycolysis / Gluconeogenesis, 
Histidine metabolism, Lysine degradation, Metabolic pathways, 
Pentose and glucuronate interconversions, Propanoate 
metabolism, Pyruvate metabolism, Tryptophan metabolism, 
Valine, leucine and isoleucine degradation 0.203 
TOP3B Homologous recombination 0.194 
EIF4E1B 
Insulin signaling pathway, mTOR signaling pathway, RNA 
transport 0.184 
UGT2B15 
Ascorbate and aldarate metabolism, Drug metabolism - 
cytochrome P450, Drug metabolism - other enzymes, Metabolic 
pathways, Metabolism of xenobiotics by cytochrome P450, 
Other types of O-glycan biosynthesis, Pentose and glucuronate 
interconversions, Porphyrin and chlorophyll metabolism, Retinol 
metabolism, Starch and sucrose metabolism, Steroid hormone 
biosynthesis 0.180 
SEMA5B Axon guidance 0.180 
TBPL1 Basal transcription factors, Huntington's disease 0.180 
LIPT2 Lipoic acid metabolism, Metabolic pathways 0.180 
ULK1 mTOR signaling pathway, Regulation of autophagy 0.180 
MBTPS2 
SREBP control of lipid synthesis, Protein processing in 
endoplasmic reticulum 0.180 
FZD9 
Basal cell carcinoma, Melanogenesis, Pathways in cancer, Wnt 
signaling pathway 0.174 
ADCY3 
Bile secretion, Calcium signaling pathway, Chemokine signaling 
pathway, Dilated cardiomyopathy, Gap junction, Gastric acid 
secretion, GnRH signaling pathway, Melanogenesis, Olfactory 
transduction, Oocyte meiosis, Pancreatic secretion, 
Progesterone-mediated oocyte maturation, Purine metabolism, 
Salivary secretion, Vascular smooth muscle contraction, 
Vasopressin-regulated water reabsorption, Vibrio cholerae 
infection 0.174 
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BMS1 Ribosome biogenesis in eukaryotes 0.162 
IL6R 
IL 6 signaling pathway, Role of ERBB2 in Signal Transduction 
and Oncology, Cytokine-cytokine receptor interaction, 
Hematopoietic cell lineage, Jak-STAT signaling pathway 0.158 
RASGRP3 B cell receptor signaling pathway, MAPK signaling pathway 0.153 
FOLH1 Vitamin digestion and absorption 0.139 
TNNI3 
Cardiac muscle contraction, Dilated cardiomyopathy, 
Hypertrophic cardiomyopathy (HCM) 0.129 
COMP 
ECM-receptor interaction, Focal adhesion, Malaria, Phagosome, 
TGF-beta signaling pathway 0.129 
B4GALT2 
Galactose metabolism, Glycosaminoglycan biosynthesis - 
keratan sulfate, Glycosphingolipid biosynthesis - lacto and 
neolacto series, Metabolic pathways, N-Glycan biosynthesis, 
Other types of O-glycan biosynthesis 0.129 
NAMPT Nicotinate and nicotinamide metabolism 0.129 
FGD1 Regulation of actin cytoskeleton 0.129 
RPL12 Ribosome 0.129 
NDUFS5 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.110 
CR1 
B Lymphocyte Cell Surface Molecules, Complement and 
coagulation cascades, Hematopoietic cell lineage, 
Leishmaniasis, Malaria 0.110 
CTSO Lysosome 0.110 
CD8B 
Antigen processing and presentation, Cell adhesion molecules 
(CAMs), Hematopoietic cell lineage, Primary immunodeficiency, 
T cell receptor signaling pathway 0.103 
POLR2K 
Huntington's disease, Metabolic pathways, Purine metabolism, 
Pyrimidine metabolism, RNA polymerase 0.086 
MAPK9 
MAPKinase Signaling Pathway, Adipocytokine signaling 
pathway, Chagas disease (American trypanosomiasis), 
Colorectal cancer, Epithelial cell signaling in Helicobacter pylori 
infection, ErbB signaling pathway, Fc epsilon RI signaling 
pathway, Focal adhesion, GnRH signaling pathway, Hepatitis C, 
Insulin signaling pathway, MAPK signaling pathway, 
Neurotrophin signaling pathway, NOD-like receptor signaling 
pathway, Osteoclast differentiation, Pancreatic cancer, 
Pathways in cancer, Progesterone-mediated oocyte maturation, 
Protein processing in endoplasmic reticulum, RIG-I-like receptor 
signaling pathway, Shigellosis, T cell receptor signaling 
pathway, Toll-like receptor signaling pathway, Toxoplasmosis, 
Type II diabetes mellitus, Wnt signaling pathway 0.078 
ATP5B 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.077 
RAF1 
Angiotensin II mediated activation of JNK Pathway via Pyk2 
dependent signaling, Aspirin Blocks Signaling Pathway Involved 
in Platelet Activation, BCR Signaling Pathway, Bioactive Peptide 
Induced Signaling Pathway, Cadmium induces DNA synthesis 0.077 
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and proliferation in macrophages, CCR3 signaling in 
Eosinophils, Ceramide Signaling Pathway, CXCR4 Signaling 
Pathway, EGF Signaling Pathway, EPO Signaling Pathway, Erk 
and PI-3 Kinase Are Necessary for Collagen Binding in Corneal 
Epithelia, Erk1/Erk2 Mapk Signaling pathway, Fc Epsilon 
Receptor I Signaling in Mast Cells, fMLP induced chemokine 
gene expression in HMC-1 cells, Growth Hormone Signaling 
Pathway, IGF-1 Signaling Pathway, IL 2 signaling pathway, IL 3 
signaling pathway, IL 6 signaling pathway, IL-2 Receptor Beta 
Chain in T cell Activation, Influence of Ras and Rho proteins on 
G1 to S Transition, Inhibition of Cellular Proliferation by Gleevec, 
Insulin Signaling Pathway, Integrin Signaling Pathway, 
Keratinocyte Differentiation. 
PSMB8 Antigen Processing and Presentation, Proteasome 0.077 
NPC1L1 Fat digestion and absorption 0.077 
TACR2 
Calcium signaling pathway, Neuroactive ligand-receptor 
interaction 0.074 
GJD2 Gap junction 0.073 
CHDH Glycine, serine and threonine metabolism 0.059 
GNAT1 Phototransduction 0.038 
ZAP70 
Activation of Csk by cAMP-dependent Protein Kinase Inhibits 
Signaling through the T Cell Receptor, Lck and Fyn tyrosine 
kinases in initiation of TCR Activation, T Cell Receptor Signaling 
Pathway, Natural killer cell mediated cytotoxicity, Primary 
immunodeficiency, T cell receptor signaling pathway 0.022 
AGTR2 
Angiotensin-converting enzyme 2 regulates heart function, 
Bioactive Peptide Induced Signaling Pathway, Role of EGF 
Receptor Transactivation by GPCRs in Cardiac Hypertrophy, 
Neuroactive ligand-receptor interaction, Renin-angiotensin 
system 0.022 
IL33 Cytosolic DNA-sensing pathway 0.022 
DEGS2 Metabolic pathways, Sphingolipid metabolism 0.022 
WASF3 
Y branching of actin filaments, Adherens junction, Fc gamma R-
mediated phagocytosis 0.022 
NDUFA11 
Alzheimer's disease, Huntington's disease, Metabolic pathways, 
Oxidative phosphorylation, Parkinson's disease 0.011 
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DISCUSSION 
Yuan et al. (2003) reported that Tetrahydrofuran (THF) from Annonaceae 
plants arrested Bax and CASP3 related pathways in G1 phase of human urinary 
bladder cancer (T24 cells).  Bax and CASP3 which both shows up regulation in 
this study are two key proteins for signaling the onset of cell death. Sun et al. 
(2014) showed that HPLC fractions of Annonaceous acetogenins fruit extract 
contained mono-tetrahydrofuran rings which resulted in anti-proliferation among 
human prostate cancer cells (PC-3 cell line).  These results were corroborated by 
Matsumoto et al. (2017) using THF in 39 human cancer cell lines.  
L19 showed induction of apoptosis and inflammation.  From the microarray, 
qRT-PCR, and RT² Profiler™ PCR Array techniques the following pathways are 
proposed:  
 
Pathway 1: Apoptosis 
CASP6 and 3, executioner caspases, which represent apoptosis, showed 
high level of expression (Foveaux et al., 2014) in protein level by Apo assay.  They 
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also showed high level gene expression by qRT-PCR and RT² Profiler™ PCR 
Array techniques.   
Apoptotic pathways that seem to be involved in the DLD1 cells in response 
to the L19, seem to be FAS mediated with induction of ER Stress. ER Stress 
pathway is demonstrated by high level of gene expression of CASP12 and 3. 
CASP12 which is known as the important genes of inflammation showed maximum 
expression which means the gene is turned on within 6 hours then declined 
gradually (25.13 ± 4.81-fold change). Zhang et al. (2016) showed CASP12 could 
also induce apoptosis by cleaving pro-caspase 3 to activate CASP3 (Figure 24). 
TNF (Tumor necrosis factor) activating TNF-R1 (Tumor necrosis factor 
receptor superfamily, member 10a) is not changed at all time points; however, 
TNF-R1 is downregulated.  TNF-R1 can activate TRAF2 (TNFRSF1A-associated 
via death domain) which can further activate TRADD. TRADD is co-factor of FADD 
(Fas (TNFRSF6)-associated via death domain FADD) which function is to cleave 
pro-caspase 8 or 10.  These CASPs are the initiator caspases of apoptosis.  Based 
on down-regulation on TNF, all other genes were down regulated consisting of 
TNF-R1, TRAF2, TRADD and FADD (Komarov et al., 2016). Thus, TNF pathway 
is not up-regulated in the DLD-1 cells.  CASP8 and 10 are up regulated based in 
RT² Profiler™ PCR Array and qRT-PCR results.  These CASPs are activated by 
FAS-L (Fas ligand (TNF superfamily, member 6) pathway (Malike et al., 2016).  
FAS-L, a protein on the surface of the cell membrane, is a death receptor which 
binds to FAS (Fas (TNF receptor superfamily, member 6)). FAS-FAS Ligand can 
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activate CASP8 and 10 by FADD (Figure 24). Although FADD Showed no 
significant changes in RT² Profiler™ PCR data. Therefore, FADD cleaved pro-
caspase 8 and 10 and activate CASP8 and 10. CASP8 or 10 releases DISC to 
cytosol and activates other executioner caspases such as CASP3, 6 or 7. CASP3 
and 6 are upregulated and induced apoptosis (Malike et al., 2016); however, 
CASP7 represents down regulation at all time points.  The genes up-regulation 
may represent FAS pathway and activate executioner CASPs which turn on 
apoptosis. 
BAD (BCL2-associated agonist of cell death) shows no changes but BAX 
(BCL2-associated X protein) is up regulated in 6-hours.  According to Adams and 
Cory (2017) these two genes are inducing apoptosis individually by inhibiting BCL-
2 which is down regulated in RT² Profiler™ PCR data. Kawamoto et al. (2016) 
showed inhibition of BCL-2 also activated BID (BH3 interacting domain death 
agonist) and BID could either release CYTC (Cytochrome c) from mitochondria 
membranes or activate AIF. BID and CYTC are both down-regulated in 8-hours, 
while AIF is upregulated at 12-hours (Figure 24).  CYTC activated APAF-1 which 
can cleave pro-caspase 9 and activated CASP9 (Kawamoto et al., 2016).  CASP9 
expressed in 6-hours showed upregulation which can activate CYTC (Cytochrome 
c) and cleave Pro-CASP9 and activate CASP9 (Figure 24). CASP9 can activate 
CASP3 by cleaving pro-caspase 3 protein.  CASP9 showed up regulation at 6 
hours and then fell off in 8 hours.  Thus, CASP3 showed a gradual increase from 
6 hours to 12 hours (Fox & Macfarlane, 2016) which is also shown on graph 14 in 
results section from this study.  Therefore, all these up- and down- regulated 
genes, indicate ER stress and show AIF pathway activation (apoptosis pathways), 
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because CASP3, Apaf-1, Bax AIF, CASP9 and p53 genes, which are key factors 
for apoptosis, are up regulated and BCL2 is down regulated.  In addition, according 
to Kadam et al. (2017) AIF shows apoptosis activity which is upregulated in this 
study.    
 
Pathway 2: Inflammatory 
 Within the 6-hour exposure period to L19, CASP12 had a huge increase in 
expression, as much as a 25-fold increase.  This change indicated the immediate 
onset of inflammation.  Consistent with this was CASP1, which is a key factor of 
inflammation and not apoptosis key factor showed increase in gene up regulation 
from 6 to 24 hours.  RT² Profiler™ is not consistent with 12 hour results showing 
no significant changes in CASP1 gene. The discrepancy could have been caused 
by the primers being different in the SA Bioscience plate as compared to the ones 
designed for the qRT PCR using the NCI primer database.  CASP1 is activated by 
HIN (domain containing (PYHIN) family) and NLR (nucleoid-binding domain, 
leucine-rich repeat containing) which are inflammasome factors. CASP1 also has 
a role in autoinflammatory disease, tumor suppression and tissue repair (Man & 
Kanneganti, 2016).  Based on Foveaux et al. (2014), CASP1 can activate 
inflammatory pathways as well as CASP6. Maximum level of CASP5 which is an 
inflammatory CASP is expressed within 8 hours (McIlwain et al., 2013). Recent 
research showed CASP3 activation was dependent on CASP5 in stretch-induced 
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apoptosis (Zhao et al., 2017). Casp5 expression was elevated followed by an 
increase in CASP1 consistent with inflammation as described by McIlwain et al. 
(2013).  The L19 has an immediate inflammatory response that would be 
undesirable as a chemotherapy agent. 
Non-Apoptotic Genes Affected by L19 
 As with most chemotherapy agents, off target responses cause unexpected 
and/or harmful side effects.  It is important in drug discovery to identify as many off 
target pathways as possible prior to moving the drug further in development.  On 
the positive side, identifying other pathways that are affected by the drug, in this 
case L19, can provide new uses for the drug.  Microarray technology allows 
screening changes that may occur in the entire transcriptome of cells in response 
to compounds.  As evidenced by Table 11 A and B, there are numerous pathways 
and cellular functions that L19 impacts either causing up-regulation or down-
regulation.  The next step in this project will be to examine these pathways more 
closely to determine if L19 may be a good candidate for treatments other than anti-
cancer.    
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Figure 24. Hypothetical apoptosis pathway in treated colorectal cancer cells (DLD-
1) by L19 through the qRT-PCR, and RT2 ProfilerTM PCR Array results for 6, 8, 
and 12 hours.  
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APPENDIX I 
Gene descriptions for RT² Profiler™ PCR Human Apoptosis Array 
(SABiosciences, Cat no: PAHS-012Z) results, contained of the transcriptome 
(UniGene) from NCBI website, The Reference Sequence (RefSeq), Gene Symbol, 
Gene Description and Gene name from left to right.  
 
UniGene Refseq Symbol Description Gname 
Hs.43104
8 
NM_00
5157 ABL1 
C-abl oncogene 1, non-
receptor tyrosine kinase 
ABL/JTK7/bcr/abl/c-
ABL/c-ABL1/p150/v-abl 
Hs.42493
2 
NM_00
4208 AIFM1 
Apoptosis-inducing 
factor, mitochondrion-
associated, 1 
AIF/CMT2D/CMTX4/C
OWCK/COXPD6/NAD
MR/NAMSD/PDCD8 
Hs.52562
2 
NM_00
5163 AKT1 
V-akt murine thymoma 
viral oncogene homolog 
1 
AKT/CWS6/PKB/PKB-
ALPHA/PRKBA/RAC/R
AC-ALPHA 
Hs.55256
7 
NM_00
1160 APAF1 
Apoptotic peptidase 
activating factor 1 APAF-1/CED4 
Hs.37025
4 
NM_00
4322 BAD 
BCL2-associated agonist 
of cell death BBC2/BCL2L8 
Hs.37748
4 
NM_00
4323 BAG1 
BCL2-associated 
athanogene BAG-1/HAP/RAP46 
Hs.52330
9 
NM_00
4281 BAG3 
BCL2-associated 
athanogene 3 
BAG-3/BIS/CAIR-
1/MFM6 
Hs.48513
9 
NM_00
1188 BAK1 BCL2-antagonist/killer 1 
BAK/BAK-
LIKE/BCL2L7/CDN1 
Hs.62429
1 
NM_00
4324 BAX 
BCL2-associated X 
protein BCL2L4 
Hs.19351
6 
NM_00
3921 BCL10 B-cell CLL/lymphoma 10 
CARMEN/CIPER/CLA
P/IMD37/c-E10/mE10 
Hs.15074
9 
NM_00
0633 BCL2 B-cell CLL/lymphoma 2 Bcl-2/PPP1R50 
Hs.22781
7 
NM_00
4049 BCL2A1 BCL2-related protein A1 
ACC-1/ACC-
2/ACC1/ACC2/BCL2L5
/BFL1/GRS/HBPA1 
  
  
137 
 
Hs.51696
6 
NM_13
8578 BCL2L1 BCL2-like 1 
BCL-
XL/S/BCL2L/BCLX/BC
LXL/BCLXS/Bcl-
X/PPP1R52/bcl-xL/bcl-
xS 
Hs.28367
2 
NM_02
0396 
BCL2L1
0 
BCL2-like 10 (apoptosis 
facilitator) 
BCL-B/Boo/Diva/bcl2-
L-10 
Hs.46965
8 
NM_00
6538 
BCL2L1
1 
BCL2-like 11 (apoptosis 
facilitator) BAM/BIM/BOD 
Hs.41002
6 
NM_00
4050 BCL2L2 BCL2-like 2 
BCL-W/BCL2-L-
2/BCLW/PPP1R51 
Hs.43555
6 
NM_01
6561 BFAR 
Bifunctional apoptosis 
regulator BAR/RNF47 
Hs.51714
5 
NM_00
1196 BID 
BH3 interacting domain 
death agonist FP497 
Hs.47505
5 
NM_00
1197 BIK 
BCL2-interacting killer 
(apoptosis-inducing) BIP1/BP4/NBK 
Hs.69623
8 
NM_00
1166 BIRC2 
Baculoviral IAP repeat 
containing 2 
API1/HIAP2/Hiap-
2/MIHB/RNF48/c-
IAP1/cIAP1 
Hs.12779
9 
NM_00
1165 BIRC3 
Baculoviral IAP repeat 
containing 3 
AIP1/API2/CIAP2/HAIP
1/HIAP1/MALT2/MIHC/
RNF49/c-IAP2 
Hs.74487
2 
NM_00
1168 BIRC5 
Baculoviral IAP repeat 
containing 5 API4/EPR-1 
Hs.15010
7 
NM_01
6252 BIRC6 
Baculoviral IAP repeat 
containing 6 APOLLON/BRUCE 
Hs.64649
0 
NM_00
4330 BNIP2 
BCL2/adenovirus E1B 
19kDa interacting protein 
2 BNIP-2/NIP2 
Hs.14487
3 
NM_00
4052 BNIP3 
BCL2/adenovirus E1B 
19kDa interacting protein 
3 NIP3 
Hs.13122
6 
NM_00
4331 BNIP3L 
BCL2/adenovirus E1B 
19kDa interacting protein 
3-like BNIP3a/NIX 
Hs.55006
1 
NM_00
4333 BRAF 
V-raf murine sarcoma 
viral oncogene homolog 
B1 
B-
RAF1/BRAF1/NS7/RA
FB1 
Hs.2490 
NM_03
3292 CASP1 
Caspase 1, apoptosis-
related cysteine 
peptidase (interleukin 1, 
beta, convertase) ICE/IL1BC/P45 
  
138 
Hs.5353 
NM_00
1230 CASP10 
Caspase 10, apoptosis-
related cysteine 
peptidase ALPS2/FLICE2/MCH4 
Hs.46605
7 
NM_01
2114 CASP14 
Caspase 14, apoptosis-
related cysteine 
peptidase - 
Hs.36898
2 
NM_03
2982 CASP2 
Caspase 2, apoptosis-
related cysteine 
peptidase 
CASP-2/ICH1/NEDD-
2/NEDD2/PPP1R57 
Hs.14112
5 
NM_00
4346 CASP3 
Caspase 3, apoptosis-
related cysteine 
peptidase 
CPP32/CPP32B/SCA-
1 
Hs.13837
8 
NM_00
1225 CASP4 
Caspase 4, apoptosis-
related cysteine 
peptidase 
ICE(rel)II/ICEREL-
II/ICH-2/Mih1/TX/TX 
Hs.21332
7 
NM_00
4347 CASP5 
Caspase 5, apoptosis-
related cysteine 
peptidase 
ICE(rel)III/ICEREL-
III/ICH-3 
Hs.65461
6 
NM_03
2992 CASP6 
Caspase 6, apoptosis-
related cysteine 
peptidase MCH2 
Hs.9216 
NM_00
1227 CASP7 
Caspase 7, apoptosis-
related cysteine 
peptidase 
CASP-7/CMH-1/ICE-
LAP3/LICE2/MCH3 
Hs.59976
2 
NM_00
1228 CASP8 
Caspase 8, apoptosis-
related cysteine 
peptidase 
ALPS2B/CAP4/Casp-
8/FLICE/MACH/MCH5 
Hs.32950
2 
NM_00
1229 CASP9 
Caspase 9, apoptosis-
related cysteine 
peptidase 
APAF-3/APAF3/ICE-
LAP6/MCH6/PPP1R56 
Hs.35530
7 
NM_00
1242 CD27 CD27 molecule 
S152/S152. 
LPFS2/T14/TNFRSF7/
Tp55 
Hs.47286
0 
NM_00
1250 CD40 
CD40 molecule, TNF 
receptor superfamily 
member 5 
Bp50/CDW40/TNFRSF
5/p50 
Hs.59224
4 
NM_00
0074 CD40LG CD40 ligand 
CD154/CD40L/HIGM1/
IGM/IMD3/T-
BAM/TNFSF5/TRAP/g
p39/hCD40L 
Hs.50149
7 
NM_00
1252 CD70 CD70 molecule 
CD27L/CD27LG/TNFS
F7 
Hs.39073
6 
NM_00
3879 CFLAR 
CASP8 and FADD-like 
apoptosis regulator 
CASH/CASP8AP1/CLA
RP/Casper/FLAME/FL
  
139 
AME-
1/FLAME1/FLIP/I-
FLICE/MRIT/c-FLIP/c-
FLIPL/c-FLIPR/c-
FLIPS 
Hs.24912
9 
NM_00
1279 CIDEA 
Cell death-inducing 
DFFA-like effector a CIDE-A 
Hs.64269
3 
NM_01
4430 CIDEB 
Cell death-inducing 
DFFA-like effector b - 
Hs.38533 
NM_00
3805 CRADD 
CASP2 and RIPK1 
domain containing 
adaptor with death 
domain MRT34/RAIDD 
Hs.43706
0 
NM_01
8947 CYCS Cytochrome c, somatic CYC/HCS/THC4 
Hs.38027
7 
NM_00
4938 DAPK1 
Death-associated protein 
kinase 1 DAPK 
Hs.48478
2 
NM_00
4401 DFFA 
DNA fragmentation 
factor, 45kDa, alpha 
polypeptide DFF-45/DFF1/ICAD 
Hs.16961
1 
NM_01
9887 DIABLO 
Diablo, IAP-binding 
mitochondrial protein DFNA64/SMAC 
Hs.86131 
NM_00
3824 FADD 
Fas (TNFRSF6)-
associated via death 
domain GIG3/MORT1 
Hs.66730
9 
NM_00
0043 FAS 
Fas (TNF receptor 
superfamily, member 6) 
ALPS1A/APO-
1/APT1/CD95/FAS1/F
ASTM/TNFRSF6 
Hs.2007 
NM_00
0639 FASLG 
Fas ligand (TNF 
superfamily, member 6) 
ALPS1B/APT1LG1/AP
TL/CD178/CD95-
L/CD95L/FASL/TNFSF
6 
Hs.80409 
NM_00
1924 
GADD4
5A 
Growth arrest and DNA-
damage-inducible, alpha DDIT1/GADD45 
Hs.87247 
NM_00
3806 HRK 
Harakiri, BCL2 
interacting protein 
(contains only BH3 
domain) DP5/HARAKIRI 
Hs.64312
0 
NM_00
0875 IGF1R 
Insulin-like growth factor 
1 receptor 
CD221/IGFIR/IGFR/JT
K13 
Hs.19371
7 
NM_00
0572 IL10 Interleukin 10 
CSIF/GVHDS/IL-
10/IL10A/TGIF 
  
140 
Hs.36 
NM_00
0595 LTA 
Lymphotoxin alpha (TNF 
superfamily, member 1) LT/TNFB/TNFSF1 
Hs.1116 
NM_00
2342 LTBR 
Lymphotoxin beta 
receptor (TNFR 
superfamily, member 3) 
CD18/D12S370/LT-
BETA-R/TNF-R-
III/TNFCR/TNFR-
RP/TNFR2-
RP/TNFR3/TNFRSF3 
Hs.63248
6 
NM_02
1960 MCL1 
Myeloid cell leukemia 
sequence 1 (BCL2-
related) 
BCL2L3/EAT/MCL1-
ES/MCL1L/MCL1S/Mcl
-1/TM/bcl2-L-
3/mcl1/EAT 
Hs.64695
1 
NM_00
4536 NAIP 
NLR family, apoptosis 
inhibitory protein BIRC1/NLRB1/psiNAIP 
Hs.61843
0 
NM_00
3998 NFKB1 
Nuclear factor of kappa 
light polypeptide gene 
enhancer in B-cells 1 
EBP-1/KBF1/NF-
kB1/NF-kappa-B/NF-
kappaB/NFKB-
p105/NFKB-
p50/NFkappaB/p105/p
50 
Hs.73873
1 
NM_00
6092 NOD1 
Nucleotide-binding 
oligomerization domain 
containing 1 
CARD4/CLR7.1/NLRC
1 
Hs.51366
7 
NM_00
3946 NOL3 
Nucleolar protein 3 
(apoptosis repressor with 
CARD domain) 
ARC/FCM/MYP/NOP/N
OP30 
Hs.49909
4 
NM_01
3258 
PYCAR
D 
PYD and CARD domain 
containing 
ASC/CARD5/TMS/TM
S-1/TMS1 
Hs.10375
5 
NM_00
3821 RIPK2 
Receptor-interacting 
serine-threonine kinase 2 
CARD3/CARDIAK/CC
K/GIG30/RICK/RIP2 
Hs.24157
0 
NM_00
0594 TNF Tumor necrosis factor 
DIF/TNF-
alpha/TNFA/TNFSF2 
Hs.59183
4 
NM_00
3844 
TNFRS
F10A 
Tumor necrosis factor 
receptor superfamily, 
member 10a 
APO2/CD261/DR4/TR
AILR-1/TRAILR1 
Hs.66166
8 
NM_00
3842 
TNFRS
F10B 
Tumor necrosis factor 
receptor superfamily, 
member 10b 
CD262/DR5/KILLER/KI
LLER/DR5/TRAIL-
R2/TRAILR2/TRICK2/T
RICK2A/TRICK2B/TRI
CKB/ZTNFR9 
Hs.81791 
NM_00
2546 
TNFRS
F11B 
Tumor necrosis factor 
receptor superfamily, 
member 11b OCIF/OPG/PDB5/TR1 
  
141 
Hs.71383
3 
NM_00
1065 
TNFRS
F1A 
Tumor necrosis factor 
receptor superfamily, 
member 1A 
CD120a/FPF/MS5/TBP
1/TNF-R/TNF-R-I/TNF-
R55/TNFAR/TNFR1/T
NFR1-
d2/TNFR55/TNFR60/p
55/p55-R/p60 
Hs.25627
8 
NM_00
1066 
TNFRS
F1B 
Tumor necrosis factor 
receptor superfamily, 
member 1B 
CD120b/TBPII/TNF-R-
II/TNF-
R75/TNFBR/TNFR1B/
TNFR2/TNFR80/p75/p
75TNFR 
Hs.44357
7 
NM_01
4452 
TNFRS
F21 
Tumor necrosis factor 
receptor superfamily, 
member 21 BM-018/CD358/DR6 
Hs.46252
9 
NM_00
3790 
TNFRS
F25 
Tumor necrosis factor 
receptor superfamily, 
member 25 
APO-
3/DDR3/DR3/LARD/TN
FRSF12/TR3/TRAMP/
WSL-1/WSL-LR 
Hs.73894
2 
NM_00
1561 
TNFRS
F9 
Tumor necrosis factor 
receptor superfamily, 
member 9 
4-
1BB/CD137/CDw137/I
LA 
Hs.47827
5 
NM_00
3810 
TNFSF1
0 
Tumor necrosis factor 
(ligand) superfamily, 
member 10 
APO2L/Apo-
2L/CD253/TL2/TRAIL 
Hs.65444
5 
NM_00
1244 TNFSF8 
Tumor necrosis factor 
(ligand) superfamily, 
member 8 
CD153/CD30L/CD30L
G 
Hs.43746
0 
NM_00
0546 TP53 Tumor protein p53 
BCC7/LFS1/P53/TRP5
3 
Hs.52396
8 
NM_00
5426 
TP53BP
2 
Tumor protein p53 
binding protein, 2 
53BP2/ASPP2/BBP/P5
3BP2/PPP1R13A 
Hs.19213
2 
NM_00
5427 TP73 Tumor protein p73 P73 
Hs.46099
6 
NM_00
3789 TRADD 
TNFRSF1A-associated 
via death domain Hs.89862 
Hs.52250
6 
NM_02
1138 TRAF2 
TNF receptor-associated 
factor 2 
MGC:45012/TRAP/TR
AP3 
Hs.51052
8 
NM_00
3300 TRAF3 
TNF receptor-associated 
factor 3 
CAP-
1/CAP1/CD40bp/CRAF
1/IIAE5/LAP1 
Hs.35607
6 
NM_00
1167 XIAP 
X-linked inhibitor of 
apoptosis 
API3/BIRC4/IAP-
3/ILP1/MIHA/XLP2/hIA
P-3/hIAP3 
  
142 
Hs.52064
0 
NM_00
1101 ACTB Actin, beta BRWS1/PS1TP5BP1 
Hs.53425
5 
NM_00
4048 B2M Beta-2-microglobulin - 
Hs.59235
5 
NM_00
2046 GAPDH 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
G3PD/GAPD/HEL-S-
162eP 
Hs.41270
7 
NM_00
0194 HPRT1 
Hypoxanthine 
phosphoribosyltransferas
e 1 HGPRT/HPRT 
Hs.54628
5 
NM_00
1002 RPLP0 
Ribosomal protein, large, 
P0 
L10E/LP0/P0/PRLP0/R
PP0 
N/A 
SA_00
105 HGDC 
Human Genomic DNA 
Contamination HIGX1A 
N/A 
SA_00
104 RTC 
Reverse Transcription 
Control RTC 
N/A 
SA_00
104 RTC 
Reverse Transcription 
Control RTC 
N/A 
SA_00
104 RTC 
Reverse Transcription 
Control RTC 
N/A 
SA_00
103 PPC Positive PCR Control PPC 
N/A 
SA_00
103 PPC Positive PCR Control PPC 
N/A 
SA_00
103 PPC Positive PCR Control PPC 
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APPENDIX II 
The whole human genes, with UniqueID, that were used in the microarray 
experiments. 
Name Symbol 
zinc finger, CCHC domain containing 9 ZCCHC9 
WD repeat domain 49 WDR49 
signal transducer and activator of transcription 5B STAT5B 
olfactory receptor, family 2, subfamily C, member 1 OR2C1 
ribosomal L1 domain containing 1 RSL1D1 
phospholipid scramblase 2 PLSCR2 
odd-skipped related transciption factor 1 OSR1 
leucine-rich repeats and calponin homology (CH) domain containing 4 LRCH4 
DnaJ (Hsp40) homolog, subfamily C, member 9 DNAJC9 
RAP2B, member of RAS oncogene family RAP2B 
galactosidase, beta 1-like 2 GLB1L2 
transmembrane and coiled-coil domain family 2 TMCC2 
forkhead box E3 FOXE3 
nudix (nucleoside diphosphate linked moiety X)-type motif 12 NUDT12 
coiled-coil domain containing 105 CCDC105 
collagen, type XXIII, alpha 1 COL23A1 
zinc finger, matrin-type 3 ZMAT3 
family with sequence similarity 69, member A FAM69A 
adenylate cyclase 2 (brain) ADCY2 
IQ motif containing J IQCJ 
muscle, skeletal, receptor tyrosine kinase MUSK 
SUMO1/sentrin specific peptidase 1 SENP1 
selectin P ligand SELPLG 
protein phosphatase 2, regulatory subunit B, gamma PPP2R2C 
polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 PKHD1L1 
DENN/MADD domain containing 1A DENND1A 
  
  
144 
 
TBC1 domain family, member 24 TBC1D24 
solute carrier family 2 (facilitated glucose transporter), member 6 SLC2A6 
myc target 1 MYCT1 
PHD finger protein 20-like 1 PHF20L1 
potassium channel, voltage gated eag related subfamily H, member 
7 KCNH7 
NLR family, pyrin domain containing 10 NLRP10 
klotho beta KLB 
chemokine (C-X-C motif) ligand 6 CXCL6 
interferon gamma receptor 2 (interferon gamma transducer 1) IFNGR2 
ubiquitin specific peptidase 20 USP20 
HGF activator HGFAC 
solute carrier family 15 (oligopeptide transporter), member 2 SLC15A2 
prolactin releasing hormone receptor PRLHR 
IQ motif containing GTPase activating protein 1 IQGAP1 
SET and MYND domain containing 4 SMYD4 
dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-
glutarate complex) DLST 
hydroxycarboxylic acid receptor 1 HCAR1 
phosphatidylinositol glycan anchor biosynthesis, class H PIGH 
leucine-rich repeat LGI family, member 4 LGI4 
POM121 and ZP3 fusion POMZP3 
COMM domain containing 7 COMMD7 
docking protein 1, 62kDa (downstream of tyrosine kinase 1) DOK1 
RAN binding protein 2 RANBP2 
solute carrier family 6 (neutral amino acid transporter), member 15 SLC6A15 
DnaJ (Hsp40) homolog, subfamily C, member 18 DNAJC18 
chondroitin sulfate N-acetylgalactosaminyltransferase 2 
CSGALNACT
2 
ubiquitin specific peptidase 45 USP45 
calcium channel, voltage-dependent, gamma subunit 1 CACNG1 
STEAP family member 1B STEAP1B 
zinc finger protein 345 ZNF345 
Nipped-B homolog (Drosophila) NIPBL 
IQ motif containing H IQCH 
lysine (K)-specific demethylase 3A KDM3A 
ribosomal protein L39 RPL39 
SH3 and SYLF domain containing 1 SH3YL1 
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solute carrier family 22, member 20 SLC22A20 
minichromosome maintenance 9 homologous recombination repair 
factor MCM9 
peroxisomal biogenesis factor 13 PEX13 
YY1 associated factor 2 YAF2 
zinc finger protein 225 ZNF225 
carbonic anhydrase VII CA7 
ribonuclease P/MRP 25kDa subunit RPP25 
chromosome 9 open reading frame 142 C9orf142 
transmembrane protein 184A TMEM184A 
ribosomal protein S6 kinase, 90kDa, polypeptide 1 RPS6KA1 
RAB37, member RAS oncogene family RAB37 
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 SERPINF1 
carcinoembryonic antigen-related cell adhesion molecule 22, 
pseudogene CEACAM22P 
SWI5 homologous recombination repair protein SWI5 
kallikrein-related peptidase 8 KLK8 
flavin containing monooxygenase 5 FMO5 
integrator complex subunit 12 INTS12 
eukaryotic translation initiation factor 3, subunit J EIF3J 
progestin and adipoQ receptor family member VII PAQR7 
apoptosis-associated tyrosine kinase AATK 
autophagy related 9B ATG9B 
MON1 secretory trafficking family member A MON1A 
replication factor C (activator 1) 2, 40kDa RFC2 
tudor domain containing 6 TDRD6 
solute carrier family 16 (aromatic amino acid transporter), member 
10 SLC16A10 
elaC ribonuclease Z 2 ELAC2 
single stranded DNA binding protein 3 SSBP3 
transmembrane protein 169 TMEM169 
leucine rich repeat neuronal 2 LRRN2 
growth arrest and DNA-damage-inducible, beta GADD45B 
Rap guanine nucleotide exchange factor (GEF) 1 RAPGEF1 
ribonucleoprotein, PTB-binding 2 RAVER2 
long intergenic non-protein coding RNA 442 LINC00442 
ets variant 5 ETV5 
golgi phosphoprotein 3 (coat-protein) GOLPH3 
glypican 6 GPC6 
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zinc finger protein 446 ZNF446 
zinc finger protein 655 ZNF655 
tetratricopeptide repeat domain 21B TTC21B 
zinc finger protein 702, pseudogene ZNF702P 
chromosome 6 open reading frame 48 C6orf48 
translational activator of mitochondrially encoded cytochrome c 
oxidase I TACO1 
proline dehydrogenase (oxidase) 1 PRODH 
Ras association (RalGDS/AF-6) domain family (N-terminal) member 
8 RASSF8 
Kv channel interacting protein 2 KCNIP2 
thiamine triphosphatase THTPA 
chromosome 3 open reading frame 67 C3orf67 
unkempt family zinc finger-like UNKL 
chromosome 1 open reading frame 95 C1orf95 
gap junction protein, beta 1, 32kDa GJB1 
olfactory receptor, family 51, subfamily B, member 2 
(gene/pseudogene) OR51B2 
hydrolethalus syndrome 1 HYLS1 
fibroblast growth factor binding protein 3 FGFBP3 
family with sequence similarity 117, member A FAM117A 
keratin 80, type II KRT80 
family with sequence similarity 20, member A FAM20A 
NK2 homeobox 2 NKX2-2 
phosphate cytidylyltransferase 2, ethanolamine PCYT2 
myosin VA MYO5A 
prolylcarboxypeptidase (angiotensinase C) PRCP 
proteasome 26S subunit, non-ATPase 3 PSMD3 
ceramide synthase 3 CERS3 
zinc finger protein 780A ZNF780A 
acyl-CoA synthetase bubblegum family member 1 ACSBG1 
transmembrane protease, serine 2 TMPRSS2 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 3 SLC25A3 
NANOG neighbor homeobox NANOGNB 
interferon-induced protein with tetratricopeptide repeats 1B IFIT1B 
prohibitin PHB 
breast carcinoma amplified sequence 4 BCAS4 
doublecortin domain containing 2C DCDC2C 
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UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. 
cerevisiae) UTP15 
Myb-like, SWIRM and MPN domains 1 MYSM1 
ATH1, acid trehalase-like 1 (yeast) ATHL1 
zinc finger protein 22 ZNF22 
solute carrier organic anion transporter family, member 3A1 SLCO3A1 
proteasome 26S subunit, non-ATPase 6 PSMD6 
protease, serine, 54 PRSS54 
BBSome interacting protein 1 BBIP1 
actin binding LIM protein 1 ABLIM1 
ADAM metallopeptidase with thrombospondin type 1 motif, 6 ADAMTS6 
abhydrolase domain containing 8 ABHD8 
placenta-specific 1 PLAC1 
myelin protein zero-like 1 MPZL1 
RIC8 guanine nucleotide exchange factor B RIC8B 
cysteine-rich protein 3 CRIP3 
chloride channel accessory 4 CLCA4 
glutathione S-transferase kappa 1 GSTK1 
gamma-aminobutyric acid (GABA) A receptor, gamma 1 GABRG1 
polypeptide N-acetylgalactosaminyltransferase 6 GALNT6 
son of sevenless homolog 2 (Drosophila) SOS2 
protein phosphatase 1, regulatory (inhibitor) subunit 1A PPP1R1A 
chromosome 9 open reading frame 84 C9orf84 
protein phosphatase 2A activator, regulatory subunit 4 PPP2R4 
serine/arginine-rich splicing factor 2 SRSF2 
late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 LAMTOR1 
ring finger protein 19A, RBR E3 ubiquitin protein ligase RNF19A 
4-aminobutyrate aminotransferase ABAT 
sterile alpha motif domain containing 3 SAMD3 
KIAA1468 KIAA1468 
fem-1 homolog c (C. elegans) FEM1C 
protein phosphatase 6, regulatory subunit 2 PPP6R2 
serine/arginine repetitive matrix 4 SRRM4 
scavenger receptor class A, member 3 SCARA3 
RNA binding motif protein 8A RBM8A 
T-cell leukemia/lymphoma 1A TCL1A 
dipeptidyl-peptidase 7 DPP7 
T-box 5 TBX5 
frequently rearranged in advanced T-cell lymphomas 1 FRAT1 
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NK3 homeobox 2 NKX3-2 
parathyroid hormone 1 receptor PTH1R 
G protein-coupled receptor 45 GPR45 
EF-hand calcium binding domain 9 EFCAB9 
signal sequence receptor, beta (translocon-associated protein beta) SSR2 
isocitrate dehydrogenase 3 (NAD+) gamma IDH3G 
proteasome subunit alpha 8 PSMA8 
chromosome 11 open reading frame 53 C11orf53 
RANBP2-like and GRIP domain containing 1 RGPD1 
peptidyl-prolyl cis-trans isomerase A pseudogene LOC390956 
carcinoembryonic antigen-related cell adhesion molecule 18 CEACAM18 
leucine-rich repeats and IQ motif containing 3 LRRIQ3 
GDP-mannose pyrophosphorylase A GMPPA 
ELOVL fatty acid elongase 1 ELOVL1 
thioredoxin-related transmembrane protein 1 TMX1 
RFT1 homolog RFT1 
ribosomal protein L4 RPL4 
paralemmin 3 PALM3 
deafness, autosomal dominant 5 DFNA5 
regulating synaptic membrane exocytosis 4 RIMS4 
plexin A4 PLXNA4 
doublecortin domain containing 1 DCDC1 
ribosomal protein L31 pseudogene 11 RPL31P11 
erythropoietin receptor EPOR 
angiomotin like 2 AMOTL2 
chromosome 3 open reading frame 38 C3orf38 
Usher syndrome 1G (autosomal recessive) USH1G 
WD repeat domain 91 WDR91 
ral guanine nucleotide dissociation stimulator-like 3 RGL3 
snail family zinc finger 2 SNAI2 
kinesin family member 1A KIF1A 
H6 family homeobox 3 HMX3 
breast carcinoma amplified sequence 1 BCAS1 
olfactory receptor, family 1, subfamily D, member 5 OR1D5 
atonal bHLH transcription factor 8 ATOH8 
endoplasmic reticulum aminopeptidase 2 ERAP2 
carboxypeptidase D CPD 
miR-17-92 cluster host gene MIR17HG 
missing oocyte, meiosis regulator, homolog (Drosophila) MIOS 
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somatostatin receptor 1 SSTR1 
alanyl (membrane) aminopeptidase ANPEP 
olfactory receptor, family 4, subfamily C, member 6 OR4C6 
DiGeorge syndrome critical region gene 5 (non-protein coding) DGCR5 
G protein-coupled receptor 22 GPR22 
canopy FGF signaling regulator 1 CNPY1 
centromere protein I CENPI 
mitochondrial translational initiation factor 3 MTIF3 
chromosome 5 open reading frame 63 C5orf63 
CD74 molecule, major histocompatibility complex, class II invariant 
chain CD74 
STEAP family member 3, metalloreductase STEAP3 
3'(2'), 5'-bisphosphate nucleotidase 1 BPNT1 
G protein-coupled receptor 39 GPR39 
heat shock factor binding protein 1 HSBP1 
v-myc avian myelocytomatosis viral oncogene homolog MYC 
olfactory receptor, family 52, subfamily K, member 2 OR52K2 
zinc finger protein 44 ZNF44 
gap junction protein, delta 3, 31.9kDa GJD3 
gem (nuclear organelle) associated protein 6 GEMIN6 
paired-like homeodomain 1 PITX1 
olfactory receptor, family 56, subfamily A, member 1 OR56A1 
transmembrane channel-like 8 TMC8 
contactin 1 CNTN1 
thyroid stimulating hormone receptor TSHR 
neuron navigator 1 NAV1 
receptor (G protein-coupled) activity modifying protein 1 RAMP1 
barrier to autointegration factor 2 BANF2 
interleukin 3 IL3 
secretagogin, EF-hand calcium binding protein SCGN 
kinase suppressor of ras 2 KSR2 
echinoderm microtubule associated protein like 3 EML3 
WD repeat domain 13 WDR13 
phosphoinositide-3-kinase, regulatory subunit 2 (beta) PIK3R2 
podocan-like 1 PODNL1 
PR domain containing 4 PRDM4 
MAP/microtubule affinity-regulating kinase 2 MARK2 
late cornified envelope 2A LCE2A 
transducin (beta)-like 2 TBL2 
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spermatogenesis associated 18 SPATA18 
metallophosphoesterase domain containing 2 MPPED2 
G protein-coupled receptor 37 (endothelin receptor type B-like) GPR37 
WNK lysine deficient protein kinase 1 WNK1 
tetra-peptide repeat homeobox 1 TPRX1 
chromosome 15 open reading frame 26 C15orf26 
SRY (sex determining region Y)-box 4 SOX4 
periostin, osteoblast specific factor POSTN 
leucine rich repeat containing 59 LRRC59 
myosin, light chain 5, regulatory MYL5 
family with sequence similarity 134, member C FAM134C 
family with sequence similarity 160, member B2 FAM160B2 
calcium/calmodulin-dependent protein kinase II beta CAMK2B 
solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 5 SLC25A5 
otopetrin 2 OTOP2 
translocase of inner mitochondrial membrane 8 homolog A (yeast) TIMM8A 
fasciculation and elongation protein zeta 1 (zygin I) FEZ1 
ADP-ribosylation factor-like 6 interacting protein 6 ARL6IP6 
solute carrier family 27 (fatty acid transporter), member 2 SLC27A2 
sodium channel, voltage gated, type III beta subunit SCN3B 
HERV-H LTR-associating 3 HHLA3 
synovial sarcoma translocation gene on chromosome 18-like 2 SS18L2 
small nuclear ribonucleoprotein 27kDa (U4/U6.U5) SNRNP27 
long intergenic non-protein coding RNA 111 LINC00111 
acid phosphatase 2, lysosomal ACP2 
cytoglobin CYGB 
uncharacterized LOC100130872 
LOC1001308
72 
zinc finger protein 654 ZNF654 
far upstream element (FUSE) binding protein 1 FUBP1 
glycerate kinase GLYCTK 
polymerase (RNA) III (DNA directed) polypeptide H (22.9kD) POLR3H 
ephrin-A2 EFNA2 
coiled-coil domain containing 68 CCDC68 
sterile alpha motif domain containing 10 SAMD10 
BPI fold containing family A, member 1 BPIFA1 
ZFP62 zinc finger protein ZFP62 
adhesion molecule with Ig-like domain 2 AMIGO2 
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chemokine (C-C motif) ligand 14 CCL14 
transmembrane protein 160 TMEM160 
chromosome 1 open reading frame 54 C1orf54 
zinc finger protein 214 ZNF214 
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) HIF1A 
DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked DDX3Y 
myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10 MLLT10 
coiled-coil domain containing 53 CCDC53 
uncharacterized LOC100506813 
LOC1005068
13 
SPANX family, member N4 SPANXN4 
FK506 binding protein 1A, 12kDa FKBP1A 
potassium channel, voltage gated eag related subfamily H, member 
4 KCNH4 
NIN1/RPN12 binding protein 1 homolog NOB1 
deoxyribonuclease II beta DNASE2B 
olfactory receptor, family 6, subfamily Y, member 1 OR6Y1 
keratin associated protein 12-4 KRTAP12-4 
polyglutamine binding protein 1 PQBP1 
gonadotropin-releasing hormone (type 2) receptor 2, pseudogene GNRHR2 
cyclin Y CCNY 
coiled-coil domain containing 63 CCDC63 
BTB (POZ) domain containing 3 BTBD3 
sterol carrier protein 2 SCP2 
EPH receptor A5 EPHA5 
SH3-domain binding protein 2 SH3BP2 
bone morphogenetic protein 8a BMP8A 
Kruppel-like factor 6 KLF6 
transducer of ERBB2, 1 TOB1 
ectonucleotide pyrophosphatase/phosphodiesterase 6 ENPP6 
RAD51 associated protein 2 RAD51AP2 
cAMP responsive element binding protein 3-like 1 CREB3L1 
dihydropyrimidine dehydrogenase DPYD 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A MGAT4A 
churchill domain containing 1 CHURC1 
F-box protein 38 FBXO38 
polypeptide N-acetylgalactosaminyltransferase-like 6 GALNTL6 
SEC24 homolog C, COPII coat complex component SEC24C 
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sperm flagellar 1 SPEF1 
WW and C2 domain containing 1 WWC1 
G patch domain and KOW motifs GPKOW 
uridine-cytidine kinase 1 UCK1 
fibroblast growth factor receptor-like 1 FGFRL1 
glyceronephosphate O-acyltransferase GNPAT 
Ras and Rab interactor-like RINL 
transmembrane protein 145 TMEM145 
failed axon connections homolog FAXC 
small G protein signaling modulator 2 SGSM2 
ALG13, UDP-N-acetylglucosaminyltransferase subunit ALG13 
non-SMC condensin I complex, subunit D2 NCAPD2 
shisa family member 3 SHISA3 
arylacetamide deacetylase-like 3 AADACL3 
solute carrier family 25 (mitochondrial carrier; citrate transporter), 
member 1 SLC25A1 
thyroid hormone receptor interactor 13 TRIP13 
potassium channel tetramerization domain containing 2 KCTD2 
dynactin 1 DCTN1 
immature colon carcinoma transcript 1 ICT1 
forkhead box K2 FOXK2 
HNF1 homeobox B HNF1B 
phosphofructokinase, muscle PFKM 
S100 calcium binding protein A8 S100A8 
mitochondrial ribosomal protein L39 MRPL39 
SNF8, ESCRT-II complex subunit SNF8 
cytochrome P450, family 2, subfamily F, polypeptide 1 CYP2F1 
beta-carotene oxygenase 2 BCO2 
solute carrier family 17 (organic anion transporter), member 1 SLC17A1 
transmembrane protein 134 TMEM134 
adenomatosis polyposis coli down-regulated 1 APCDD1 
ring finger protein 183 RNF183 
heat shock transcription factor 2 HSF2 
chromosome 15 open reading frame 53 C15orf53 
integrin-binding sialoprotein IBSP 
olfactory receptor, family 4, subfamily C, member 16 
(gene/pseudogene) OR4C16 
extracellular matrix protein 2, female organ and adipocyte specific ECM2 
MIR205 host gene MIR205HG 
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zinc finger, C3H1-type containing ZFC3H1 
fibroblast growth factor binding protein 2 FGFBP2 
parvin, alpha PARVA 
long intergenic non-protein coding RNA 336 LINC00336 
proline dehydrogenase (oxidase) 2 PRODH2 
major histocompatibility complex, class I-related MR1 
dysbindin (dystrobrevin binding protein 1) domain containing 2 DBNDD2 
PNN-interacting serine/arginine-rich protein PNISR 
glycine receptor, beta GLRB 
neurexophilin 3 NXPH3 
ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa UQCRQ 
solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 2 SLC24A2 
sorting nexin 22 SNX22 
chromosome 11 open reading frame 40 C11orf40 
kin of IRRE like 2 (Drosophila) KIRREL2 
zinc finger protein 524 ZNF524 
elongation factor RNA polymerase II ELL 
Rho family GTPase 3 RND3 
phosphotyrosine interaction domain containing 1 PID1 
chromosome 20 open reading frame 78 C20orf78 
keratin 28, type I KRT28 
transcription elongation regulator 1-like TCERG1L 
t-complex 10-like 2 TCP10L2 
NFAT activating protein with ITAM motif 1 NFAM1 
filaggrin FLG 
chromosome 19 open reading frame 81 C19orf81 
solute carrier family 39 (zinc transporter), member 14 SLC39A14 
Rho GTPase activating protein 35 ARHGAP35 
solute carrier family 38, member 9 SLC38A9 
lipocalin-like 1 LCNL1 
tyrosine kinase 2 TYK2 
transforming growth factor beta regulator 1 TBRG1 
aarF domain containing kinase 1 ADCK1 
YLP motif containing 1 YLPM1 
islet cell autoantigen 1,69kDa-like ICA1L 
zinc finger protein 551 ZNF551 
olfactory receptor, family 4, subfamily A, member 15 OR4A15 
actin binding LIM protein family, member 2 ABLIM2 
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secretoglobin, family 1D, member 1 SCGB1D1 
class II, major histocompatibility complex, transactivator CIITA 
keratin associated protein 20-2 KRTAP20-2 
sphingosine-1-phosphate receptor 3 S1PR3 
chromosome 8 open reading frame 34 C8orf34 
EF-hand calcium binding domain 12 EFCAB12 
methyltransferase like 10 METTL10 
adipocyte plasma membrane associated protein APMAP 
interleukin 6 receptor IL6R 
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 CHST5 
chromosome 9 open reading frame 72 C9orf72 
paired box 3 PAX3 
pleckstrin homology-like domain, family A, member 2 PHLDA2 
synaptotagmin XVI SYT16 
CD99 molecule pseudogene 1 CD99P1 
apolipoprotein E APOE 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and 
ITIM domains), member 2 LILRB2 
sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4D SEMA4D 
ring finger protein 121 RNF121 
trafficking protein particle complex 10 TRAPPC10 
reelin RELN 
RNA guanylyltransferase and 5'-phosphatase RNGTT 
anaplastic lymphoma receptor tyrosine kinase ALK 
structural maintenance of chromosomes 1B SMC1B 
zinc finger protein 680 ZNF680 
apolipoprotein L, 5 APOL5 
N-acetylglutamate synthase NAGS 
FERM domain containing 1 FRMD1 
aquaporin 3 (Gill blood group) AQP3 
Sin3A-associated protein, 25kDa SAP25 
keratin 85, type II KRT85 
ubiquitously transcribed tetratricopeptide repeat containing, Y-linked UTY 
protein arginine methyltransferase 6 PRMT6 
potassium channel subfamily M regulatory beta subunit 1 KCNMB1 
uncharacterized LOC283440 LOC283440 
androgen-induced 1 AIG1 
synaptopodin 2-like SYNPO2L 
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tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase TRMU 
SET domain and mariner transposase fusion gene SETMAR 
transmembrane protein 192 TMEM192 
F-box protein 41 FBXO41 
TBC1 domain family, member 24 TBC1D24 
cadherin 8, type 2 CDH8 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 SMARCC1 
potassium channel, voltage gated eag related subfamily H, member 
7 KCNH7 
AT hook containing transcription factor 1 AHCTF1 
Fanconi anemia, complementation group A FANCA 
ATM serine/threonine kinase ATM 
cyclin-dependent kinase 5, regulatory subunit 2 (p39) CDK5R2 
reticulocalbin 2, EF-hand calcium binding domain RCN2 
low density lipoprotein receptor-related protein 1 LRP1 
COMM domain containing 6 COMMD6 
lin-28 homolog B (C. elegans) LIN28B 
SH3 and multiple ankyrin repeat domains 2 SHANK2 
caspase 5, apoptosis-related cysteine peptidase CASP5 
sorcin SRI 
chromosome 10 open reading frame 111 C10orf111 
centrosomal protein 85kDa CEP85 
filaggrin family member 2 FLG2 
melanoregulin MREG 
coiled-coil domain containing 50 CCDC50 
v-rel avian reticuloendotheliosis viral oncogene homolog A RELA 
abhydrolase domain containing 16A ABHD16A 
hes family bHLH transcription factor 2 HES2 
MIS18 kinetochore protein A MIS18A 
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